[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 310
1. Ben-Josef E, Moughan J, Ajani JA, Flam M, Gunderson L, Pollock J, Myerson R, Anne R, Rosenthal SA, Willett C: Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11. J Clin Oncol; 2010 Dec 1;28(34):5061-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11.
  • PURPOSE: To determine whether increased duration of radiation therapy (RT) and overall treatment (RX) time has a detrimental effect in anal cancer.
  • Cox proportional hazards models were used with the following variables: RT duration, RT intensity, RX duration, treatment group, age, sex, Karnofsky performance score (KPS), T stage, N stage, and RT dose.
  • Age, sex, KPS, T stage, N stage, and RT dose, but not RT duration, RT intensity, or RX duration, were found to be statistically significant predictors of OS and colostomy-free survival.
  • CONCLUSION: Total treatment time, but not duration of radiation therapy, seems to have a detrimental effect on local failure and colostomy rate in anal cancer.

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiother Oncol. 1994 Feb;30(2):109-20 [8184108.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):428-35 [19251377.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Radiother Oncol. 2000 May;55(2):101-10 [10799721.001]
  • [Cites] Radiother Oncol. 2001 May;59(2):187-94 [11325448.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):675-80 [11395235.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):483-93 [11567825.001]
  • [Cites] Lancet Oncol. 2002 Nov;3(11):693-701 [12424072.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Mar 15;55(4):1074-81 [12605987.001]
  • [Cites] Radiother Oncol. 2003 Apr;67(1):69-76 [12758242.001]
  • [Cites] Oncology. 2003;65(1):14-22 [12837978.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1259-73 [12873670.001]
  • [Cites] Eur J Cancer. 1967 Nov;3(4):361-9 [6078936.001]
  • [Cites] Radiat Res. 1969 Feb;37(2):423-34 [5765551.001]
  • [Cites] Br J Radiol. 1973 May;46(545):381-7 [4715162.001]
  • [Cites] Cancer Res. 1976 Oct;36(10):3718-25 [953998.001]
  • [Cites] Br J Cancer. 1977 Sep;36(3):313-21 [921888.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1983 Mar;9(3):321-8 [6841183.001]
  • [Cites] Acta Oncol. 1988;27(2):131-46 [3390344.001]
  • [Cites] Eur J Cancer. 1991;27(5):537-43 [1828958.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1195-202 [1938517.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Nov;21(6):1529-34 [1938563.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Feb 15;25(3):391-7 [8436516.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Dec 1;27(5):1051-6 [8262826.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):313-24 [9069302.001]
  • [Cites] Cancer. 1997 Jun 15;79(12):2329-35 [9191520.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):651-7 [9336145.001]
  • [Cites] Lancet. 1998 May;351 Suppl 2:SII9-16 [9606361.001]
  • [Cites] Oncology. 1998 Nov-Dec;55(6):525-32 [9778618.001]
  • [Cites] Acta Oncol. 2006;45(6):728-35 [16938816.001]
  • [Cites] Lancet. 2006 Sep 2;368(9538):843-54 [16950362.001]
  • [Cites] JAMA. 2008 Apr 23;299(16):1914-21 [18430910.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):114-8 [18472363.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Oct 15;33(3):549-62 [7558943.001]
  • (PMID = 20956625.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA021661; United States / NCI NIH HHS / CA / U10 CA037422; United States / NCI NIH HHS / CA / U10 CA21661; United States / NCI NIH HHS / CA / U10 CA37422
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC3018356
  •  go-up   go-down


2. Du CZ, Xue WC, Cai Y, Li M, Gu J: Lymphovascular invasion in rectal cancer following neoadjuvant radiotherapy: a retrospective cohort study. World J Gastroenterol; 2009 Aug 14;15(30):3793-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphovascular invasion in rectal cancer following neoadjuvant radiotherapy: a retrospective cohort study.
  • AIM: To investigate the meaning of lymphovascular invasion (LVI) in rectal cancer after neoadjuvant radiotherapy.
  • METHODS: A total of 325 patients who underwent radical resection using total mesorectal excision (TME) from January 2000 to January 2005 in Beijing cancer hospital were included retrospectively, divided into a preoperative radiotherapy (PRT) group and a control group, according to whether or not they underwent preoperative radiation.
  • In the control group, LVI was significantly associated with histological differentiation and pathologic TNM stage, whereas these associations were not observed in the PRT group.
  • Multivariate analysis showed the distance of tumor from the anal verge, pretreatment serum carcinoembryonic antigen level, pathologic TNM stage and LVI were the major factors affecting OS.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2000 Jul;124(7):979-94 [10888773.001]
  • [Cites] Lancet. 2009 Mar 7;373(9666):811-20 [19269519.001]
  • [Cites] Dis Colon Rectum. 2002 Jul;45(7):895-903 [12130878.001]
  • [Cites] Chin Med J (Engl). 2002 Jul;115(7):1070-3 [12150745.001]
  • [Cites] Hum Pathol. 2003 Jun;34(6):541-8 [12827607.001]
  • [Cites] World J Surg. 1992 Sep-Oct;16(5):848-57 [1462619.001]
  • [Cites] Radiother Oncol. 1997 May;43(2):133-7 [9192957.001]
  • [Cites] Am J Surg. 1999 May;177(5):392-5 [10365877.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jul 15;44(5):1027-38 [10421535.001]
  • [Cites] BMC Med. 2003 Nov 24;1:1 [14633275.001]
  • [Cites] Acta Chir Iugosl. 2004;51(2):99-108 [15771300.001]
  • [Cites] Ann Surg. 2005 May;241(5):829-36; discussion 836-8 [15849519.001]
  • [Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8653-60 [16361550.001]
  • [Cites] Eur Surg Res. 2006;38(5):438-44 [16912482.001]
  • [Cites] Adv Anat Pathol. 2006 Nov;13(6):308-15 [17075296.001]
  • [Cites] Hum Pathol. 2007 Apr;38(4):537-545 [17270246.001]
  • [Cites] J Clin Oncol. 2007 Oct 1;25(28):4379-86 [17906203.001]
  • [Cites] Dis Colon Rectum. 2007 Nov;50(11):1867-72 [17665249.001]
  • [Cites] World J Gastroenterol. 2008 Jun 7;14(21):3281-9 [18528924.001]
  • [Cites] Colorectal Dis. 2008 Nov;10(9):879-86 [19037929.001]
  • [Cites] Am J Surg Pathol. 2008 Dec;32(12):1816-21 [18779725.001]
  • [Cites] Colorectal Dis. 2009 Mar;11(3):245-8 [18637934.001]
  • [Cites] JAMA. 2000 Aug 23-30;284(8):1008-15 [10944647.001]
  • (PMID = 19673022.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2726459
  •  go-up   go-down


3. Friedrich K, von Heydebreck A, Haroske G, Scheithauer J, Meyer W, Kunze KD, Baretton G: Comparative genomic hybridization-based oncogenetic tree model for genetic classification of breast cancer. Anal Quant Cytol Histol; 2009 Apr;31(2):101-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative genomic hybridization-based oncogenetic tree model for genetic classification of breast cancer.
  • OBJECTIVE: To describe a genetic progression pathway in breast cancer by a maximum likelihood-based tree model representing the dependencies between chromosomal imbalances.
  • The imbalances nearest the root of the tree were the loss at 13q (cluster 1), the gain at 1q (cluster 2) and the loss at 18q (cluster 3), reflecting an early change in breast cancer evolution.
  • Cox regression analysis revealed the tumor stage and the grade as relevant for overall survival (p = 0.001) and the tumor stage, the grade and the loss at 16q as relevant for disease-free survival (p = 0.001).
  • CONCLUSION: Methods like oncogenetic tree analysis provide insights into the genetic progression of breast cancer and may extract relevant markers detected by screening methods like comparative genomic hybridization for further studies.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19402387.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


Advertisement
4. Horisberger K, Treschl A, Mai S, Barreto-Miranda M, Kienle P, Ströbel P, Erben P, Woernle C, Dinter D, Kähler G, Hochhaus A, Post S, Willeke F, Wenz F, Hofheinz RD, MARGIT (Mannheimer Arbeitsgruppe für Gastrointestinale Tumoren): Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial. Int J Radiat Oncol Biol Phys; 2009 Aug 1;74(5):1487-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial.
  • PURPOSE: To evaluate the safety and efficacy of preoperative radiotherapy (RT) in combination with cetuximab, capecitabine, and irinotecan in patients with locally advanced rectal cancer.
  • METHODS AND MATERIALS: Patients with rectal cancer (clinical stage T3/4 or N+) were scheduled to receive cetuximab (400 mg/m(2) Day 1, 250 mg/m(2) Days 8, 15, 22, 29) in combination with weekly irinotecan 40 mg/m(2) and capecitabine 500 mg/m(2) twice daily (Days 1-38).
  • RESULTS: Fifty patients were enrolled; 88% showed T3 or T4 and 76% nodal-positive tumors with a median distance from the anal verge of 7.5 cm.
  • Main adverse events Grades 2/3/4 were (National Cancer Institute common toxicity criteria version 3.0, %): leukocytopenia 6/2/2, nausea/vomiting 4/2/0, diarrhea 34/30/0, proctitis 26/2/0, elevation of liver transaminases 8/10/0, and acnelike skin rash 46/6/0.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19131187.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; 7673326042 / irinotecan; PQX0D8J21J / Cetuximab; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


5. Manohar K, Suneetha PV, Sukriti, Pati NT, Gupta AC, Hissar S, Sakhuja P, Sarin SK: Association of IL-18 promoter polymorphism with liver disease severity in HCV-infected patients. Hepatol Int; 2009 Jun;3(2):371-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The -607 A/A allele was more common in group A patients with mild liver disease than in patients with severe liver disease on the basis of HAI (38.6% vs. 21%, P = 0.05; odds ratio [OR] = 0.424, confidence interval [CI] = 0.233-0.773; R (2) = 0.631) and stage of fibrosis (38.7% vs. 16.7%, P = 0.008; OR = 0282, CI = 0.134-0.596; R (2) = 0.434).

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Respir Med. 2007 Apr;101(4):722-8 [17015003.001]
  • [Cites] Br Med Bull. 1999;55(2):401-13 [10723865.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15136-41 [17018642.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4265-73 [16857801.001]
  • [Cites] Immunogenetics. 2006 Jun;58(5-6):471-3 [16738942.001]
  • [Cites] Ann Clin Lab Sci. 2006 Spring;36(2):144-50 [16682509.001]
  • [Cites] Virol J. 2005;2:88 [16321149.001]
  • [Cites] Int J Cancer. 2006 Feb 1;118(3):564-70 [16108033.001]
  • [Cites] Inflamm Bowel Dis. 2005 Dec;11(12):1031-7 [16306764.001]
  • [Cites] Circulation. 2005 Aug 2;112(5):643-50 [16043644.001]
  • [Cites] Hepatogastroenterology. 2005 Mar-Apr;52(62):547-51 [15816475.001]
  • [Cites] Am J Respir Cell Mol Biol. 2004 Dec;31(6):619-25 [15308504.001]
  • [Cites] Lancet. 1990 Oct 27;336(8722):1022-5 [1977017.001]
  • [Cites] Anal Biochem. 1989 Aug 1;180(2):276-8 [2554754.001]
  • [Cites] J Med Virol. 2004 Jan;72(1):60-5 [14635012.001]
  • [Cites] Int Immunol. 2002 Dec;14(12):1449-57 [12456593.001]
  • [Cites] J Virol. 2002 Nov;76(21):10702-7 [12368312.001]
  • [Cites] Clin Exp Immunol. 2002 Aug;129(2):332-8 [12165091.001]
  • [Cites] J Hematother Stem Cell Res. 2001 Dec;10(6):769-76 [11798503.001]
  • [Cites] J Neuroimmunol. 2001 Jan 1;112(1-2):146-52 [11108943.001]
  • [Cites] Semin Liver Dis. 2000;20(2):211-26 [10946425.001]
  • [Cites] Lab Invest. 2006 Nov;86(11):1126-35 [16983331.001]
  • (PMID = 19669363.001).
  • [ISSN] 1936-0533
  • [Journal-full-title] Hepatology international
  • [ISO-abbreviation] Hepatol Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2716760
  •  go-up   go-down


6. Alatise OI, Lawal OO, Adesunkanmi AK, Osasan SA: Surgical outcome of abdominoperineal resection for low rectal cancer in a Nigerian tertiary institution. World J Surg; 2009 Feb;33(2):233-9; discussion 240-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical outcome of abdominoperineal resection for low rectal cancer in a Nigerian tertiary institution.
  • BACKGROUND: Rectal cancer is a lifestyle-related illness with an increasing incidence in all developing countries in the last decade.
  • Abdominoperineal resection (APR) offers a good oncologic clearance for low rectal cancer.
  • This accounts for 24.0% of all patients that had low rectal cancer.
  • Operative blood loss (p = 0.006), degree of differentiation of the tumor (p = 0.011), distance from the anal verge (p = 0.033), and operative stage (p = 0.005) were found to significantly affect the outcome of treatment for the patients who underwent APR.
  • The operative stage similarly affected the survival of patients (Mantel Cox = 0.026).

  • Genetic Alliance. consumer health - Rectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] ANZ J Surg. 2002 Apr;72(4):265-70 [11982512.001]
  • [Cites] Int J Surg. 2006;4(2):127-30 [17462328.001]
  • [Cites] Am Surg. 2005 Oct;71(10):837-40 [16468531.001]
  • [Cites] N Engl J Med. 1997 Apr 3;336(14 ):980-7 [9091798.001]
  • [Cites] Br J Surg. 2002 Sep;89(9):1142-9 [12190680.001]
  • [Cites] Lancet. 1990 May 5;335(8697):1055-9 [1691810.001]
  • [Cites] Br J Surg. 1995 Oct;82(10):1297-9 [7489148.001]
  • [Cites] J Clin Oncol. 2005 Jul 10;23(20):4553-60 [16002847.001]
  • [Cites] Arch Surg. 2006 Dec;141(12):1246-52; discussion 1253 [17178968.001]
  • [Cites] CA Cancer J Clin. 1971 Nov-Dec;21(6):361-4 [5001853.001]
  • [Cites] World J Surg. 2005 Aug;29(8):1013-21; discussion 1021-2 [15981044.001]
  • [Cites] Dis Colon Rectum. 2002 Sep;45(9):1255-60 [12352245.001]
  • [Cites] S Afr Med J. 2001 Aug;91(8):689-93 [11584786.001]
  • [Cites] Hepatogastroenterology. 2000 May-Jun;47(33):709-13 [10919015.001]
  • [Cites] World J Surg. 2008 Feb;32(2):217-23 [18057984.001]
  • [Cites] Am Surg. 2005 Feb;71(2):117-22 [16022009.001]
  • [Cites] Lancet Oncol. 2005 Nov;6(11):871-6 [16257795.001]
  • [Cites] Ann Surg. 2008 Jan;247(1):77-84 [18156926.001]
  • [Cites] Ann Surg Oncol. 2005 Feb;12(2):117-23 [15827791.001]
  • [Cites] Int J Colorectal Dis. 2003 Nov;18(6):463-9 [14517685.001]
  • [Cites] Eur J Surg Oncol. 1995 Feb;21(1):11-5 [7851543.001]
  • [Cites] Colorectal Dis. 2006 Mar;8(3):160-7 [16466553.001]
  • [Cites] Br J Surg. 1994 Aug;81(8):1224-6 [7953369.001]
  • [Cites] Dis Colon Rectum. 2002 Jul;45(7):895-903 [12130878.001]
  • [Cites] Cancer Control. 2003 May-Jun;10(3):212-8 [12794619.001]
  • [Cites] N Engl J Med. 2005 Feb 3;352(5):476-87 [15689586.001]
  • [Cites] Indian J Cancer. 2004 Jul-Sep;41(3):120-4 [15472410.001]
  • [Cites] N Z Med J. 2003 May 16;116(1174):U437 [12766783.001]
  • [Cites] Br J Surg. 2006 Jan;93(1):19-32 [16273532.001]
  • [Cites] Dis Colon Rectum. 2004 Jan;47(1):48-58 [14719151.001]
  • [Cites] Dis Colon Rectum. 1997 Feb;40(2):131-9 [9075745.001]
  • (PMID = 19023618.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Iancu C, Mocan LC, Todea-Iancu D, Mocan T, Acalovschi I, Ionescu D, Zaharie FV, Osian G, Puia CI, Muntean V: Host-related predictive factors for anastomotic leakage following large bowel resections for colorectal cancer. J Gastrointestin Liver Dis; 2008 Sep;17(3):299-303
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Host-related predictive factors for anastomotic leakage following large bowel resections for colorectal cancer.
  • AIM: To identify the risk, the host-related prognostic factors and their predictive value for anastomotic leakage after colorectal resections following cancer.
  • METHOD: 993 patients who underwent large bowel resection and primary anastomosis above 12 centimeters from the anal verge, without a temporary or permanent stoma at the Surgical Hospital No.3 (Cluj-Napoca, Romania) were retrospectively reviewed.
  • Alcohol use, cerebrovascular disease, bowel preparation, type of anastomosis, tumor location, stage and histology were not significant variables.
  • CONCLUSION. A serum protein level lower than 5.5 g/dl and serum hemoglobin lower than 9.4 g/dl could be considered as host-related predictive markers for anastomotic leak in large bowel resections for cancer.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18836623.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Blood Proteins; 0 / Hemoglobins
  •  go-up   go-down


8. Lim U, Flood A, Choi SW, Albanes D, Cross AJ, Schatzkin A, Sinha R, Katki HA, Cash B, Schoenfeld P, Stolzenberg-Solomon R: Genomic methylation of leukocyte DNA in relation to colorectal adenoma among asymptomatic women. Gastroenterology; 2008 Jan;134(1):47-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The association was also moderately more protective with low rather than high total folate intake but did not differ by other nutrients involved in 1-carbon metabolism or colorectal cancer risk factors.
  • CONCLUSIONS: Our findings regarding asymptomatic CRA implicate systemic genomic methylation as a potential etiologic factor for an early stage of CRA.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2002 Aug 12;21(35):5400-13 [12154403.001]
  • [Cites] J Nutr. 2002 Aug;132(8 Suppl):2340S-2344S [12163689.001]
  • [Cites] Int J Cancer. 2002 Oct 10;101(5):403-8 [12216066.001]
  • [Cites] Anal Chem. 2002 Sep 1;74(17):4526-31 [12236365.001]
  • [Cites] Science. 2003 Apr 18;300(5618):455 [12702868.001]
  • [Cites] Science. 2003 Apr 18;300(5618):489-92 [12702876.001]
  • [Cites] Gastroenterology. 2003 May;124(5):1240-8 [12730865.001]
  • [Cites] J Nutr. 2003 Nov;133(11 Suppl 1):3731S-3739S [14608107.001]
  • [Cites] Int J Colorectal Dis. 2004 Mar;19(2):95-101 [14534800.001]
  • [Cites] Cancer Res. 1988 Mar 1;48(5):1159-61 [3342396.001]
  • [Cites] Carcinogenesis. 1992 Jun;13(6):1039-42 [1376218.001]
  • [Cites] J Natl Cancer Inst. 1993 Jun 2;85(11):875-84 [8492316.001]
  • [Cites] Drug Metab Rev. 1994;26(1-2):185-99 [8082564.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 7;90(1):57-62 [9428784.001]
  • [Cites] Int J Epidemiol. 1998 Jun;27(3):382-7 [9698124.001]
  • [Cites] Nat Genet. 1999 Feb;21(2):163-7 [9988266.001]
  • [Cites] Exp Biol Med (Maywood). 2004 Nov;229(10):988-95 [15522834.001]
  • [Cites] Oncogene. 2004 Nov 18;23(54):8841-6 [15480421.001]
  • [Cites] Int J Cancer. 2005 Feb 20;113(5):825-8 [15499620.001]
  • [Cites] N Engl J Med. 2005 May 19;352(20):2061-8 [15901859.001]
  • [Cites] Nutr Rev. 2005 Jun;63(6 Pt 1):183-95 [16028562.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1317-9 [16174847.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13580-5 [16174748.001]
  • [Cites] Semin Oncol. 2005 Oct;32(5):521-30 [16210093.001]
  • [Cites] J Nutr. 2005 Nov;135(11):2703-9 [16251634.001]
  • [Cites] J Nutr. 2005 Dec;135(12 Suppl):2967S-2971S [16317156.001]
  • [Cites] Curr Opin Gastroenterol. 2006 Jul;22(4):382-90 [16760754.001]
  • [Cites] Curr Top Microbiol Immunol. 2006;310:251-74 [16909914.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):108-14 [17220338.001]
  • [Cites] JAMA. 2007 Jun 6;297(21):2351-9 [17551129.001]
  • [Cites] JAMA. 2007 Jun 6;297(21):2408-9 [17551134.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jul;16(7):1325-9 [17626997.001]
  • [Cites] J Nutr. 2007 Sep;137(9):2114-20 [17709451.001]
  • [Cites] J Nutr. 2000 Feb;130(2):129-32 [10720158.001]
  • [Cites] Semin Thromb Hemost. 2000;26(3):227-32 [11011840.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Jan;10(1):69-74 [11205492.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):559-62 [11352869.001]
  • [Cites] J Med Genet. 2001 May;38(5):285-303 [11333864.001]
  • [Cites] Am J Epidemiol. 2001 Dec 15;154(12):1089-99 [11744511.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5606-11 [11929966.001]
  • (PMID = 18166347.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K07 CA108910-01A1; United States / NCI NIH HHS / CA / K07-CA108910-01A1; United States / Intramural NIH HHS / / NIH0011451923; United States / PHS HHS / / NIH0011451923; None / None / / K07 CA108910-01A1; United States / NCI NIH HHS / CA / K07 CA108910
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS36885; NLM/ PMC2211566
  •  go-up   go-down


9. Yuan W, Chen Z, Wu S, Ge J, Chang S, Wang X, Chen J, Chen Z: Expression of EphA2 and E-cadherin in gastric cancer: correlated with tumor progression and lymphogenous metastasis. Pathol Oncol Res; 2009 Sep;15(3):473-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of EphA2 and E-cadherin in gastric cancer: correlated with tumor progression and lymphogenous metastasis.
  • In this study, gastric cancer progression was correlated with the over-expression of erythropoietin-producing hepatocellular (Eph)A2 receptor and down-expression of epithelial cadherin (E-cadherin).
  • Immunohistochemistry of EphA2 and E-cadherin were performed on these tumor samples from 165 primary lesions of gastric cancer.
  • The results showed that expression of EphA2 was obviously increased in gastric cancer tissues (P < 0.01), which was positively correlated with the depth of cancer invasion, tumor-node-metastasis (TNM) stage and lymph node metastasis (P < 0.05).
  • Meanwhile, the expression of E-cadherin was significantly reduced (P < 0.01), which was negatively correlated with the depth of cancer invasion, grade of tumor differentiation, TNM stage and lymph node metastasis (P < 0.05).
  • In conclusion, either the over-expression of EphA2 or the down-expression of E-cadherin is correlated with cancer progression and lymphogenous metastasis in gastric cancer, suggesting that both of them may play an important role in tumor progression and metastasis.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):353-60 [16428472.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3640-8 [11705887.001]
  • [Cites] J Cell Sci. 2001 Jan;114(Pt 1):111-118 [11112695.001]
  • [Cites] J Biol Chem. 2003 Jan 10;278(2):1372-9 [12393869.001]
  • [Cites] Cancer Biol Ther. 2008 Jul;7(7):1098-103 [18443431.001]
  • [Cites] Int J Cancer. 2003 Feb 20;103(5):657-63 [12494475.001]
  • [Cites] Cancer Lett. 2003 Nov 10;201(1):97-106 [14580691.001]
  • [Cites] J Cell Sci. 1997 Feb;110 ( Pt 3):345-56 [9057087.001]
  • [Cites] Am J Pathol. 2003 Dec;163(6):2271-6 [14633601.001]
  • [Cites] Gastroenterology. 1997 Jan;112(1):46-54 [8978342.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:155-63 [15153430.001]
  • [Cites] Curr Opin Cell Biol. 1993 Oct;5(5):806-11 [8240824.001]
  • [Cites] Oncol Rep. 2006 Oct;16(4):823-30 [16969501.001]
  • [Cites] Crit Rev Oncol Hematol. 2005 Jun;54(3):209-41 [15890270.001]
  • [Cites] J Biol Chem. 2005 Oct 7;280(40):34008-18 [16051609.001]
  • [Cites] Hum Mutat. 1999;14(3):249-55 [10477433.001]
  • [Cites] J Biol Chem. 2002 Oct 18;277(42):39274-9 [12167657.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2301-6 [11280802.001]
  • [Cites] Genomics. 1997 Mar 1;40(2):371-4 [9119409.001]
  • [Cites] Oncogene. 2005 Nov 24;24(53):7859-68 [16103880.001]
  • [Cites] Mol Biol Rep. 1993 Feb;17(2):123-8 [8459805.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5145-50 [15297418.001]
  • [Cites] Oncogene. 2000 Dec 7;19(52):6043-52 [11146556.001]
  • [Cites] Gynecol Oncol. 2005 Nov;99(2):278-86 [16061279.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):613-8 [12576426.001]
  • [Cites] Nucleic Acids Res. 2002 Nov 1;30(21):4770-80 [12409468.001]
  • [Cites] Oncol Rep. 2004 Mar;11(3):605-11 [14767510.001]
  • [Cites] Clin Exp Metastasis. 2003;20(1):59-68 [12650608.001]
  • [Cites] Cell Growth Differ. 1999 Sep;10(9):629-38 [10511313.001]
  • [Cites] Am J Pathol. 1991 Jul;139(1):17-23 [1713020.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1037-42 [12651595.001]
  • [Cites] J Cell Sci. 2000 May;113 ( Pt 10):1793-802 [10769210.001]
  • [Cites] J Natl Cancer Inst. 2000 Apr 5;92(7):569-73 [10749913.001]
  • [Cites] Ann Surg. 2005 Jan;241(1):27-39 [15621988.001]
  • [Cites] Anal Biochem. 2006 Oct 15;357(2):277-88 [16945320.001]
  • [Cites] Cancer Biol Ther. 2007 Feb;6(2):269-75 [17224647.001]
  • [Cites] Cancer. 2007 Jan 15;109(2):332-40 [17154180.001]
  • (PMID = 19048396.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; EC 2.7.10.1 / Receptor, EphA2
  •  go-up   go-down


10. Cibula D, Velechovska P, Sláma J, Fischerova D, Pinkavova I, Pavlista D, Dundr P, Hill M, Freitag P, Zikan M: Late morbidity following nerve-sparing radical hysterectomy. Gynecol Oncol; 2010 Mar;116(3):506-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Nerve-sparing (NS) modification of radical hysterectomy (RH) has been developed with the main purpose of improving the quality of life after radical surgical treatment of early-stage cervical cancer.
  • [MeSH-minor] Adult. Aged. Anal Canal / physiology. Female. Humans. Middle Aged. Morbidity. Neoplasm Staging. Prospective Studies. Rectum / physiology. Surveys and Questionnaires. Urinary Bladder / innervation. Urinary Bladder / physiology. Young Adult


11. Jeong WK, Park JW, Choi HS, Chang HJ, Jeong SY: Transanal endoscopic microsurgery for rectal tumors: experience at Korea's National Cancer Center. Surg Endosc; 2009 Nov;23(11):2575-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transanal endoscopic microsurgery for rectal tumors: experience at Korea's National Cancer Center.
  • METHODS: From November 2001 to October 2007, 45 patients underwent TEM for excision of adenoma (13 patients), carcinoid tumor (6 patients), and carcinoma (26 patients).
  • RESULTS: The median tumor distance from the anal verge was 7 cm (range, 3-15 cm), and the median tumor size was 17 mm (range, 2-60 mm).
  • However, one patient with rectal carcinoma died of lung cancer during the follow-up period.
  • Histologic examination of the carcinomas showed pathologic tumor (pT) stage 0 (ypT0) in 2 patients, pT1 in 17 patients (including ypT1 in 1 patient), pT2 in 6 patients, and pT3 in 1 patient.
  • The overall and disease-free 5-year survival rates for patients with carcinoma were 96.2% and 88.5%, respectively.
  • With strict patient selection, it is oncologically safe for early-stage rectal carcinomas.
  • [MeSH-major] Anal Canal / surgery. Microsurgery / methods. Neoplasm Recurrence, Local / pathology. Proctoscopy / methods. Rectal Neoplasms / pathology. Rectal Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adenoma / mortality. Adenoma / pathology. Adenoma / surgery. Adult. Aged. Cancer Care Facilities. Carcinoid Tumor / mortality. Carcinoid Tumor / pathology. Carcinoid Tumor / surgery. Cohort Studies. Disease-Free Survival. Female. Follow-Up Studies. Humans. Immunohistochemistry. Intestinal Mucosa / pathology. Intestinal Mucosa / surgery. Korea. Male. Middle Aged. Minimally Invasive Surgical Procedures / adverse effects. Minimally Invasive Surgical Procedures / methods. Neoplasm Staging. Patient Selection. Postoperative Complications / diagnosis. Postoperative Complications / surgery. Reoperation. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2001 Sep;234(3):352-8; discussion 358-9 [11524588.001]
  • [Cites] Br J Surg. 1996 Feb;83(2):207-10 [8689164.001]
  • [Cites] Chirurg. 1984 Oct;55(10):677-80 [6510078.001]
  • [Cites] Anticancer Res. 2004 Mar-Apr;24(2C):1167-72 [15154642.001]
  • [Cites] Dis Colon Rectum. 1991 Oct;34(10):880-5 [1914721.001]
  • [Cites] J Clin Oncol. 1989 Aug;7(8):1003-8 [2754446.001]
  • [Cites] Arch Surg. 1998 Aug;133(8):894-9 [9711965.001]
  • [Cites] Surg Endosc. 2007 Jan;21(1):97-102 [17111281.001]
  • [Cites] Surg Endosc. 2003 Aug;17(8):1283-7 [12739119.001]
  • [Cites] Am J Surg. 2007 Nov;194(5):694-8 [17936438.001]
  • [Cites] Ann Surg Oncol. 2006 Apr;13(4):547-56 [16514476.001]
  • [Cites] Dis Colon Rectum. 2008 Jul;51(7):1026-30; discussion 1030-1 [18481147.001]
  • [Cites] Br J Surg. 2005 Dec;92(12):1546-52 [16252312.001]
  • [Cites] Dis Colon Rectum. 1996 Aug;39(8):886-92 [8756844.001]
  • [Cites] Am J Clin Oncol. 1994 Oct;17(5):411-6 [8092113.001]
  • [Cites] Colorectal Dis. 2004 Sep;6(5):350-5 [15335369.001]
  • [Cites] World J Surg. 1992 May-Jun;16(3):437-46 [1317077.001]
  • [Cites] Surg Endosc. 2002 Jun;16(6):989-95 [12163970.001]
  • [Cites] Ann Surg Oncol. 2003 Nov;10(9):1106-11 [14597451.001]
  • [Cites] Surg Endosc. 2007 Jun;21(6):970-4 [17285371.001]
  • [Cites] Br J Surg. 2007 May;94(5):627-33 [17335125.001]
  • [Cites] Dis Colon Rectum. 1996 Sep;39(9):969-76 [8797643.001]
  • [Cites] Dis Colon Rectum. 2000 Aug;43(8):1064-71; discussion 1071-4 [10950004.001]
  • [Cites] Arch Surg. 1998 Jun;133(6):595-8; discussion 598-9 [9637456.001]
  • [Cites] Colorectal Dis. 2006 Sep;8(7):581-5 [16919110.001]
  • [Cites] Dis Colon Rectum. 2005 Feb;48(2):270-84 [15711865.001]
  • (PMID = 19347399.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


12. Li H, Graubard BI, Gail MH: Covariate adjustment and ranking methods to identify regions with high and low mortality rates. Biometrics; 2010 Jun;66(2):613-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Based on a two-stage Poisson-Gamma model with covariates, we use information on known risk factors, such as smoking prevalence, to adjust mortality rates and reveal residual variation in relative risks that may reflect previously masked etiological associations.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Stat Med. 2000 Sep 15-30;19(17-18):2295-308 [10960854.001]
  • [Cites] Biometrics. 1987 Sep;43(3):671-81 [3663823.001]
  • [Cites] Biometrics. 1999 Sep;55(3):774-81 [11315006.001]
  • (PMID = 19508235.001).
  • [ISSN] 1541-0420
  • [Journal-full-title] Biometrics
  • [ISO-abbreviation] Biometrics
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / NIH0013603472; United States / PHS HHS / / NIH0013603472; United States / Intramural NIH HHS / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS117728; NLM/ PMC2889169
  •  go-up   go-down


13. Cheung MC, Perez EA, Molina MA, Jin X, Gutierrez JC, Franceschi D, Livingstone AS, Koniaris LG: Defining the role of surgery for primary gastrointestinal tract melanoma. J Gastrointest Surg; 2008 Apr;12(4):731-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumors were identified in the oral-nasopharynx (32.8%), anal canal (31.4%), rectum (22.2%), esophagus (5.9%), stomach (2.7%), small bowel (2.3%), gallbladder (1.4%), and large bowel (0.9%).
  • Univariate analysis demonstrated age, tumor location, stage, surgery, and lymph node status were significant predictors of improved survival.
  • Multivariate analysis of the cohort identified that location, advanced tumor stage, failure to undertake surgical resection, positive lymph node status, and age were all independent predictors of poorer outcome.
  • CONCLUSION: PGIM occurs most often in the oral-nasopharynx and anal canal.

  • Genetic Alliance. consumer health - Primary gastrointestinal melanoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 2006 Apr;202(4):623-9 [16571433.001]
  • [Cites] Minerva Chir. 2006 Feb;61(1):45-9 [16568022.001]
  • [Cites] Br J Urol. 1985 Oct;57(5):593-4 [4063746.001]
  • [Cites] Cancer. 1963 Jan;16:48-50 [14025842.001]
  • [Cites] Surg Endosc. 2005 Dec;19(12):1610-2 [16211437.001]
  • [Cites] Pediatr Surg Int. 2007 Jul;23(7):637-46 [17476512.001]
  • [Cites] Tumori. 2005 Jan-Feb;91(1):73-6 [15850009.001]
  • [Cites] World J Surg. 2007 May;31(5):1022-30 [17429568.001]
  • [Cites] J Gastrointest Surg. 2008 Jan;12(1):77-85 [17701264.001]
  • [Cites] Arch Surg. 1964 Jun;88:969-73 [14132002.001]
  • [Cites] Trop Gastroenterol. 2004 Oct-Dec;25(4):187-8 [15912983.001]
  • [Cites] Ann Thorac Surg. 1985 May;39(5):472-75 [3994450.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3622-34 [11504744.001]
  • [Cites] Dis Esophagus. 2002;15(3):244-9 [12444999.001]
  • [Cites] Histopathology. 1991 Mar;18(3):237-41 [2045074.001]
  • [Cites] J Gastrointest Surg. 2007 Jan;11(1):114-25 [17390197.001]
  • [Cites] Cancer Control. 2002 Jan-Feb;9(1):9-15 [11907461.001]
  • [Cites] Dis Colon Rectum. 2003 Apr;46(4):441-7 [12682534.001]
  • [Cites] Indian J Gastroenterol. 1999 Oct-Nov;18(4):176 [10531723.001]
  • [Cites] Am Surg. 2004 Jul;70(7):649-51 [15279192.001]
  • [Cites] Am J Surg. 1978 Jun;135(6):807-10 [665907.001]
  • [Cites] Ann Surg. 2007 Jun;245(6):952-8 [17522521.001]
  • [Cites] Int J Dermatol. 1997 Feb;36(2):129-31 [9109012.001]
  • [Cites] Ann Thorac Surg. 1995 Jul;60(1):217-22 [7598604.001]
  • [Cites] J Clin Gastroenterol. 2000 Jun;30(4):441-4 [10875478.001]
  • [Cites] Am J Gastroenterol. 1996 May;91(5):1001-6 [8633538.001]
  • [Cites] Am Surg. 1992 Jul;58(7):418-22 [1616187.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3635-48 [11504745.001]
  • [Cites] Surg Today. 2002;32(9):831-3 [12203066.001]
  • [Cites] Gut. 1991 Jul;32(7):828-30 [1855693.001]
  • [Cites] Ann Surg. 2002 Jun;235(6):879-87 [12035046.001]
  • [Cites] Am J Gastroenterol. 1999 Dec;94(12):3427-33 [10606298.001]
  • (PMID = 18058185.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Jahangir T, Sultana S: Modulatory effects of Pluchea lanceolata against chemically induced oxidative damage, hyperproliferation and two-stage renal carcinogenesis in Wistar rats. Mol Cell Biochem; 2006 Oct;291(1-2):175-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modulatory effects of Pluchea lanceolata against chemically induced oxidative damage, hyperproliferation and two-stage renal carcinogenesis in Wistar rats.
  • [MeSH-minor] Animals. Catalase / metabolism. Cell Proliferation / drug effects. Ferric Compounds. Flavonols / chemistry. Glucosephosphate Dehydrogenase / metabolism. Glutathione / metabolism. Glutathione Peroxidase / metabolism. Hydrogen Peroxide / metabolism. Lipid Peroxidation. Male. Neoplasm Staging. Nitrilotriacetic Acid / analogs & derivatives. Ornithine Decarboxylase / metabolism. Plant Extracts / chemistry. Plant Extracts / pharmacology. Quinone Reductases / metabolism. Rats. Rats, Wistar. Xanthine Oxidase / metabolism

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. NITRILOTRIACETIC ACID .
  • Hazardous Substances Data Bank. IRON (3+) NTA .
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1994 Mar 29;91(7):2616-20 [8146163.001]
  • [Cites] J Biol Chem. 1969 Jul 25;244(14):3855-63 [4308738.001]
  • [Cites] J Biol Chem. 1989 Dec 5;264(34):20509-12 [2584227.001]
  • [Cites] Free Radic Res. 1999 Oct;31(4):273-300 [10517533.001]
  • [Cites] Science. 1990 Aug 31;249(4972):1007-11 [2204108.001]
  • [Cites] Carcinogenesis. 1986 Nov;7(11):1865-70 [3769135.001]
  • [Cites] Redox Rep. 2004;9(1):19-28 [15035824.001]
  • [Cites] Arch Biochem Biophys. 1965 Mar;109:646-8 [14320509.001]
  • [Cites] J Pharm Pharmacol. 2005 Sep;57(9):1199-204 [16105241.001]
  • [Cites] Biochem Pharmacol. 1983 Apr 1;32(7):1141-8 [6342623.001]
  • [Cites] Proc Soc Exp Biol Med. 1950 May;74(1):148-51 [15430417.001]
  • [Cites] Cancer Res. 1984 Nov;44(11):5086-91 [6149017.001]
  • [Cites] Methods Enzymol. 1990;186:343-55 [2172711.001]
  • [Cites] J Ethnopharmacol. 1991 May-Jun;33(1-2):135-41 [1943162.001]
  • [Cites] Pharmacology. 1974;11(3):151-69 [4831804.001]
  • [Cites] Proc Nutr Soc. 1990 Jul;49(2):173-83 [2236085.001]
  • [Cites] Cancer Res. 1994 May 1;54(9):2424-8 [8162591.001]
  • [Cites] Cell Immunol. 1981 Apr;59(2):301-18 [6269759.001]
  • [Cites] J Biol Chem. 1974 Nov 25;249(22):7130-9 [4436300.001]
  • [Cites] Pathol Int. 1996 May;46(5):311-32 [8809878.001]
  • [Cites] Carcinogenesis. 1998 Jun;19(6):1133-9 [9667754.001]
  • [Cites] Cancer Lett. 1990 Oct 8;54(1-2):95-100 [1698534.001]
  • [Cites] Indian J Med Res. 1966 Jun;54(6):582-9 [5947023.001]
  • [Cites] Altern Med Rev. 2000 Jun;5(3):196-208 [10869101.001]
  • [Cites] Indian J Med Res. 1965 Jan;53:71-80 [14266449.001]
  • [Cites] Cancer Res. 1975 Jul;35(7):1662-70 [48421.001]
  • [Cites] Cancer Res. 1987 Apr 1;47(7):1867-9 [3815378.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Sep;77(9):5216-20 [6933553.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Jul 17;212(2):557-63 [7626070.001]
  • [Cites] Biochem Pharmacol. 1991 Aug 22;42(6):1177-9 [1653565.001]
  • [Cites] Mutat Res. 1988 Dec;202(2):285-306 [3057362.001]
  • [Cites] Arch Biochem Biophys. 1981 Feb;206(2):296-304 [7224639.001]
  • [Cites] Eur J Cancer. 2000 Jun;36(10):1235-47 [10882862.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] J Clin Lab Anal. 1997;11(5):287-313 [9292395.001]
  • (PMID = 16767495.001).
  • [ISSN] 0300-8177
  • [Journal-full-title] Molecular and cellular biochemistry
  • [ISO-abbreviation] Mol. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Ferric Compounds; 0 / Flavonols; 0 / Plant Extracts; BBX060AN9V / Hydrogen Peroxide; EC 1.1.1.49 / Glucosephosphate Dehydrogenase; EC 1.11.1.6 / Catalase; EC 1.11.1.9 / Glutathione Peroxidase; EC 1.17.3.2 / Xanthine Oxidase; EC 1.6.99.- / Quinone Reductases; EC 4.1.1.17 / Ornithine Decarboxylase; GAN16C9B8O / Glutathione; KA90006V9D / Nitrilotriacetic Acid; Z3U5ED15B9 / ferric nitrilotriacetate
  •  go-up   go-down


15. Yagi H, Miyamoto S, Tanaka Y, Sonoda K, Kobayashi H, Kishikawa T, Iwamoto R, Mekada E, Nakano H: Clinical significance of heparin-binding epidermal growth factor-like growth factor in peritoneal fluid of ovarian cancer. Br J Cancer; 2005 May 9;92(9):1737-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of heparin-binding epidermal growth factor-like growth factor in peritoneal fluid of ovarian cancer.
  • Epidermal growth factor receptor (EGFR) has been implicated in tumour growth and extension of ovarian cancer.
  • Peritoneal fluid in ovarian cancer patients contains various growth factors that can promote tumour growth and extension.
  • In order to investigate the clinical significance of EGFR ligands as activating factors of ovarian cancer, we examined the cell proliferation-promoting activity and the level of EGFR ligands in peritoneal fluid obtained from 99 patients.
  • Proliferation-promoting activity in peritoneal fluid from 63 ovarian cancer patients (OVCA) was much higher than peritoneal fluid from 18 ovarian cyst patients (OVC) and 18 normal ovary patients (NO), and the activity was suppressed only by antibodies against EGFR or heparin-binding epidermal growth factor (HB-EGF).
  • In peritoneal fluid, HB-EGF is sufficiently elevated to activate cancer cells even at an early stage of OVCA.
  • These results suggested that HB-EGF in peritoneal fluid might play a key role in cell survival and in the proliferation of OVCA.
  • [MeSH-minor] Amphiregulin. Cell Proliferation / drug effects. Cell Survival / drug effects. Dose-Response Relationship, Drug. EGF Family of Proteins. Female. Glycoproteins / metabolism. Heparin-binding EGF-like Growth Factor. Humans. Intercellular Signaling Peptides and Proteins / metabolism. Middle Aged. Transforming Growth Factor alpha / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Compr Ther. 1998 Oct;24(10):477-87 [9801846.001]
  • [Cites] J Biol Chem. 1995 Feb 24;270(8):3980-8 [7876145.001]
  • [Cites] Proc Assoc Am Physicians. 1999 May-Jun;111(3):259-69 [10354366.001]
  • [Cites] Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232 [7612182.001]
  • [Cites] Nature. 1999 Dec 23-30;402(6764):884-8 [10622253.001]
  • [Cites] Cancer Treat Rev. 1997 Mar;23(2):113-31 [9225962.001]
  • [Cites] Biochim Biophys Acta. 1997 Dec 9;1333(3):F179-99 [9426203.001]
  • [Cites] Ann Oncol. 1998 Apr;9(4):437-42 [9636836.001]
  • [Cites] Br J Cancer. 2000 Mar;82(6):1233-8 [10735511.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2482-91 [10873103.001]
  • [Cites] Cytokine Growth Factor Rev. 2000 Dec;11(4):335-44 [10959080.001]
  • [Cites] Anal Biochem. 2001 Mar15;290(2):302-13 [11237333.001]
  • [Cites] J Biol Chem. 2001 May 25;276(21):18265-71 [11278323.001]
  • [Cites] J Biol Chem. 2001 Aug 10;276(32):30475-82 [11402047.001]
  • [Cites] Int J Oncol. 2002 Nov;21(5):941-8 [12370739.001]
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4292-302 [12409327.001]
  • [Cites] Endocr Relat Cancer. 2003 Mar;10(1):1-21 [12653668.001]
  • [Cites] EMBO J. 2003 May 15;22(10):2411-21 [12743035.001]
  • [Cites] Nat Rev Cancer. 2003 Aug;3(8):582-91 [12894246.001]
  • [Cites] Biochem Soc Trans. 2003 Dec;31(Pt 6):1203-8 [14641026.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5720-7 [15313912.001]
  • [Cites] Cancer Res. 1988 Mar 1;48(5):1066-71 [3422589.001]
  • [Cites] Cancer Res. 1991 Oct 1;51(19):5322-8 [1717146.001]
  • [Cites] J Immunol. 1991 Oct 15;147(8):2609-16 [1918981.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):529-35 [1548517.001]
  • [Cites] EMBO J. 1994 May 15;13(10):2322-30 [8194524.001]
  • [Cites] Kidney Int. 1994 Sep;46(3):690-5 [7996789.001]
  • [Cites] Clin Cancer Res. 1995 Oct;1(10):1223-32 [9815916.001]
  • (PMID = 15827558.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AREG protein, human; 0 / Amphiregulin; 0 / EGF Family of Proteins; 0 / Glycoproteins; 0 / HBEGF protein, human; 0 / Heparin-binding EGF-like Growth Factor; 0 / Intercellular Signaling Peptides and Proteins; 0 / Transforming Growth Factor alpha; 62229-50-9 / Epidermal Growth Factor
  • [Other-IDs] NLM/ PMC2362036
  •  go-up   go-down


16. Wang H, Fu CG, Zheng JM, Gong HF, Tao LY, Yu ED, Zhang W, Liu LJ, Hao LQ, Meng RG: [Impact of meticulousness of pathologists on lymph node harvest after radical resection of invasive rectal carcinoma]. Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Nov;12(6):569-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Impact of meticulousness of pathologists on lymph node harvest after radical resection of invasive rectal carcinoma].
  • OBJECTIVE: To analyze the impact of meticulousness of pathologists on the lymph node harvest after radical resection of invasive rectal carcinoma.
  • METHODS: From January 2008 to May 2009, the clinical data of rectal cancer patients undergone operation were reviewed retrospectively.
  • After multidisciplinary cooperation on rectal cancer, a new rule was applied to request the pathologists to find no less than 15 nodes in single colorectal specimen from January 2009.
  • Excluded criteria were recurrent colorectal tumor, Tis tumor, R(1) or R(2) resection, tumor resection transanally or endoscopically, the cases enrolled in other prospective research, synchronous diseases affecting the surgical procedure for the rectal cancer (familial adenomatous polyposis, synchronous colorectal carcinoma) and rectal cancer receiving neoadjuvant chemoradiation.
  • There were no significant differences in gender (46/76 vs 86/156, P=0.436), age (58.1+/-1.3 vs 59.2+/-1.1, P=0.527), distance from tumor to anal verge (7.4+/-0.4 vs 7.1+/-0.3, P=0.761), proportion of sphincter-sparing surgery (67/76 vs 140/156, P=0.715), ratio of well and moderate differentiated tumors (68/76 vs 125/156, P=0.074) and overall TNM stage (P=0.167) between the two groups.
  • The good performance of pathologists could produce adequate number of lymph nodes for rectal cancer without neoadjuvant chemoradiation.

  • MedlinePlus Health Information. consumer health - Biopsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19921565.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


17. He W, Kularatne SA, Kalli KR, Prendergast FG, Amato RJ, Klee GG, Hartmann LC, Low PS: Quantitation of circulating tumor cells in blood samples from ovarian and prostate cancer patients using tumor-specific fluorescent ligands. Int J Cancer; 2008 Oct 15;123(8):1968-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitation of circulating tumor cells in blood samples from ovarian and prostate cancer patients using tumor-specific fluorescent ligands.
  • Quantitation of circulating tumor cells (CTCs) can provide information on the stage of a malignancy, onset of disease progression and response to therapy.
  • Here we determine whether these tumor-specific dyes can be exploited for quantitation of CTCs in peripheral blood samples from cancer patients.
  • A CTC-enriched fraction was isolated from the peripheral blood of ovarian and prostate cancer patients by an optimized density gradient centrifugation protocol and labeled with the aforementioned fluorescent ligands.
  • CTCs were detected in 18 of 20 ovarian cancer patients (mean 222 CTCs/ml; median 15 CTCs/ml; maximum 3,118 CTCs/ml), whereas CTC numbers in 16 gender-matched normal volunteers were negligible (mean 0.4 CTCs/ml; median 0.3 CTCs/ml; maximum 1.5 CTCs/ml; p < 0.001, chi(2)).
  • CTCs were also detected in 10 of 13 prostate cancer patients (mean 26 CTCs/ml, median 14 CTCs/ml, maximum 94 CTCs/ml) but not in 18 gender-matched healthy donors (mean 0.8 CTCs/ml, median 1, maximum 3 CTC/ml; p < 0.0026, chi(2)).
  • Use of tumor-specific fluorescent ligands to label CTCs in peripheral blood can provide a simple, accurate and sensitive method for determining the number of cancer cells circulating in the bloodstream.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Folic Acid.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1432-9 [10735890.001]
  • [Cites] Br J Cancer. 1999 Nov;81(5):870-3 [10555760.001]
  • [Cites] Anticancer Res. 2005 Jan-Feb;25(1A):343-6 [15816557.001]
  • [Cites] Cancer Res. 1992 Jun 15;52(12):3396-401 [1596899.001]
  • [Cites] Am J Pathol. 1993 Feb;142(2):557-67 [8434649.001]
  • [Cites] Cancer. 1994 May 1;73(9):2432-43 [7513252.001]
  • [Cites] J Urol. 1994 Jun;151(6):1571-4 [7514690.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2634-9 [7527455.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10501-4 [15249663.001]
  • [Cites] N Engl J Med. 2004 Aug 19;351(8):781-91 [15317891.001]
  • [Cites] Cancer Res. 1969 Feb;29(2):414-8 [4885389.001]
  • [Cites] Cancer Res. 1974 May;34(5):997-1004 [4841969.001]
  • [Cites] Cancer Res. 1975 Mar;35(3):512-6 [1090362.001]
  • [Cites] Cell. 1976 Feb;7(2):267-77 [986246.001]
  • [Cites] Nature. 1988 Jun 30;333(6176):858-60 [3290682.001]
  • [Cites] Urology. 2005 Apr;65(4):713-8 [15833514.001]
  • [Cites] Aust N Z J Obstet Gynaecol. 2006 Aug;46(4):350-5 [16866799.001]
  • [Cites] Clin Colorectal Cancer. 2006 Jul;6(2):125-32 [16945168.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 12;103(37):13872-7 [16950881.001]
  • [Cites] Cancer Metastasis Rev. 2007 Mar;26(1):141-52 [17333345.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 10;104(28):11760-5 [17601776.001]
  • [Cites] Mol Pharm. 2007 Sep-Oct;4(5):707-12 [17708654.001]
  • [Cites] J Clin Oncol. 1995 May;13(5):1195-200 [7537803.001]
  • [Cites] Anticancer Res. 1995 Mar-Apr;15(2):631-4 [7763049.001]
  • [Cites] JAMA. 1995 Oct 18;274(15):1214-20 [7563511.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Oct-Nov;4(7):709-14 [8672986.001]
  • [Cites] Geburtshilfe Frauenheilkd. 1996 Jul;56(7):365-7 [8964451.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4589-94 [9539782.001]
  • [Cites] J Assist Reprod Genet. 1998 Jul;15(6):390-4 [9673885.001]
  • [Cites] Ann Oncol. 1998 Dec;9(12):1269-76 [9932154.001]
  • [Cites] Lancet. 1999 Apr 10;353(9160):1207-10 [10217079.001]
  • [Cites] Cancer. 1999 May 1;85(9):2068-72 [10223249.001]
  • [Cites] Int J Biol Markers. 1998 Oct-Dec;13(4):231-7 [10228907.001]
  • [Cites] Cytometry. 1999 Aug 15;38(4):139-52 [10440852.001]
  • [Cites] Cancer. 1964 Apr;17:450-60 [14136528.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1420-30 [15735118.001]
  • [Cites] Anal Biochem. 2005 Mar 15;338(2):284-93 [15745749.001]
  • [Cites] Aust N Z J Obstet Gynaecol. 1999 May;39(2):269-70 [10755799.001]
  • [Cites] J Clin Oncol. 2000 May;18(9):1914-20 [10784632.001]
  • [Cites] Med Oncol. 2001;18(1):33-8 [11778968.001]
  • [Cites] Blood. 2002 Mar 15;99(6):1952-8 [11877265.001]
  • [Cites] J Gynecol Obstet Biol Reprod (Paris). 2002 Nov;31(7):681-3 [12457142.001]
  • [Cites] J Nucl Med. 2003 May;44(5):700-7 [12732670.001]
  • [Cites] Chang Gung Med J. 2003 Sep;26(9):695-9 [14651169.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3291-300 [15161682.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Apr;86(8):2617-21 [2495532.001]
  • [Cites] Int J Gynecol Pathol. 1991;10(1):15-25 [2007534.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5572-6 [2062838.001]
  • (PMID = 18661519.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA091956-05; United States / NCI NIH HHS / CA / P50 CA091956; United States / NCI NIH HHS / CA / P50 CA091956-05
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fluorescent Dyes; 0 / Ligands; 935E97BOY8 / Folic Acid; I223NX31W9 / Fluorescein-5-isothiocyanate
  • [Other-IDs] NLM/ NIHMS127794; NLM/ PMC2778289
  •  go-up   go-down


18. Barriger RB, Calley C, Cárdenes HR: Treatment of anal carcinoma in immune-compromised patients. Clin Transl Oncol; 2009 Sep;11(9):609-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of anal carcinoma in immune-compromised patients.
  • This study was undertaken to evaluate local control (LC), overall survival (OS) and toxicity in immune-compromised patients with anal carcinoma treated with radiotherapy with or without chemotherapy.
  • METHODS: We identified 25 patients with anal carcinoma and human immunodeficiency virus (HIV) infection or history of solid-organ transplant on chronic medical immune-suppression.
  • AJCC T-stages were Tis (4%), T1 (8%), T2 (58%) and T3 (29%).
  • One patient had metastatic disease at diagnosis.
  • All patients had acute grade 2-3 skin toxicity.
  • Acute grade 3-4 gastrointestinal (GI), genitourinary (GU) and haematological toxicity occurred in 8%, 0% and 38%.
  • Late grade 3-4 skin, GI and GU toxicity occurred in 8%, 4% and 0%.
  • T-stage and CD4 level in HIV-positive patients predict for LC.
  • T-stage and TT predict for OS.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma / therapy. Immunocompromised Host

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):206-11 [16904522.001]
  • [Cites] JAMA. 2008 Apr 23;299(16):1914-21 [18430910.001]
  • [Cites] Dis Colon Rectum. 1994 Sep;37(9):861-5 [8076484.001]
  • [Cites] Transplant Proc. 2006 Dec;38(10):3533-5 [17175324.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Radiology. 1994 Oct;193(1):251-4 [8090901.001]
  • [Cites] Transpl Int. 2007 Jun;20(6):497-504 [17343685.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1176-81 [15906137.001]
  • [Cites] Dis Colon Rectum. 2001 Apr;44(4):506-12 [11330577.001]
  • [Cites] Dis Colon Rectum. 2001 Oct;44(10):1496-502 [11598480.001]
  • [Cites] Clin Nephrol. 1994 Feb;41(2):101-5 [8004825.001]
  • [Cites] Lancet. 1994 Mar 12;343(8898):636-9 [7906812.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1101-5 [9169819.001]
  • [Cites] Cancer. 1986 Aug 1;58(3):611-6 [3524788.001]
  • [Cites] Eur J Cancer. 2000 Apr;36(6):754-8 [10762748.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Apr 1;44(1):127-31 [10219805.001]
  • (PMID = 19776001.001).
  • [ISSN] 1699-3055
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


19. Smith A, Farmer KC, Chapple K: Clinical and endorectal ultrasound staging of circumferential rectal cancers. J Med Imaging Radiat Oncol; 2008 Apr;52(2):161-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Circumferential rectal cancers present at a more advanced stage than those located in a single quadrant.
  • Although accurate staging is an important aspect of the preoperative management of the patient with a rectal cancer, the clinical and radiological staging of this subgroup of rectal cancer patients has been poorly studied.
  • All patients with a rectal cancer were assessed clinically (by digital rectal examination and rigid sigmoidoscopy) before the radiological assessment by endorectal ultrasound (ERUS).
  • Data collected included tumour height (distance from anal verge in centimetre) and tumour type (circumferential or non-circumferential).
  • Fifty-nine subjects (33 men, 26 women; median age 65 years (range 38-86 years)) were identified with a circumferential rectal cancer.
  • Mean height of the cancer was 8 +/- 0.4 cm (standard error of the mean; range 2-13 cm).
  • Tumour stage as assessed by ERUS was either T3 (n = 57) or T4 (n = 2).
  • All rectal cancers assessed as circumferential on clinical examination have an ERUS stage of T3 or greater.
  • [MeSH-major] Rectal Neoplasms / diagnosis. Rectum / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18373808.001).
  • [ISSN] 1754-9485
  • [Journal-full-title] Journal of medical imaging and radiation oncology
  • [ISO-abbreviation] J Med Imaging Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


21. Stewart D, Yan Y, Kodner IJ, Birnbaum E, Fleshman J, Myerson R, Dietz D: Salvage surgery after failed chemoradiation for anal canal cancer: should the paradigm be changed for high-risk tumors? J Gastrointest Surg; 2007 Dec;11(12):1744-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage surgery after failed chemoradiation for anal canal cancer: should the paradigm be changed for high-risk tumors?
  • It is common belief that patients failing chemoradiation therapy (CRT) for squamous cell cancer of the anus (SCCA) can be salvaged with subsequent surgery.
  • Initial tumors were AJCC stage 2 (16 cases), 3A (3 cases), and 4 (1 case).
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Salvage Therapy


22. Hoffner G, van der Rest G, Dansette PM, Djian P: The end product of transglutaminase crosslinking: simultaneous quantitation of [Nepsilon-(gamma-glutamyl) lysine] and lysine by HPLC-MS3. Anal Biochem; 2009 Jan 15;384(2):296-304
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These enzymes are thought to participate in a number of diseases, including neurological disease and cancer.
  • A method associating liquid chromatography and multiple stage mass spectrometry has been developed for the simultaneous quantitation of [Nepsilon-(gamma-glutamyl) lysine] isodipeptide and lysine on an ion trap mass spectrometer.

  • Hazardous Substances Data Bank. L-Lysine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18938126.001).
  • [ISSN] 1096-0309
  • [Journal-full-title] Analytical biochemistry
  • [ISO-abbreviation] Anal. Biochem.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cross-Linking Reagents; 0 / Dipeptides; 17105-15-6 / epsilon-(gamma-glutamyl)-lysine; EC 2.3.2.13 / Transglutaminases; K3Z4F929H6 / Lysine
  •  go-up   go-down


23. Assenat E, Thézenas S, Samalin E, Bibeau F, Portales F, Azria D, Quenet F, Rouanet P, Saint Aubert B, Senesse P: The value of endoscopic rectal ultrasound in predicting the lateral clearance and outcome in patients with lower-third rectal adenocarcinoma. Endoscopy; 2007 Apr;39(4):309-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND STUDY AIMS: The aim of this study was to assess whether preoperative endorectal ultrasound (ERUS) is able to predict histological infiltration of the external anal sphincter or the levator ani muscle in patients with a lower-third rectal neoplasm and so the possibility of treatment by sphincter-saving surgery.
  • An abdominoperineal resection was performed mainly when the lower extent of the tumor was within 3.5 cm from the anal verge (P = 0.011), but no correlation was observed between the lateral clearance determined by ERUS 1 and the histological clearance (P = 0.091).
  • With regard to the performance of ERUS 2 for predicting histological infiltration of the external anal sphincter or the levator ani muscle, the sensitivity was 100%, the negative predictive value was 100%, the specificity was 87%, and the positive predictive value was 53%.
  • In a multivariate analysis, the histological clearance and tumor T stage were statistically correlated with disease-free survival (P = 0.035 and P = 0.05, respectively).
  • [MeSH-minor] Anal Canal / pathology. Humans. Multivariate Analysis. Neoadjuvant Therapy. Neoplasm Invasiveness. Neoplasm Staging. Prospective Studies. Sensitivity and Specificity. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17354183.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


24. Bean SM, Chhieng DC, Roberson J, Raper JL, Broker TR, Hoesley CJ, Eltoum IA, Jin G: Anal-rectal cytology: correlation with human papillomavirus status and biopsy diagnoses in a population of HIV-positive patients. J Low Genit Tract Dis; 2010 Apr;14(2):90-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal-rectal cytology: correlation with human papillomavirus status and biopsy diagnoses in a population of HIV-positive patients.
  • OBJECTIVES: We describe the cytological distribution of disease, correlate cytological diagnoses with human papillomavirus (HPV) DNA status and surgical biopsy diagnoses, determine if CD4 counts correlate with lesion severity, and compare anal-rectal data of HIV-infected patients (primarily men) with cervical data.
  • MATERIALS AND METHODS: A retrospective search of the computerized database identified 118 HIV-positive patients who had anal-rectal cytology.
  • Cytology results were compared with available follow-up data including repeat anal-rectal cytology tests, surgical biopsy, CD4 counts, and HPV DNA polymerase chain reaction-based genotyping.
  • RESULTS: Cytological diagnoses included 3% unsatisfactory for diagnosis, 41% negative for intraepithelial lesion or malignancy (NILM), 23% atypical squamous cells of undermined significance (ASC-US), 31% low-grade squamous intraepithelial lesion (LSIL), and 2% high-grade squamous intraepithelial lesion (HSIL) (ASC-US/squamous intraepithelial lesion, 0.7:1).
  • Two anal intraepithelial neoplasia (AIN) II, 10 AIN III, and 1 invasive squamous cell carcinoma were histologically detected (11%).
  • The majority of AIN II was preceded by LSIL, 54%; ASC-US, 15%; and HSIL, 8%.
  • CONCLUSIONS: Anal-rectal cytology is a useful screening test.
  • A high percentage of AIN II lesions were detected in this at-risk population, and the majority was detected following cytological abnormality.
  • [MeSH-major] Anal Canal / pathology. HIV Infections / complications. Papillomaviridae / isolation & purification. Papillomavirus Infections / epidemiology. Rectal Neoplasms / epidemiology. Rectum / pathology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20354415.001).
  • [ISSN] 1526-0976
  • [Journal-full-title] Journal of lower genital tract disease
  • [ISO-abbreviation] J Low Genit Tract Dis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA83679
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


25. Krajewska M, Kitada S, Winter JN, Variakojis D, Lichtenstein A, Zhai D, Cuddy M, Huang X, Luciano F, Baker CH, Kim H, Shin E, Kennedy S, Olson AH, Badzio A, Jassem J, Meinhold-Heerlein I, Duffy MJ, Schimmer AD, Tsao M, Brown E, Sawyers A, Andreeff M, Mercola D, Krajewski S, Reed JC: Bcl-B expression in human epithelial and nonepithelial malignancies. Clin Cancer Res; 2008 May 15;14(10):3011-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: We investigated Bcl-B expression in normal human tissues and several types of human epithelial and nonepithelial malignancy by immunohistochemistry, correlating results with tumor stage, histologic grade, and patient survival.
  • Bcl-B immunostaining was also present in normal germinal center centroblasts and centrocytes and in approximately half of diffuse large B-cell lymphoma (n = 48) specimens, whereas follicular lymphomas (n = 57) did not contain Bcl-B.
  • In breast (n = 119), prostate (n = 66), gastric (n = 180), and colorectal (n = 106) adenocarcinomas, as well as in non-small cell lung cancers (n = 82), tumor-specific overexpression of Bcl-B was observed.
  • Bcl-B expression was associated with variables of poor prognosis, such as high tumor grade in breast cancer (P = 0.009), microsatellite stability (P = 0.0002), and left-sided anatomic location (P = 0.02) of colorectal cancers, as well as with greater incidence of death from prostate cancer (P = 0.005) and shorter survival of patients with small cell lung cancer (P = 0.009).

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18483366.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / GM-60554; United States / NCI NIH HHS / CA / U19 CA113318; United States / NCI NIH HHS / CA / P01 CA081534; United States / NCI NIH HHS / CA / U01 CA114810; United States / NIGMS NIH HHS / GM / R01 GM060554; United States / NCI NIH HHS / CA / P30CA06055; United States / NCI NIH HHS / CA / CA-113318; United States / NCI NIH HHS / CA / CA-81534; United States / NCI NIH HHS / CA / CA114810
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL2-like 10 protein; 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2
  • [Other-IDs] NLM/ NIHMS620311; NLM/ PMC4171052
  •  go-up   go-down


26. Ye C, Shu XO, Wen W, Pierce L, Courtney R, Gao YT, Zheng W, Cai Q: Quantitative analysis of mitochondrial DNA 4977-bp deletion in sporadic breast cancer and benign breast diseases. Breast Cancer Res Treat; 2008 Apr;108(3):427-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative analysis of mitochondrial DNA 4977-bp deletion in sporadic breast cancer and benign breast diseases.
  • Only a few studies have evaluated DeltamtDNA(4977) mutation in breast cancer tissue, and the findings have been inconsistent, which may be due to methodological differences.
  • In this study, we developed a quantitative real-time PCR assay to assess the level of the DeltamtDNA(4977) mutation in tumor tissue samples from 55 primary breast cancer patients and 21 patients with benign breast disease (BBD).
  • The DeltamtDNA(4977) mutation levels were lower in tumor tissues than in adjacent normal tissues in both breast cancer and BBD subjects.
  • No significant difference between breast cancer and BBD patients was found in the DeltamtDNA(4977) mutation levels of tumor tissues and adjacent normal tissues.
  • The DeltamtDNA(4977) mutation levels were not significantly associated with clinicopathological characteristics (age, histology, tumor stage, and ER/PR status) in breast cancer or BBD patients.

  • Genetic Alliance. consumer health - Mitochondrial Disorders.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2000 Jan 1;28(1):352-5 [10592272.001]
  • [Cites] Ai Zheng. 2004 Nov;23(11):1297-301 [15522177.001]
  • [Cites] Int J Cancer. 2000 Jul 15;87(2):295-300 [10861490.001]
  • [Cites] J Pathol. 2000 Jul;191(3):274-81 [10878549.001]
  • [Cites] Anal Biochem. 2000 Aug 15;284(1):70-6 [10933858.001]
  • [Cites] Mutat Res. 2001 Jun 27;493(1-2):67-74 [11516716.001]
  • [Cites] Nucleic Acids Res. 2002 Jan 1;30(1):158-62 [11752280.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Clin Chim Acta. 2002 Apr;318(1-2):33-40 [11880110.001]
  • [Cites] Nucleic Acids Res. 2002 Jul 15;30(14):e68 [12136116.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):7031-41 [12460924.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):985-93 [14871829.001]
  • [Cites] Cancer Detect Prev. 2004;28(2):119-26 [15068836.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1011:154-67 [15126293.001]
  • [Cites] World J Gastroenterol. 2004 Jun 1;10(11):1560-4 [15162525.001]
  • [Cites] Carcinogenesis. 2005 Jan;26(1):145-52 [15375011.001]
  • [Cites] Genet Mol Res. 2004;3(3):395-409 [15614730.001]
  • [Cites] Cancer Biol Ther. 2004 Dec;3(12):1270-4 [15477759.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jun 24;332(1):43-9 [15896297.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Sep;44(1):19-28 [15892105.001]
  • [Cites] Int J Neuropsychopharmacol. 2005 Dec;8(4):515-22 [16202181.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jul;45(7):629-38 [16568452.001]
  • [Cites] BMC Cancer. 2006;6:93 [16620376.001]
  • [Cites] Br J Cancer. 2004 Jun 14;90(12):2390-6 [15150555.001]
  • [Cites] Anticancer Res. 2004 May-Jun;24(3a):1753-8 [15274351.001]
  • [Cites] Environ Mol Mutagen. 2004;44(4):313-20 [15476199.001]
  • [Cites] Nature. 1981 Apr 9;290(5806):457-65 [7219534.001]
  • [Cites] Cytogenet Cell Genet. 1995;71(1):99-103 [7606938.001]
  • [Cites] Eur J Biochem. 1998 Oct 1;257(1):192-201 [9799119.001]
  • [Cites] Mutat Res. 1999 Mar 8;424(1-2):107-15 [10064854.001]
  • [Cites] Nat Genet. 1999 Oct;23(2):147 [10508508.001]
  • [Cites] Br J Haematol. 1999 Dec;107(4):861-9 [10606895.001]
  • (PMID = 17541740.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA064277; United States / NCI NIH HHS / CA / R01 CA 064277
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Mitochondrial
  • [Other-IDs] NLM/ NIHMS526435; NLM/ PMC3836503
  •  go-up   go-down


27. Best S, Sawers Y, Fu VX, Almassi N, Huang W, Jarrard DF: Integrity of prostatic tissue for molecular analysis after robotic-assisted laparoscopic and open prostatectomy. Urology; 2007 Aug;70(2):328-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: The warm ischemia time of tissue before fixation for pathologic analysis has been linked to changes in cell morphology and nucleic acid and protein integrity.
  • Tissue integrity was suitable for the assessment of pathologic grade and stage for all samples.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Biospecimen Research Database. Biospecimen Research Database .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Lett. 2002 Nov 28;185(2):191-9 [12169393.001]
  • [Cites] Urology. 2002 Oct;60(4):569-72 [12385908.001]
  • [Cites] Am J Clin Pathol. 2002 Nov;118(5):733-41 [12428794.001]
  • [Cites] Nephron Exp Nephrol. 2003;95(4):e144-51 [14694268.001]
  • [Cites] Anal Biochem. 2004 May 15;328(2):101-8 [15113684.001]
  • [Cites] Exp Mol Pathol. 2004 Oct;77(2):98-103 [15351232.001]
  • [Cites] Mod Pathol. 1993 Mar;6(2):201-7 [8483892.001]
  • [Cites] Mod Pathol. 1998 Mar;11(3):276-81 [9521475.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):2957-64 [10383161.001]
  • [Cites] Nucleic Acids Res. 2005;33(6):e56 [15800207.001]
  • [Cites] Int J Mol Med. 2005 Dec;16(6):979-85 [16273275.001]
  • [Cites] Mol Aspects Med. 2006 Apr-Jun;27(2-3):126-39 [16469371.001]
  • [Cites] Mod Pathol. 2001 Feb;14(2):116-28 [11235903.001]
  • (PMID = 17826499.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / P50 DK065303; United States / NCI NIH HHS / CA / R01 CA097131; United States / NCI NIH HHS / CA / R01 CA097131-05; United States / NIDDK NIH HHS / DK / P50 DK065303-010003; United States / NIDDK NIH HHS / DK / 1P50DK065303; United States / NCI NIH HHS / CA / CA097131-05; United States / NIDDK NIH HHS / DK / DK065303-010003; United States / NCI NIH HHS / CA / R01CA97131
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS30002; NLM/ PMC2693382
  •  go-up   go-down


28. Larsen SG, Wiig JN, Dueland S, Giercksky KE: Prognostic factors after preoperative irradiation and surgery for locally advanced rectal cancer. Eur J Surg Oncol; 2008 Apr;34(4):410-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors after preoperative irradiation and surgery for locally advanced rectal cancer.
  • AIMS: The experience of preoperative irradiation in clinically locally advanced rectal cancer for the period 1991-2003 is reported.
  • METHODS: A prospective cohort study of 204 M0 patients given >45 Gy preoperatively (median age 66 years; 29% women; tumour level <16 cm from the anal verge).
  • R-stage, N-stage, age, type of rectal resection and pelvic wall resection remained significant in Cox multivariate analysis for survival.
  • Regarding local recurrence, the following parameters were independent: N-stage, carcinoembryonic antigen (CEA) response and pelvic wall resection.
  • CONCLUSIONS: After preoperative irradiation and surgery, about 50% of the patients with locally advanced rectal cancer without overt metastases (M0) can be cured.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17614249.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


29. Randall LM, Monk BJ, Darcy KM, Tian C, Burger RA, Liao SY, Peters WA, Stock RJ, Fruehauf JP: Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study. Gynecol Oncol; 2009 Mar;112(3):583-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study.
  • OBJECTIVES: To determine whether markers of tumor angiogenesis were associated with progression-free survival (PFS) and overall survival (OS) in women with high-risk, early-stage cervical cancer treated on a phase III trial.
  • METHODS: One hundred seventy-three tumor specimens were analyzed by semi-quantitative immunohistochemical (IHC) staining for vascular endothelial growth factor (VEGF, pro-angiogenesis factor), thrombospondin-1 (TSP-1, anti-angiogenesis factor), CD31 (non-specific endothelial marker), and CD105 (tumor-specific endothelial marker).
  • CONCLUSIONS: Tumor angiogenesis measured by CD31 MVD is an independent prognostic factor for both PFS and OS in high-risk, early-stage cervical cancer.

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 1999 Sep-Oct;19(5C):4375-8 [10650779.001]
  • [Cites] J Clin Oncol. 2009 Mar 1;27(7):1069-74 [19139430.001]
  • [Cites] Anticancer Res. 2000 Mar-Apr;20(2B):1317-22 [10810442.001]
  • [Cites] Obstet Gynecol. 2000 Aug;96(2):224-8 [10908767.001]
  • [Cites] Oncogene. 2000 Sep 21;19(40):4611-20 [11030150.001]
  • [Cites] Clin Cancer Res. 2001 Jan;7(1):81-8 [11205922.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2907-10 [11306466.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2826-31 [11555600.001]
  • [Cites] Lung Cancer. 2002 May;36(2):143-50 [11955648.001]
  • [Cites] Gynecol Oncol. 2002 Jun;85(3):469-75 [12051876.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):768-79 [12377329.001]
  • [Cites] J Cell Sci. 2003 Jul 1;116(Pt 13):2677-85 [12746487.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):922-8 [12829126.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4145-50 [14519638.001]
  • [Cites] Anal Quant Cytol Histol. 2003 Dec;25(6):303-11 [14714296.001]
  • [Cites] Cancer J. 2004 Jan-Feb;10(1):27-32 [15000492.001]
  • [Cites] Oncogene. 2004 Apr 15;23(17):2988-95 [14968115.001]
  • [Cites] Gynecol Oncol. 1990 Sep;38(3):352-7 [2227547.001]
  • [Cites] J Biol Chem. 1992 Sep 25;267(27):19027-30 [1326540.001]
  • [Cites] Science. 1994 Sep 9;265(5178):1582-4 [7521539.001]
  • [Cites] Anticancer Res. 1995 Jul-Aug;15(4):1549-51 [7544572.001]
  • [Cites] Am J Obstet Gynecol. 1996 Jan;174(1 Pt 1):126-31 [8571995.001]
  • [Cites] Int J Gynecol Pathol. 1995 Apr;14(2):114-8 [8601522.001]
  • [Cites] J Natl Cancer Inst. 1996 Oct 2;88(19):1361-8 [8827013.001]
  • [Cites] Gynecol Oncol. 1997 Oct;67(1):27-33 [9345352.001]
  • [Cites] Br J Cancer. 1997;76(11):1410-5 [9400935.001]
  • [Cites] Am J Obstet Gynecol. 1998 Feb;178(2):314-9 [9500492.001]
  • [Cites] Clin Cancer Res. 1998 Nov;4(11):2795-800 [9829744.001]
  • [Cites] Eur J Cancer. 1999 Mar;35(3):485-9 [10448304.001]
  • [Cites] Br J Cancer. 1999 Sep;81(2):354-8 [10496365.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8405-12 [15623619.001]
  • [Cites] Oral Oncol. 2005 Feb;41(2):147-55 [15695116.001]
  • [Cites] Gynecol Oncol. 2005 Mar;96(3):721-8 [15721417.001]
  • [Cites] Int J Clin Oncol. 2005 Feb;10(1):35-9 [15729599.001]
  • [Cites] Gynecol Oncol. 2005 Oct;99(1):80-3 [16009408.001]
  • [Cites] Microvasc Res. 2007 Sep-Nov;74(2-3):72-84 [17560615.001]
  • [Cites] Gynecol Oncol. 2008 Jan;108(1):112-20 [17936343.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1606-13 [10764420.001]
  • (PMID = 19110305.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K23 CA087558-06; United States / NCI NIH HHS / CA / CA037517-19; United States / NCI NIH HHS / CA / CA087558-06; United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / U10 CA027469; United States / NCI NIH HHS / CA / K23 CA 087558; United States / NCI NIH HHS / CA / CA027469-23; United States / NCI NIH HHS / CA / CA087558-05; United States / NCI NIH HHS / CA / U10 CA037517; United States / NCI NIH HHS / CA / U10 CA027469-23; United States / NCI NIH HHS / CA / CA 37517; United States / NCI NIH HHS / CA / P30 CA062203; United States / NCI NIH HHS / CA / K23 CA087558; United States / NCI NIH HHS / CA / K23 CA087558-05; United States / NCI NIH HHS / CA / U10 CA037517-19
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD31; 0 / Biomarkers, Tumor; 0 / ENG protein, human; 0 / Receptors, Cell Surface; 0 / Thrombospondin 1; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ NIHMS192713; NLM/ PMC2858218
  •  go-up   go-down


30. Bollito E, Terrone C, Volpe A, Porpiglia F, Cracco C, Poggio M, Grande S, Righi L, Bellina M, Papotti M, Scarpa RM: Changes in prostate cancer at radical prostatectomy during the prostate specific antigen era: an Italian experience. Anal Quant Cytol Histol; 2008 Jun;30(3):152-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in prostate cancer at radical prostatectomy during the prostate specific antigen era: an Italian experience.
  • OBJECTIVE: To assess changes in prostate cancer clinical and pathologic features by review of 15 years' experience with radical prostatectomy.
  • All had clinically localized prostate cancer.
  • RESULTS: Median prostate specific antigen (PSA) values at diagnosis significantly decreased over time.
  • Definite stage migration was observed, with significant increase of organ-confined tumors.
  • PSA value has progressively lost correlation with prostate cancer volume and today correlates only with prostate gland volume.
  • CONCLUSION: Prostate cancer stage and volume at diagnosis have steadily decreased in the last 15 years, likely reflecting increasing use of PSA testing.
  • In early prostate cancer, PSA level no longer correlates with tumor volume.


31. Ahmed HG, Babiker AE: Assessment of cytological atypia, AgNOR and nuclear area in epithelial cells of normal oral mucosa exposed to toombak and smoking. Rare Tumors; 2009;1(1):e18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Smears were collected from normal-appearing mouth floor mucosa and tongue of 75 toombak dippers, 75 smokers and 50 non-tobacco users between the ages of 20 and 70 with a mean age of 36 years.
  • AgNORs were counted in the first 50 well-fixed, nucleated squamous cells and nuclear areas were calculated via microscopic stage micrometer.
  • Cytological atypia was ascertained in 6 tobacco users and could not be ascertained in non-tobacco users.
  • Statistically mean AgNOR numbers per nucleus in the non-tobacco users (2.45±0.30) was lower than the toombak dippers (3.081±0.39, p<0.004), and the smokers (2.715±0.39, p<0.02), and mean nuclear areas of epithelial cells of toombak dippers (6.081±0.39, p<0.009) and smokers (5.68±10.08, p<0.01) was also significantly higher than non-smokers (5.39±9.4).
  • The mean number of nuclei having more than 3 AgNORs was 28%, 19% and 7% in toombak dippers, smokers and non-tobacco users, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21139889.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2994448
  • [Keywords] NOTNLM ; AgNOR / nuclear area. / oral mucosa / smoking / toombak
  •  go-up   go-down


32. Vuong T, Kopek N, Ducruet T, Portelance L, Faria S, Bahoric B, Devic S: Conformal therapy improves the therapeutic index of patients with anal canal cancer treated with combined chemotherapy and external beam radiotherapy. Int J Radiat Oncol Biol Phys; 2007 Apr 1;67(5):1394-400
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conformal therapy improves the therapeutic index of patients with anal canal cancer treated with combined chemotherapy and external beam radiotherapy.
  • PURPOSE: To evaluate the clinical outcomes of three-dimensional conformal radiotherapy (3D-CRT) in patients with anal canal cancer, in terms of local control (LC), freedom from relapse (FFR), and overall survival (OS) rates, and to estimate long-term toxicity data.
  • Chemotherapy consisted of 5-fluorouracil with either mitomycin-C or cis-platinum given concurrently with radiation.
  • RESULTS: No differences in stage and age distribution were observed between the two groups.
  • CONCLUSION: The use of 3D-CRT allows patients with anal canal cancer to complete radiation and chemotherapy without interruption for toxicity, with significant improvements in LC, FFR, and OS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Radiotherapy, Conformal

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17276620.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


33. Chang JE, Voorhees PM, Kolesar JM, Ahuja HG, Sanchez FA, Rodriguez GA, Kim K, Werndli J, Bailey HH, Kahl BS: Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study. Hematol Oncol; 2009 Mar;27(1):11-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cell death from As(2)O(3) may be the result of oxidative stress.
  • The median age was 71, and the majority of enrolled patients had non-Hodgkin's lymphoma (12/17).
  • Sixteen patients were evaluable, and one patient with mantle cell lymphoma achieved an unconfirmed complete response after five cycles of therapy for an overall response rate of 6%.
  • The trial, which had been designed as a two-stage study, was closed after the first stage analysis due to lack of activity.
  • Haematologic toxicities were the most commonly reported events in this heavily pre-treated population, and comprised the majority of grade 3 and 4 toxicities.

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Vitamin C.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 John Wiley & Sons, Ltd.
  • [Cites] N Engl J Med. 1998 Nov 5;339(19):1341-8 [9801394.001]
  • [Cites] Leukemia. 1998 Sep;12(9):1383-91 [9737686.001]
  • [Cites] J Natl Cancer Inst. 1999 May 5;91(9):772-8 [10328107.001]
  • [Cites] Blood. 1999 Sep 15;94(6):2102-11 [10477740.001]
  • [Cites] Leuk Lymphoma. 2004 Dec;45(12):2387-401 [15621751.001]
  • [Cites] Cancer. 2005 Oct 15;104(8):1687-92 [16130126.001]
  • [Cites] Leuk Lymphoma. 2006 Mar;47(3):521-9 [16396776.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2627-32 [16352810.001]
  • [Cites] Med Oncol. 2006;23(2):263-72 [16720927.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2465-71 [16651646.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2456-64 [16651647.001]
  • [Cites] Cancer. 2006 Jun 15;106(12):2624-9 [16688776.001]
  • [Cites] Haematologica. 2006 Aug;91(8):1105-8 [16870552.001]
  • [Cites] Br J Haematol. 2006 Oct;135(2):174-83 [17010047.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3315-24 [10552940.001]
  • [Cites] Br J Cancer. 1999 Nov;81(5):796-9 [10555748.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Blood. 2000 Feb 1;95(3):1014-22 [10648417.001]
  • [Cites] Br J Haematol. 2001 Mar;112(3):783-6 [11260084.001]
  • [Cites] Oncologist. 2001;6 Suppl 2:17-21 [11331436.001]
  • [Cites] Oncologist. 2001;6 Suppl 2:22-8 [11331437.001]
  • [Cites] Blood. 2001 Aug 1;98(3):805-13 [11468182.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1835-7 [12200700.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3658-68 [12473574.001]
  • [Cites] Leukemia. 2003 Jan;17(1):271-2 [12529694.001]
  • [Cites] Hum Exp Toxicol. 2002 Dec;21(12):675-80 [12540038.001]
  • [Cites] Cancer. 2003 May 1;97(9):2218-24 [12712474.001]
  • [Cites] Blood. 2003 Aug 1;102(3):1028-34 [12676792.001]
  • [Cites] J Nutr Biochem. 2003 Jul;14(7):416-20 [12915223.001]
  • [Cites] Br J Haematol. 2004 May;125(4):470-6 [15142117.001]
  • [Cites] Anal Biochem. 1969 Mar;27(3):502-22 [4388022.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] J Clin Oncol. 1994 Jan;12(1):194-205 [8270977.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7 Suppl):1969s-1975s [8137322.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Blood. 1996 Aug 1;88(3):1052-61 [8704214.001]
  • [Cites] Blood. 1997 May 1;89(9):3345-53 [9129041.001]
  • [Cites] Blood. 1997 May 1;89(9):3354-60 [9129042.001]
  • [Cites] Blood. 1997 Jul 15;90(2):562-70 [9226155.001]
  • [Cites] J Natl Cancer Inst. 1997 Dec 3;89(23):1789-96 [9392620.001]
  • [Cites] Br J Haematol. 1998 Sep;102(4):1055-60 [9734658.001]
  • [Cites] Blood. 1999 Jan 1;93(1):268-77 [9864170.001]
  • (PMID = 18668698.001).
  • [ISSN] 1099-1069
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K12 CA087718-09; United States / NCI NIH HHS / CA / CA087718-08; United States / NCI NIH HHS / CA / K12 CA087718-07; United States / NCI NIH HHS / CA / K12 CA087718; United States / NCI NIH HHS / CA / CA087718-09; United States / NCI NIH HHS / CA / CA087718-10; United States / NCI NIH HHS / CA / K12 CA087718-10; United States / NCI NIH HHS / CA / K12 CA087718-08
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Oxides; GAN16C9B8O / Glutathione; PQ6CK8PD0R / Ascorbic Acid; S7V92P67HO / arsenic trioxide
  • [Other-IDs] NLM/ NIHMS212975; NLM/ PMC2897137
  •  go-up   go-down


34. Urquhart BL, Freeman DJ, Cutler MJ, Mainra R, Spence JD, House AA: Mesna for treatment of hyperhomocysteinemia in hemodialysis patients: a placebo-controlled, double-blind, randomized trial. Clin J Am Soc Nephrol; 2008 Jul;3(4):1041-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • More than 90% of patients with end-stage renal disease have hyperhomocysteinemia despite vitamin supplementation.
  • DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Patients with end-stage renal disease were randomly assigned to receive either intravenous mesna 5 mg/kg or placebo thrice weekly before dialysis.

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1995 Nov 25;346(8987):1395-8 [7475822.001]
  • [Cites] J Pharm Sci. 2006 Aug;95(8):1742-50 [16795014.001]
  • [Cites] Metabolism. 2000 Feb;49(2):215-9 [10690947.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1314-21 [10778956.001]
  • [Cites] Circulation. 2000 Jun 20;101(24):2829-32 [10859289.001]
  • [Cites] Nephrol Dial Transplant. 2000 Jul;15(7):1029-34 [10862642.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2000 Jul;20(7):1704-6 [10894806.001]
  • [Cites] Clin Invest Med. 2001 Feb;24(1):5-11 [11266032.001]
  • [Cites] J Biol Chem. 2001 Aug 10;276(32):30111-7 [11371573.001]
  • [Cites] J Am Soc Nephrol. 2002 Jan;13(1):265-8 [11752047.001]
  • [Cites] Kidney Int. 2002 Feb;61(2):609-14 [11849403.001]
  • [Cites] Nephrol Dial Transplant. 2002 May;17(5):865-70 [11981075.001]
  • [Cites] Am J Kidney Dis. 2007 Jan;49(1):109-17 [17185151.001]
  • [Cites] Lancet. 2007 Jan 20;369(9557):208-16 [17240287.001]
  • [Cites] Lancet. 2007 Jun 2;369(9576):1876-82 [17544768.001]
  • [Cites] JAMA. 2007 Sep 12;298(10):1163-70 [17848650.001]
  • [Cites] Metabolism. 2002 Jul;51(7):881-6 [12077735.001]
  • [Cites] JAMA. 2002 Oct 23-30;288(16):2015-22 [12387654.001]
  • [Cites] J Nephrol. 2002 Nov-Dec;15(6):671-5 [12495282.001]
  • [Cites] Am J Kidney Dis. 2003 Feb;41(2):442-6 [12552508.001]
  • [Cites] Arch Intern Med. 2003 Sep 8;163(16):1933-7 [12963566.001]
  • [Cites] Nephrol Dial Transplant. 2003 Dec;18(12):2596-600 [14605283.001]
  • [Cites] J Clin Pharmacol. 2003 Dec;43(12):1324-8 [14615468.001]
  • [Cites] Circulation. 2004 Jan 27;109(3):369-74 [14732754.001]
  • [Cites] J Am Soc Nephrol. 2004 Feb;15(2):420-6 [14747389.001]
  • [Cites] JAMA. 2004 Feb 4;291(5):565-75 [14762035.001]
  • [Cites] Clin Invest Med. 2004 Feb;27(1):10-3 [15061579.001]
  • [Cites] Eur J Cardiovasc Prev Rehabil. 2004 Jun;11(3):250-3 [15179109.001]
  • [Cites] Am J Kidney Dis. 2004 Oct;44(4):689-94 [15384020.001]
  • [Cites] Anal Biochem. 1992 Feb 1;200(2):218-29 [1632485.001]
  • [Cites] J Am Soc Nephrol. 1992 Jul;3(1):1-11 [1391700.001]
  • [Cites] Br J Cancer. 1993 Sep;68(3):590-3 [8353049.001]
  • [Cites] Clin Chem. 1994 Jun;40(6):873-81 [8087981.001]
  • [Cites] J Nutr. 1994 Oct;124(10):1927-33 [7931701.001]
  • [Cites] Cancer Chemother Pharmacol. 1994;35(2):132-6 [7987989.001]
  • [Cites] Atherosclerosis. 1995 Feb;113(1):129-32 [7755649.001]
  • [Cites] Atherosclerosis. 1995 Apr 7;114(1):93-103 [7605381.001]
  • [Cites] Adv Ren Replace Ther. 1995 Oct;2(4):295-304 [8591121.001]
  • [Cites] Kidney Int. 1996 Jan;49(1):147-52 [8770960.001]
  • [Cites] J Am Soc Nephrol. 1996 Nov;7(11):2414-8 [8959634.001]
  • [Cites] Kidney Int. 1997 Jul;52(1):10-20 [9211341.001]
  • [Cites] Circulation. 1998 Jan 20;97(2):138-41 [9445164.001]
  • [Cites] ASAIO J. 1999 Jan-Feb;45(1):94-7 [9952016.001]
  • [Cites] J Am Soc Nephrol. 1999 May;10(5):1095-9 [10232697.001]
  • [Cites] Am J Nephrol. 1999;19(3):405-10 [10393379.001]
  • [Cites] Clin Chem. 2005 Jan;51(1):196-201 [15528294.001]
  • [Cites] Am J Kidney Dis. 2005 Apr;45(4):702-7 [15806473.001]
  • [Cites] Stroke. 2005 Nov;36(11):2404-9 [16239629.001]
  • [Cites] N Engl J Med. 2006 Apr 13;354(15):1567-77 [16531613.001]
  • [Cites] N Engl J Med. 2006 Apr 13;354(15):1578-88 [16531614.001]
  • [Cites] N Engl J Med. 2006 Apr 13;354(15):1629-32 [16531615.001]
  • [Cites] Atherosclerosis. 1999 Dec;147(2):379-86 [10559524.001]
  • (PMID = 18337551.001).
  • [ISSN] 1555-905X
  • [Journal-full-title] Clinical journal of the American Society of Nephrology : CJASN
  • [ISO-abbreviation] Clin J Am Soc Nephrol
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0LVT1QZ0BA / Homocysteine; NR7O1405Q9 / Mesna
  • [Other-IDs] NLM/ PMC2440266
  •  go-up   go-down


35. Silberfein EJ, Kattepogu KM, Hu CY, Skibber JM, Rodriguez-Bigas MA, Feig B, Das P, Krishnan S, Crane C, Kopetz S, Eng C, Chang GJ: Long-term survival and recurrence outcomes following surgery for distal rectal cancer. Ann Surg Oncol; 2010 Nov;17(11):2863-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival and recurrence outcomes following surgery for distal rectal cancer.
  • BACKGROUND: Treatment of distal rectal cancer remains clinically challenging and includes proctectomy and coloanal anastomosis (CAA) or abdominoperineal resection (APR).
  • The purpose of this study is to evaluate operative and pathologic factors associated with long-term survival and local recurrence outcomes in patients treated for distal rectal cancer.
  • METHODS: A retrospective consecutive cohort study of 304 patients treated for distal rectal cancer with radical resection from 1993 to 2003 was performed.
  • RESULTS: The median tumor distance from the anal verge was 2 cm [interquartile range (IQR) 0.5-4 cm].
  • The 5-year overall survival rate was 82% (88.6% stage pI, 80.5% stage pII, 67.9% stage pIII).
  • Older age, advanced pathologic stage, presence of lymphovascular or perineural invasion, earlier treatment period, and APR surgery type were associated with worse survival on multivariate analysis.
  • CONCLUSIONS: Low rates of local recurrence and good overall survival can be achieved after treatment of distal rectal cancer with stage-appropriate chemoradiation and proctectomy with CAA or APR.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2001 Mar;8(2):163-9 [11258782.001]
  • [Cites] Cancer. 2009 Dec 1;115(23):5432-40 [19673001.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):350-7 [11859207.001]
  • [Cites] Br J Surg. 2002 Mar;89(3):327-34 [11872058.001]
  • [Cites] Ann Surg Oncol. 2003 Jan-Feb;10(1):80-5 [12513965.001]
  • [Cites] Dis Colon Rectum. 2004 Jan;47(1):48-58 [14719151.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] Br J Surg. 1982 Oct;69(10):613-6 [6751457.001]
  • [Cites] Br J Surg. 1983 Mar;70(3):150-4 [6831156.001]
  • [Cites] Ann Surg. 1983 Aug;198(2):159-63 [6870373.001]
  • [Cites] Lancet. 1986 Jun 28;1(8496):1479-82 [2425199.001]
  • [Cites] Ann Surg. 1986 Oct;204(4):480-9 [3532972.001]
  • [Cites] Lancet. 1986 Nov 1;2(8514):996-9 [2430152.001]
  • [Cites] JAMA. 1990 Sep 19;264(11):1444-50 [2202842.001]
  • [Cites] Dis Colon Rectum. 1994 Jul;37(7):651-9 [8026230.001]
  • [Cites] Br J Surg. 1994 Sep;81(9):1376-8 [7953423.001]
  • [Cites] Br J Surg. 1995 Aug;82(8):1031-3 [7648142.001]
  • [Cites] Dis Colon Rectum. 1997 Jan;40(1):25-9 [9102256.001]
  • [Cites] Dis Colon Rectum. 1997 Jul;40(7):747-51 [9221846.001]
  • [Cites] Br J Surg. 2004 Nov;91(11):1493-9 [15455362.001]
  • [Cites] Surg Gynecol Obstet. 1954 Oct;99(4):421-30 [13205412.001]
  • [Cites] Ann Surg. 2005 Mar;241(3):465-9 [15729069.001]
  • [Cites] Ann Surg. 2005 May;241(5):829-36; discussion 836-8 [15849519.001]
  • [Cites] Dis Colon Rectum. 2005 Mar;48(3):411-23 [15875292.001]
  • [Cites] Dis Colon Rectum. 2006 Jan;49(1):41-9 [16283562.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9257-64 [16361623.001]
  • [Cites] Am J Clin Oncol. 2006 Jun;29(3):219-24 [16755173.001]
  • [Cites] Colorectal Dis. 2006 Nov;8(9):800-7 [17032329.001]
  • [Cites] Dis Colon Rectum. 2006 Nov;49(11):1663-72 [17041749.001]
  • [Cites] Cancer. 2007 May 1;109(9):1750-5 [17387743.001]
  • [Cites] Dis Colon Rectum. 2007 Nov;50(11):1860-6 [17899273.001]
  • [Cites] Cancer. 2008 Jul 1;113(1):57-64 [18442099.001]
  • [Cites] Ann Surg Oncol. 2008 Oct;15(10):2668-76 [18618181.001]
  • [Cites] Ann Surg Oncol. 2008 Nov;15(11):3124-31 [18766404.001]
  • [Cites] Colorectal Dis. 2008 Nov;10(9):879-86 [19037929.001]
  • [Cites] Ann Surg. 2009 Feb;249(2):236-42 [19212176.001]
  • [Cites] Lancet. 2009 Mar 7;373(9666):821-8 [19269520.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):583-96 [11309435.001]
  • (PMID = 20552409.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / K07-CA133187; United States / NCI NIH HHS / CA / K07 CA133187; United States / NHLBI NIH HHS / HL / HL004137-06; United States / NHLBI NIH HHS / HL / K30 HL004137-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS279629; NLM/ PMC3071558
  •  go-up   go-down


36. Tsao KC, Wu TL, Chang PY, Hong JH, Wu JT: Detection of carcinomas in an asymptomatic Chinese population: advantage of screening with multiple tumor markers. J Clin Lab Anal; 2006;20(2):42-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 73,443 asymptomatic individuals were screened on a voluntary basis for cancer at Chang Gung Memorial Hospital in Taiwan using a panel of tumor markers, including alpha fetoprotein (AFP), CA 125, CA 15-3, CA 19-9, carcinoembryonic antigen (CEA), prostate specific antigen (PSA), chromogranin A (CgA), and squamous cell specific antigen (SCC).
  • Of the tumor markers monitored, elevated CA 19-9, CEA, and CA 125 were the most frequently detected in a variety of cancers.
  • Screening with multiple circulating tumor markers provides improved sensitivity for cancer detection in asymptomatic individuals before they reach the fatal advanced stage.
  • [MeSH-major] Asian Continental Ancestry Group. Biomarkers, Tumor / analysis. Carcinoma / diagnosis. Mass Screening / methods
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. CA-19-9 Antigen / analysis. Cohort Studies. Female. Humans. Male. Middle Aged. Sensitivity and Specificity. Sex Distribution. Taiwan / epidemiology


37. Koutros S, Mahajan R, Zheng T, Hoppin JA, Ma X, Lynch CF, Blair A, Alavanja MC: Dichlorvos exposure and human cancer risk: results from the Agricultural Health Study. Cancer Causes Control; 2008 Feb;19(1):59-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dichlorvos exposure and human cancer risk: results from the Agricultural Health Study.
  • OBJECTIVES: We evaluated cancer risk from DDVP (2,2-Dichloroethenyl dimethylphosphate) exposure among pesticide applicators enrolled in the Agricultural Health Study (AHS) cohort.
  • METHODS: The AHS is a cohort of 57,311 pesticide applicators in North Carolina and Iowa, enrolled from 1993 to 1997 and followed for cancer through 2004.
  • Poisson regression analysis was used to calculate rate ratios (RR) and 95% confidence intervals (CI) to evaluate the association of DDVP exposure among 2,943 incident cases of cancer.
  • RESULTS: DDVP exposure was not associated with any cancer studied here.
  • We observed no elevation in risk among lymphohematopoietic cancers, RR = 1.00 (95% CI 0.51, 1.96) and a small excess risk associated with exposure among those with a family history of prostate cancer (RR = 1.18 (95% CI 0.73, 1.82).
  • CONCLUSION: We find little evidence of an association between cumulative lifetime use of DDVP and risk of any cancer at this stage of follow up of the AHS.

  • MedlinePlus Health Information. consumer health - Farm Health and Safety.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DICHLORVOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Epidemiology. 2002 Jan;13(1):94-9 [11805592.001]
  • [Cites] Environ Health Perspect. 2006 Dec;114(12):1838-42 [17185272.001]
  • [Cites] J Expo Anal Environ Epidemiol. 2002 Sep;12(5):313-8 [12198579.001]
  • [Cites] Bull Exp Biol Med. 2002 Jun;133(6):594-6 [12447476.001]
  • [Cites] J Occup Environ Med. 2003 Mar;45(3):249-58 [12661182.001]
  • [Cites] Am J Epidemiol. 2003 May 1;157(9):800-14 [12727674.001]
  • [Cites] Occup Environ Med. 2003 Sep;60(9):E11 [12937207.001]
  • [Cites] Environ Health Perspect. 2004 Apr;112(5):631-5 [15064173.001]
  • [Cites] Toxicology. 2004 Nov 1;204(1):41-50 [15369847.001]
  • [Cites] Lancet. 1981 Aug 8;2(8241):300-1 [6114336.001]
  • [Cites] Cancer Res. 1990 Oct 15;50(20):6585-91 [2208120.001]
  • [Cites] Ecotoxicol Environ Saf. 1991 Aug;22(1):79-87 [1914997.001]
  • [Cites] Cancer Res. 1992 May 1;52(9):2447-55 [1568215.001]
  • [Cites] Arch Environ Contam Toxicol. 1992 Apr;22(3):260-6 [1616309.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1991;53:5-586 [1688189.001]
  • [Cites] Toxicology. 1996 Apr 15;108(1-2):49-56 [8644117.001]
  • [Cites] Environ Health Perspect. 1996 Apr;104(4):362-9 [8732939.001]
  • [Cites] Adv Ther. 2005 Mar-Apr;22(2):107-16 [16020401.001]
  • [Cites] Regul Toxicol Pharmacol. 2006 Apr;44(3):238-48 [16439043.001]
  • [Cites] Ann Occup Hyg. 2002 Mar;46(2):245-60 [12074034.001]
  • (PMID = 17943454.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / TU2 CA105666; United States / Intramural NIH HHS / / Z01 ES049030-11; United States / NCI NIH HHS / CA / TU2 CA 105666
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Insecticides; 7U370BPS14 / Dichlorvos
  • [Other-IDs] NLM/ NIHMS44535; NLM/ PMC2822646
  •  go-up   go-down


38. Wolff MS, Teitelbaum SL, Pinney SM, Windham G, Liao L, Biro F, Kushi LH, Erdmann C, Hiatt RA, Rybak ME, Calafat AM, Breast Cancer and Environment Research Centers: Investigation of relationships between urinary biomarkers of phytoestrogens, phthalates, and phenols and pubertal stages in girls. Environ Health Perspect; 2010 Jul;118(7):1039-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We measured urinary exposure biomarkers at visit 1 and examined associations with breast and pubic hair development (present or absent, assessed 1 year later) using multivariate adjusted prevalence ratios (PR) and 95% confidence intervals (CIs).
  • High-molecular-weight phthalate (high MWP) metabolites were weakly associated with pubic hair development [adjusted PR, 0.94 (95% CI, 0.88-1.00), fifth vs. first quintile].
  • Small inverse associations were seen for daidzein with breast stage and for triclosan and high MWP with pubic hair stage; a positive trend was observed for low-molecular-weight phthalate biomarkers with breast and pubic hair development.
  • In the first enterolactone quintile, for the association of high BMI with any development, the PR was 1.34 (95% CI, 1.23-1.45 vs. low BMI).

  • MedlinePlus Health Information. consumer health - Puberty.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. PHTHALIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Data. 2000 Jun 8;(314):1-27 [11183293.001]
  • [Cites] Pediatrics. 2010 Sep;126(3):e583-90 [20696727.001]
  • [Cites] J Steroid Biochem Mol Biol. 2002 Dec;83(1-5):113-8 [12650707.001]
  • [Cites] N Engl J Med. 2003 Apr 17;348(16):1527-36 [12700372.001]
  • [Cites] Environ Health Perspect. 2003 May;111(5):737-41 [12727603.001]
  • [Cites] Am J Epidemiol. 2004 Apr 1;159(7):702-6 [15033648.001]
  • [Cites] Clin Chem. 2004 May;50(5):924-32 [15105350.001]
  • [Cites] Environ Health Perspect. 2004 May;112(6):751-3 [15121520.001]
  • [Cites] Tijdschr Kindergeneeskd. 1985 Aug;53(4):147-52 [4082170.001]
  • [Cites] Am J Epidemiol. 1993 Jan 1;137(1):1-8 [8434568.001]
  • [Cites] Cancer Causes Control. 1995 Nov;6(6):567-73 [8580306.001]
  • [Cites] Epidemiology. 1999 Jan;10(1):37-48 [9888278.001]
  • [Cites] Anal Chem. 2005 May 1;77(9):2985-91 [15859620.001]
  • [Cites] Anal Chem. 2005 Aug 15;77(16):5407-13 [16097788.001]
  • [Cites] J Pharm Biomed Anal. 2006 Mar 3;40(4):928-42 [16182503.001]
  • [Cites] Mol Cell Endocrinol. 2006 Jul 25;254-255:187-201 [16720078.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Nov 21;844(1):53-9 [16893688.001]
  • [Cites] Environ Health Perspect. 2007 Jan;115(1):116-21 [17366830.001]
  • [Cites] Environ Health Perspect. 2007 Oct;115(10):1467-73 [17938737.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jan 1;861(1):145-50 [18068558.001]
  • [Cites] Basic Clin Pharmacol Toxicol. 2008 Feb;102(2):168-75 [18226071.001]
  • [Cites] Environ Res. 2008 Feb;106(2):257-69 [17976571.001]
  • [Cites] Pediatrics. 2008 Feb;121 Suppl 3:S208-17 [18245513.001]
  • [Cites] Environ Health Perspect. 2008 Apr;116(4):467-73 [18414628.001]
  • [Cites] Environ Res. 2008 Jul;107(3):393-400 [18479682.001]
  • [Cites] Curr Opin Endocrinol Diabetes Obes. 2009 Feb;16(1):25-30 [19115521.001]
  • [Cites] J Pediatr Endocrinol Metab. 2009 Jan;22(1):69-77 [19344077.001]
  • [Cites] Toxicol Lett. 2009 Dec 1;191(1):9-14 [19643168.001]
  • [Cites] Environ Health Perspect. 2000 Aug;108(8):723-9 [10964792.001]
  • (PMID = 20308033.001).
  • [ISSN] 1552-9924
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / ES/CA012770; United States / NIEHS NIH HHS / ES / U01 ES012800; United States / NIEHS NIH HHS / ES / P01 ES009584; United States / NIEHS NIH HHS / ES / ES012800; United States / NCRR NIH HHS / RR / UL1 RR024131; United States / NIEHS NIH HHS / ES / ES012645; United States / NCRR NIH HHS / RR / M01 RR000071; United States / NIEHS NIH HHS / ES / K01 ES012645; United States / NIEHS NIH HHS / ES / ES012801; United States / NIEHS NIH HHS / ES / U01 ES012771; United States / NIEHS NIH HHS / ES / ES012771; United States / NCI NIH HHS / CA / CA93447; United States / NCRR NIH HHS / RR / UL1-RR024131; United States / NIEHS NIH HHS / ES / U01 ES012801; United States / NIEHS NIH HHS / ES / ES009584; United States / NIEHS NIH HHS / ES / U01 ES019454; United States / NCI NIH HHS / CA / K07 CA093447; United States / NCRR NIH HHS / RR / MO1-RR-00071
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Phenols; 0 / Phthalic Acids; 0 / Phytoestrogens; 6O7F7IX66E / phthalic acid
  • [Other-IDs] NLM/ PMC2920905
  • [Investigator] Collman G; Winn D; Maull E; Reinlib L; Lynch S; Ellison G; Dilworth C; Galvez M; Brenner B; Wetmur J; Chen J; Sheffield P; Vangeepurum N; Forman J; Boguski L; Britton J; Peter S; Mejia A; Richiez A; Montana J; Chae E; Osborne R; Moshier E; Zhu C; McGovern K; Dahl C; Baker C; Myatt S; Ford K; Bornschein B; Yaghjyan L; Roda S; Greenspan L; Sternfeld B; Ambrosone C; Deardorff J; Stewart S; Balke K; Ashley C; Bonnell C; Beeck A; Chan C; Davis D; Landaverde E; Burleson S; Lum R; Mirabedi A; Trotter M; Silva M; Samandar E; Preau J; Ye X; Bishop A; Reidy J; Pfeiffer C; Parker D; Olive P; Kimberly M; Dodson C; Claudio L; Williams S; Duncan D; Fonfa A; Barlow J; Koblick K; Brown K; Ball K
  •  go-up   go-down


39. de Graeff P, Crijns AP, Ten Hoor KA, Klip HG, Hollema H, Oien K, Bartlett JM, Wisman GB, de Bock GH, de Vries EG, de Jong S, van der Zee AG: The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. Br J Cancer; 2008 Jul 22;99(2):341-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer.
  • Ovarian cancer is the most frequent cause of death from gynaecological cancer in the Western world.
  • Current prognostic factors do not allow reliable prediction of response to chemotherapy and survival for individual ovarian cancer patients.
  • Epidermal growth factor receptor (EGFR) and HER-2/neu are frequently expressed in ovarian cancer but their prognostic value remains unclear.
  • In this study, we investigated the expression and prognostic value of EGFR, EGFR variant III (EGFRvIII), HER-2/neu and important downstream signalling components in a large series of epithelial ovarian cancer patients.
  • Our results show that negative PTEN immunostaining was associated with stage I/II disease (P=0.006), non-serous tumour type (P=0.042) and in multivariate analysis with a longer progression-free survival (P=0.015).
  • Negative PTEN staining also predicted improved progression-free survival in patients with grade III or undifferentiated serous carcinomas (P=0.011).
  • Positive pAKT staining was associated with advanced-stage disease (P=0.006).


40. Gavioli M, Losi L, Luppi G, Iacchetta F, Zironi S, Bertolini F, Falchi AM, Bertoni F, Natalini G: Preoperative therapy for lower rectal cancer and modifications in distance from anal sphincter. Int J Radiat Oncol Biol Phys; 2007 Oct 1;69(2):370-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative therapy for lower rectal cancer and modifications in distance from anal sphincter.
  • PURPOSE: To assess the frequency and magnitude of changes in lower rectal cancer resulting from preoperative therapy and its impact on sphincter-saving surgery.
  • Preoperative therapy can increase the rate of preserving surgery by shrinking the tumor and enhancing its distance from the anal sphincter.
  • METHODS AND MATERIALS: A total of 98 cases of locally advanced cancer of the lower rectum (90 Stage uT3-T4N0-N+ and 8 uT2N+M0) that had undergone preoperative therapy were studied by endorectal ultrasonography.
  • The maximal size of the tumor and its distance from the anal sphincter were measured in millimeters before and after preoperative therapy.
  • The distance between the tumor and the anal sphincter increased in 60.2% of cases.
  • It was possible in nearly 30% of patients in whom the cancer had reached the anal sphincter before the preoperative therapy.
  • CONCLUSION: The results of our study have shown that in very low rectal cancer, preoperative therapy causes tumor downsizing in >80% of cases and in more than one-half enhances the distance between the tumor and anal sphincter.
  • [MeSH-major] Anal Canal / pathology. Rectal Neoplasms / pathology. Rectal Neoplasms / therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17524570.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


41. Dai Y, Jiang JB, Bi DS, Jin ZT, Sun JZ, Hu SY: Preservation of the continence function after intersphincteric resection using a prolapsing technique in the patients with low rectal cancer and its clinical prognosis. Chin Med J (Engl); 2008 Oct 20;121(20):2016-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preservation of the continence function after intersphincteric resection using a prolapsing technique in the patients with low rectal cancer and its clinical prognosis.
  • BACKGROUND: The technique of intersphincteric resection of tumors combined with coloanal anastomosis has been used to avoid permanent colostomy for patients with a rectal cancer located < 5 cm from the anal verge.
  • This study aimed at assessing the preservation of continence function of the residual rectum and the clinical prognosis of patients with lower rectal cancer after intersphincteric resection using a prolapsing technique.
  • (1) pathological evidence of rectal cancer and the tumors within distal margins located 5 cm or less from the anus by preoperative endoscopic examination;.
  • From January 2000 to June 2004, 23 patients with low rectal cancer were included in this study.
  • The patients were followed for assessment of the function of the residual rectum and of cancer recurrence after the operations.
  • RESULTS: The median tumor distance from the anal margin was 4.5 (range 3.5 - 5.0) cm and the mean distal surgical margin 1.6 (range 1.0 - 2.0) cm.
  • Cancer was classified into Stage I (30.4%), Stage II (47.8%), and Stage III (21.7%) according to the TNM classification.
  • Anal manometer measurements showed a decrease of pressure during the resting time after intersphincteric resection and this change remained during the period of follow-up.
  • CONCLUSIONS: More residual rectum function after the surgery may be preserved by intersphincteric resection of low rectum cancer.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19080267.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


42. Jeon SH, Jeon SH, Chang SG: Clinical prognostic factors for radical cystectomy in bladder cancer. Cancer Res Treat; 2005 Feb;37(1):48-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical prognostic factors for radical cystectomy in bladder cancer.
  • PURPOSE: We investigated the effects of radical cystectomy and the prognostic factors that affect the survival of bladder cancer patients.
  • Indications for surgery included muscle invasive bladder cancer and high-risk superficial bladder cancer.
  • The cancer specific and recurrence free survival rates with respect to the possible prognostic factors were determined using Kaplan-Meier statistics.
  • Pathologic stage, tumor grade, mean nuclear area, sex and lymphatic invasion were significant factors by univariate analysis (p<0.05).
  • Multivariate analysis identified pathologic stage and lymphatic invasion as independent prognostic factors.
  • CONCLUSIONS: Radical cystectomy for organ-confined cancer showed favorable 5- and 10-year survival rates.
  • The most significant independent prognostic factors were the pathologic stage and the presence of lymphatic invasion, which were highly correlated with all the investigated disease endpoints.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1979 Jun;43(6):2532-9 [455239.001]
  • [Cites] J Korean Med Sci. 1992 Jun;7(2):154-61 [1524728.001]
  • [Cites] J Urol. 1991 Jan;145(1):45-50 [1984097.001]
  • [Cites] J Urol. 1991 Mar;145(3):459-64; discussion 464-7 [1997689.001]
  • [Cites] J Urol. 1983 Jul;130(1):56-60 [6864915.001]
  • [Cites] Urology. 1980 Aug;16(2):142-4 [7404907.001]
  • [Cites] Br J Cancer. 2004 Jun 1;90(11):2142-4 [15150549.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):666-75 [11157016.001]
  • [Cites] Anal Quant Cytol Histol. 2001 Aug;23(4):251-6 [11531139.001]
  • [Cites] BJU Int. 2002 Mar;89(4):374-8 [11872027.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(4):460-7 [11872337.001]
  • [Cites] Urology. 2002 Dec;60(6):1124-30 [12475695.001]
  • [Cites] Urol Int. 2004;72(2):103-11 [14963349.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):89-93 [11134199.001]
  • (PMID = 19956510.001).
  • [ISSN] 2005-9256
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2785423
  • [Keywords] NOTNLM ; Bladder cancer / Prognostic factor / Radical cystectomy
  •  go-up   go-down


43. Yatsuoka T, Suto Y, Yokoyama Y, Yamaura T, Nishimura Y, Sakamoto H, Tanaka Y, Nozu S, Nishimura Y, Kurosumi M: [Intramucosal colorectal carcinomas treated by surgical resection]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2563-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Stage 0 colorectal cancer was found only in the innermost lining of the colon and rectum.
  • Treatments for an early stage colorectal cancer were available including endoscopic polypectomy, endoscopic mucosal resection (EMR) and trans-anal or -sacral local excision, laparoscopy-assisted colectomy and open colectomy.
  • Our study indicated that endoscopic therapy for the early stage colorectal cancer was more advantageous than the conventional operative treatment.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224640.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


44. van der Snoek EM, Amelink A, van der Ende ME, den Hollander JC, den Hollander JG, Kroon FP, Vriesendorp R, Neumann HA, Robinson DJ: Photodynamic therapy with topical metatetrahydroxychlorin (Fosgel) is ineffective for the treatment of anal intraepithelial neoplasia, grade III. J Acquir Immune Defic Syndr; 2009 Sep 1;52(1):141-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy with topical metatetrahydroxychlorin (Fosgel) is ineffective for the treatment of anal intraepithelial neoplasia, grade III.
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / virology. HIV Infections / complications. Mesoporphyrins / administration & dosage. Photochemotherapy / methods. Photosensitizing Agents / administration & dosage

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19704267.001).
  • [ISSN] 1525-4135
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Liposomes; 0 / Mesoporphyrins; 0 / Photosensitizing Agents; FU21S769PF / temoporfin
  •  go-up   go-down


45. Scholefield JH, Castle MT, Watson NF: Malignant transformation of high-grade anal intraepithelial neoplasia. Br J Surg; 2005 Sep;92(9):1133-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of high-grade anal intraepithelial neoplasia.
  • BACKGROUND: The natural history of anal intraepithelial neoplasia (AIN) is uncertain.
  • METHODS: All patients were diagnosed with high-grade AIN (AIN III) between 1994 and 2003.
  • Diagnosis was by full-thickness biopsy and histopathological examination.
  • Prospective data were collected regarding recurrence, postoperative complications and progression to invasive carcinoma.
  • Excision of localized high-grade AIN was carried out in 28 patients with minimal morbidity.
  • Six patients were systemically immunosuppressed at diagnosis, all of whom had multifocal perianal lesions.
  • Three immunosuppressed patients developed invasive anal squamous carcinoma during follow-up.
  • CONCLUSION: AIN III appears to have a relatively low potential for malignant transformation in the immunocompetent patient.
  • However, immunosuppressed patients are more likely to have extensive AIN III and a greater risk of malignant change.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma in Situ / pathology. Cell Transformation, Neoplastic / pathology
  • [MeSH-minor] Adult. Carcinoma, Squamous Cell / pathology. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local. Prospective Studies

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 British Journal of Surgery Society Ltd.
  • (PMID = 16044425.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


46. Park NY, Valacchi G, Lim Y: Effect of dietary conjugated linoleic acid supplementation on early inflammatory responses during cutaneous wound healing. Mediators Inflamm; 2010;2010
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Moreover, the wound closure rate was improved significantly in mice fed a 1% CLA-supplemented diet during early stage of wound healing (inflammatory stage).
  • We conclude that dietary CLA supplementation enhances the early stage of cutaneous wound healing as a result of modulating oxidative stress and inflammatory responses.
  • [MeSH-major] Dietary Supplements. Inflammation / pathology. Linoleic Acids, Conjugated. Skin. Wound Healing / drug effects

  • MedlinePlus Health Information. consumer health - Dietary Supplements.
  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nutr. 2000 Sep;130(9):2285-91 [10958825.001]
  • [Cites] J Trauma. 2009 Jul;67(1):108-12; discussion 112-4 [19590318.001]
  • [Cites] J Agric Food Chem. 2000 Sep;48(9):4162-7 [10995331.001]
  • [Cites] J Agric Food Chem. 2000 Nov;48(11):5469-75 [11087504.001]
  • [Cites] Diabetes. 2001 May;50(5):1149-57 [11334420.001]
  • [Cites] Prog Lipid Res. 2001 Jul;40(4):283-98 [11412893.001]
  • [Cites] J Agric Food Chem. 2001 Jul;49(7):3452-6 [11453790.001]
  • [Cites] Mutat Res. 2001 Sep 1;480-481:243-68 [11506818.001]
  • [Cites] Biochim Biophys Acta. 2002 Apr 15;1581(3):89-99 [12020636.001]
  • [Cites] J Agric Food Chem. 2002 Jul 3;50(14):4135-40 [12083897.001]
  • [Cites] J Neuroimmunol. 2002 Aug;129(1-2):74-83 [12161023.001]
  • [Cites] Toxicology. 2002 Sep 30;179(1-2):163-70 [12204552.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2002 Dec;67(6):435-43 [12468265.001]
  • [Cites] Exp Biol Med (Maywood). 2003 Jan;228(1):51-8 [12524473.001]
  • [Cites] Blood. 2003 Jul 15;102(2):521-8 [12649161.001]
  • [Cites] Physiol Rev. 2003 Jul;83(3):835-70 [12843410.001]
  • [Cites] J Agric Food Chem. 2004 Jan 14;52(1):71-8 [14709015.001]
  • [Cites] J Nutr. 2004 Apr;134(4):811-6 [15051830.001]
  • [Cites] J Clin Invest. 1972 Aug;51(8):2009-23 [5054460.001]
  • [Cites] Am J Pathol. 1975 Jan;78(1):71-100 [1109560.001]
  • [Cites] Anal Biochem. 1979 Jun;95(2):351-8 [36810.001]
  • [Cites] Cancer Lett. 1979 Jul;7(2-3):63-9 [476611.001]
  • [Cites] Biochem J. 1989 Oct 15;263(2):539-45 [2556998.001]
  • [Cites] Clin Plast Surg. 1990 Jul;17(3):433-42 [2199135.001]
  • [Cites] Arch Surg. 1993 Nov;128(11):1235-41 [8239986.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Feb 15;198(3):1107-12 [8117267.001]
  • [Cites] Atherosclerosis. 1994 Jul;108(1):19-25 [7980704.001]
  • [Cites] Cytokine. 1996 Jul;8(7):548-56 [8891436.001]
  • [Cites] Science. 1997 Apr 4;276(5309):75-81 [9082989.001]
  • [Cites] Trends Pharmacol Sci. 1997 Feb;18(2):46-50 [9090308.001]
  • [Cites] Artery. 1997;22(5):266-77 [9209699.001]
  • [Cites] Lipids. 1997 Aug;32(8):853-8 [9270977.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Mar 27;244(3):678-82 [9535724.001]
  • [Cites] N Engl J Med. 1999 Sep 2;341(10):738-46 [10471461.001]
  • [Cites] Toxicol Lett. 2006 Jan 5;160(2):127-34 [16129572.001]
  • [Cites] J Trauma. 2005 Nov;59(5):1048-51; discussion 1051 [16385276.001]
  • [Cites] J Nutr Biochem. 2006 May;17(5):328-36 [16214328.001]
  • [Cites] Plast Reconstr Surg. 2006 Jun;117(7 Suppl):42S-58S [16799374.001]
  • [Cites] J Am Coll Surg. 2006 Oct;203(4):539-45 [17000399.001]
  • [Cites] J Investig Dermatol Symp Proc. 2006 Sep;11(1):106-11 [17069017.001]
  • [Cites] Carcinogenesis. 2007 Feb;28(2):363-71 [16950795.001]
  • [Cites] Vet J. 2007 Mar;173(2):413-21 [16495095.001]
  • [Cites] Br Poult Sci. 2008 Mar;49(2):213-21 [18409096.001]
  • [Cites] Pharmacol Res. 2008 Aug;58(2):165-71 [18617006.001]
  • [Cites] Annu Rev Biochem. 2000;69:145-82 [10966456.001]
  • (PMID = 20871865.001).
  • [ISSN] 1466-1861
  • [Journal-full-title] Mediators of inflammation
  • [ISO-abbreviation] Mediators Inflamm.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Linoleic Acids, Conjugated; 0 / Reactive Oxygen Species; 4Y8F71G49Q / Malondialdehyde; EC 1.14.99.- / Ptgs2 protein, mouse; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.3 / Heme Oxygenase-1; EC 1.15.1.1 / Superoxide Dismutase
  • [Other-IDs] NLM/ PMC2943105
  •  go-up   go-down


47. Lundqvist H, Antoni G, Långström B: Genotoxic hazard of radiopharmaceuticals in humans: chemical and radiation aspects coupled to microdosing. Eur J Clin Pharmacol; 2007 Jul;63(7):641-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: To obtain the pharmacokinetic properties of drug candidates at an early stage of the development process, a microdosing (phase 0) concept to radiolabel drug candidates and administer them at subtoxic mass to a few volunteers has been suggested.
  • Radiopharmaceuticals are special in the sense that the chemical carrier might be genotoxic, whereas it is well established that ionizing radiation coupled to the molecule is genotoxic, and that the mechanism that causes cancer is similar to certain genotoxic chemicals.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Clin Pharmacol. 2003 Sep;59(5-6):357-66 [12937873.001]
  • [Cites] Toxicol Sci. 2005 Aug;86(2):226-30 [15829616.001]
  • [Cites] Risk Anal. 2000 Apr;20(2):163-72 [10859777.001]
  • [Cites] Drug Metab Rev. 1998 May;30(2):359-404 [9606609.001]
  • [Cites] J Org Chem. 2002 May 31;67(11):3687-92 [12027681.001]
  • [Cites] Regul Toxicol Pharmacol. 2006 Apr;44(3):198-211 [16412543.001]
  • [Cites] Eur J Nucl Med. 1985;11(5):166-70 [2998797.001]
  • [Cites] Eur J Nucl Med. 2001 Apr;28(4):541-61 [11357507.001]
  • [Cites] Mutat Res. 1991 Jun;248(2):213-6 [2046679.001]
  • (PMID = 17457579.001).
  • [ISSN] 0031-6970
  • [Journal-full-title] European journal of clinical pharmacology
  • [ISO-abbreviation] Eur. J. Clin. Pharmacol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radioisotopes; 0 / Radiopharmaceuticals
  •  go-up   go-down


48. Oono Y, Fu K, Nakamura H, Iriguchi Y, Yamamura A, Kishi D, Oda J, Ikematsu H, Mizutani M, Takayanagi S, Tomino Y: Narrowband imaging colonoscopy with a transparent hood for diagnosis of a squamous cell carcinoma in situ in the anal canal. Endoscopy; 2010;42 Suppl 2:E183-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Narrowband imaging colonoscopy with a transparent hood for diagnosis of a squamous cell carcinoma in situ in the anal canal.
  • [MeSH-major] Anus Neoplasms / diagnosis. Carcinoma, Squamous Cell / diagnosis. Colonoscopy / methods


49. Myerson RJ, Outlaw ED, Chang A, Birnbaum EH, Fleshman JW, Grigsby PW, Kodner IJ, Malayapa RS, Mutch MG, Parikh P, Picus J, Tan BR: Radiotherapy for epidermoid carcinoma of the anus: thirty years' experience. Int J Radiat Oncol Biol Phys; 2009 Oct 1;75(2):428-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy for epidermoid carcinoma of the anus: thirty years' experience.
  • PURPOSE: To evaluate the factors associated with disease control and morbidity after radiotherapy for anal carcinoma.
  • METHODS AND MATERIALS: Between 1975 and 2005, 194 patients with localized epidermoid anal carcinoma underwent radiotherapy.
  • Univariate analysis for UNED survival showed a strong association with the T and N stage (5-year UNED rate, 88.5% +/- 3.4% for those with Stage T1-T2N0; 70.1% +/- 4.2% for Stage T3N0; and 52.7% +/- 6.6% for Stage III; p > .001) and mobility on palpation (5-year UNED rate, 89.2% +/- 4.6% for those with mobile tumors vs. 59.3% +/- 6.1% for those with tethered/fixed tumor; p > .001).
  • The radiotherapy factors associated with Grade 3 or greater late morbidity included anorectal morbidity with tumor dose (29% with a dose > or =55 Gy vs. 9% otherwise), small bowel injury with technique (9% with anteroposterior-posteroanterior supine vs. 0.7% with multiple fields prone), and bone injury with femoral head dose (9% with a dose of > or =44 Gy vs. 0.7% otherwise).
  • Of the 194 patients, 56 had 68 additional malignancies, mainly either antedating the anal cancer or outside the radiation fields.
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy


50. Kim CW, Kim JH, Yu CS, Shin US, Park JS, Jung KY, Kim TW, Yoon SN, Lim SB, Kim JC: Complications after sphincter-saving resection in rectal cancer patients according to whether chemoradiotherapy is performed before or after surgery. Int J Radiat Oncol Biol Phys; 2010 Sep 1;78(1):156-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complications after sphincter-saving resection in rectal cancer patients according to whether chemoradiotherapy is performed before or after surgery.
  • PURPOSE: The aim of the present study was to compare the influence of preoperative chemoradiotherapy (CRT) with postoperative CRT on the incidence and types of postoperative complications in rectal cancer patients who underwent sphincter-saving resection.
  • RESULTS: There was no between-group difference in age, gender, or cancer stage.
  • In the pre-CRT group, the mean level of anastomosis from the anal verge was lower (3.5 +/- 1.4 cm vs. 4.3 +/- 1.7 cm, p < 0.001) and the rate of T4 lesion and temporary diverting ileostomy was higher than in the post-CRT group.
  • [MeSH-major] Adenocarcinoma. Anal Canal / surgery. Neoadjuvant Therapy / methods. Postoperative Complications / etiology. Rectal Neoplasms

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20106604.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


51. Altayli E, Gunes S, Yilmaz AF, Goktas S, Bek Y: CYP1A2, CYP2D6, GSTM1, GSTP1, and GSTT1 gene polymorphisms in patients with bladder cancer in a Turkish population. Int Urol Nephrol; 2009;41(2):259-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CYP1A2, CYP2D6, GSTM1, GSTP1, and GSTT1 gene polymorphisms in patients with bladder cancer in a Turkish population.
  • Genetic differences in the metabolism of xenobiotics have recently been suggested as modifiers of individual susceptibility to bladder cancer (BC).
  • We investigated the distribution of these polymorphisms in 135 BC patients and in 128 age and sex-matched cancer-free controls.
  • Genotype and allele frequencies and their associations with BC risk, demographic factors, smoking status, and tumor stage were investigated.

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2006 Mar 13;25(11):1679-91 [16550168.001]
  • [Cites] Cancer Invest. 2006 Feb;24(1):41-5 [16466991.001]
  • [Cites] Urol Oncol. 2008 Jan-Feb;26(1):1-8 [18190823.001]
  • [Cites] Eur Urol. 2005 Aug;48(2):339-44 [16005379.001]
  • [Cites] Pain Med. 2004 Mar;5(1):81-93 [14996240.001]
  • [Cites] Otol Neurotol. 2005 May;26(3):392-7 [15891640.001]
  • [Cites] Carcinogenesis. 2003 Mar;24(3):483-9 [12663508.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Oct 1;154(1):81-5 [15381379.001]
  • [Cites] Arch Toxicol. 2001 Oct;75(8):459-64 [11757669.001]
  • [Cites] Anal Biochem. 1996 Apr 5;236(1):184-6 [8619490.001]
  • [Cites] IARC Sci Publ. 1999;(148):173-95 [10493258.001]
  • [Cites] Nucleic Acids Res. 1988 Feb 11;16(3):1215 [3344216.001]
  • [Cites] Int J Urol. 2008 Mar;15(3):216-21 [18304215.001]
  • [Cites] Cell Biochem Funct. 2005 Jul-Aug;23(4):267-72 [15473001.001]
  • [Cites] Am J Otolaryngol. 2004 Sep-Oct;25(5):318-22 [15334395.001]
  • [Cites] Cancer. 2005 Dec 1;104(11):2400-8 [16240451.001]
  • [Cites] BMC Cancer. 2006 Oct 06;6:239 [17026750.001]
  • [Cites] Int Urol Nephrol. 2007;39(4):1043-8 [17340208.001]
  • [Cites] Cancer Lett. 2003 Dec 30;202(2):193-9 [14643449.001]
  • [Cites] Cancer Lett. 2004 Aug 10;211(2):199-207 [15219943.001]
  • [Cites] Mol Psychiatry. 2000 Jul;5(4):410-7 [10889552.001]
  • [Cites] Mutat Res. 2001 Oct 1;482(1-2):21-6 [11535245.001]
  • [Cites] Physiol Res. 1999;48(6):465-71 [10783912.001]
  • [Cites] Pharmacogenetics. 2001 Jul;11(5):429-35 [11470995.001]
  • [Cites] J Occup Health. 2004 Nov;46(6):440-7 [15613766.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Feb;125(1):1-4 [11297759.001]
  • [Cites] Carcinogenesis. 2004 May;25(5):729-34 [14688016.001]
  • [Cites] Arch Biochem Biophys. 1997 Sep 1;345(1):32-8 [9281308.001]
  • [Cites] Urology. 2005 Jan;65(1):70-5 [15667866.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Jan 1;156(1):68-73 [15588859.001]
  • (PMID = 18690546.001).
  • [ISSN] 1573-2584
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 1.14.14.1 / CYP1A2 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP1A2; EC 1.14.14.1 / Cytochrome P-450 CYP2D6; EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1
  •  go-up   go-down


52. Yun HR, Lee LJ, Park JH, Cho YK, Cho YB, Lee WY, Kim HC, Chun HK, Yun SH: Local recurrence after curative resection in patients with colon and rectal cancers. Int J Colorectal Dis; 2008 Nov;23(11):1081-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND AIMS: There are a range of rates and a number of prognostic factors associated with the local recurrence of colorectal cancer after curative resection.
  • MATERIALS AND METHODS: A retrospective review of 1,838 patients who underwent curative resection of non-metastatic colorectal cancer was conducted.
  • RESULTS: There were 994 patients with colon cancer and 844 patients with rectal cancer.
  • With respect to colon cancer, the local recurrence rate was 6.1% (61 patients).
  • With respect to rectal cancer, 95 patients had a local recurrence (11.3%), the rate of which was statistically greater than the local recurrence rate for colon cancer (p < 0.001).
  • In patients with colon and rectal cancer, the pathologic T stage (p = 0.044 and p = 0.034, respectively), pathologic N stage (p = 0.001 and p < 0.001, respectively), and lymphovascular invasion (p = 0.013 and p = 0.004, respectively) were adverse risk factors for local recurrence.
  • The level of the anastomosis from the anal verge was an additional prognostic factor (p = 0.007) in patients with rectal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Gynecol Obstet. 1981 Feb;152(2):131-6 [7209752.001]
  • [Cites] Br J Surg. 1984 Jan;71(1):12-6 [6689962.001]
  • [Cites] J Am Coll Surg. 1997 Jul;185(1):55-9 [9208961.001]
  • [Cites] J Am Coll Surg. 2002 Jul;195(1):33-40 [12113543.001]
  • [Cites] Br J Surg. 2007 Dec;94(12):1548-54 [17668888.001]
  • [Cites] Br J Surg. 2006 Jul;93(7):866-71 [16622901.001]
  • [Cites] Cancer. 1980 Jun 15;45(12):2969-74 [7388740.001]
  • [Cites] Br J Surg. 1987 May;74(5):370-2 [3594126.001]
  • [Cites] World J Surg. 2008 Jun;32(6):1124-9 [18259805.001]
  • [Cites] Br J Surg. 2007 Apr;94(4):491-9 [17262751.001]
  • [Cites] Dis Colon Rectum. 2000 Apr;43(4):492-8 [10789744.001]
  • [Cites] Dis Colon Rectum. 2001 Jul;44(7):947-54 [11496074.001]
  • [Cites] Semin Surg Oncol. 1993 Jan-Feb;9(1):33-8 [8356383.001]
  • [Cites] Eur J Surg Oncol. 2000 Dec;26(8):730-2 [11087635.001]
  • [Cites] Ann Surg. 1994 Feb;219(2):174-82 [8129488.001]
  • [Cites] Dis Colon Rectum. 1985 Jun;28(6):413-5 [2988881.001]
  • [Cites] Dis Colon Rectum. 2005 Aug;48(8):1597-602 [15937624.001]
  • [Cites] Dis Colon Rectum. 2002 Aug;45(8):1029-34 [12195186.001]
  • [Cites] Eur J Surg Oncol. 2000 Dec;26(8):725-9 [11087634.001]
  • [Cites] Int J Colorectal Dis. 1991 Feb;6(1):17-23 [2033347.001]
  • [Cites] Br J Surg. 1984 Sep;71(9):659-63 [6478151.001]
  • [Cites] Dis Colon Rectum. 1997 Jan;40(1):15-24 [9102255.001]
  • [Cites] Br J Surg. 2001 Sep;88(9):1221-7 [11531871.001]
  • [Cites] Surg Oncol. 1995;4(6):283-93 [8809950.001]
  • [Cites] Jpn J Clin Oncol. 2000 Jan;30(1):12-6 [10770562.001]
  • [Cites] Dis Colon Rectum. 2001 Jun;44(6):815-21 [11391141.001]
  • [Cites] Am J Clin Oncol. 2006 Jun;29(3):219-24 [16755173.001]
  • [Cites] Ann Surg. 1982 Aug;196(2):162-9 [7046656.001]
  • [Cites] J Surg Oncol. 2003 Nov;84(3):127-31 [14598355.001]
  • [Cites] Dis Colon Rectum. 1998 Sep;41(9):1127-33 [9749496.001]
  • [Cites] Cancer. 1976 Jun;37(6):2861-5 [949706.001]
  • [Cites] Ann Surg Oncol. 2003 Jan-Feb;10(1):80-5 [12513965.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1729-34 [11919228.001]
  • [Cites] Int J Colorectal Dis. 1995;10(3):126-32 [7561427.001]
  • (PMID = 18688621.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


53. Zamboni BA, Yothers G, Choi M, Fuller CD, Dignam JJ, Raich PC, Thomas CR Jr, O'Connell MJ, Wolmark N, Wang SJ: Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07. J Clin Oncol; 2010 May 20;28(15):2544-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07.
  • PURPOSE: Colon cancer overall survival (OS) is usually computed from the time of diagnosis.
  • Conditional survival (probability of surviving y additional years given they have survived x years [CS or OS|OS]) is an alternative measure that accounts for elapsed time since diagnosis, providing more relevant prognostic information.
  • We extend the concept of CS to condition on the set of patients alive, recurrence-free, and second primary cancer-free (disease-free survival [OS|DFS]).
  • PATIENTS AND METHODS: Using data from National Surgical Adjuvant Breast and Bowel Project trials C-03 through C-07, 5-year OS|DFS was calculated on patients who were disease free up to 5 years after diagnosis, stratified by age, stage, nodal status, and performance status (PS).
  • RESULTS: For stage II, OS|DFS improved from 87% to 92% at 5 years.
  • For stage III, OS|DFS improved from 69% to 88%.
  • CONCLUSION: Prognosis improves over time for almost all groups of patients with colon cancer, especially those with positive nodes.
  • OS|DFS is a more relevant measure of prognosis for those who have already survived disease free a period of time after diagnosis.
  • [MeSH-minor] Age Factors. Aged. Clinical Trials, Phase III as Topic. Disease-Free Survival. Humans. Kaplan-Meier Estimate. Lymphatic Metastasis. Middle Aged. Prognosis. Quality Assurance, Health Care / methods. Randomized Controlled Trials as Topic. United States / epidemiology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3553-9 [10550154.001]
  • [Cites] Lifetime Data Anal. 2008 Dec;14(4):447-63 [18836831.001]
  • [Cites] Cancer. 2001 Oct 15;92(8):2211-9 [11596040.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3035-40 [12915592.001]
  • [Cites] Surg Neurol. 2003 Nov;60(5):402-6; discussion 406 [14572960.001]
  • [Cites] Oncologist. 2003;8(6):541-52 [14657533.001]
  • [Cites] Eur J Cancer. 2004 May;40(8):1233-43 [15110888.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1879-87 [8410113.001]
  • [Cites] Semin Surg Oncol. 1994 Jan-Feb;10(1):2-6 [8115782.001]
  • [Cites] Cancer. 1995 Jul 15;76(2):237-42 [8625098.001]
  • [Cites] J Clin Epidemiol. 1997 Nov;50(11):1289-96 [9393385.001]
  • [Cites] Dis Colon Rectum. 1998 Sep;41(9):1097-106 [9749492.001]
  • [Cites] J Natl Cancer Inst. 1998 Dec 2;90(23):1810-6 [9839521.001]
  • [Cites] Cancer. 1999 Jan 15;85(2):485-91 [10023719.001]
  • [Cites] Breast Cancer Res Treat. 1998;51(3):239-53 [10068082.001]
  • [Cites] Chest. 1999 Sep;116(3):697-703 [10492274.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8664-70 [16260700.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2059-64 [16648506.001]
  • [Cites] Cancer. 2006 May 15;106(10):2165-70 [16586498.001]
  • [Cites] Oncologist. 2006 Jun;11(6):624-9 [16794241.001]
  • [Cites] Cancer. 2007 Apr 1;109(7):1331-43 [17326199.001]
  • [Cites] J Thorac Oncol. 2007 Mar;2(3):180-90 [17410040.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2198-204 [17470851.001]
  • [Cites] Ann Oncol. 2007 Aug;18(8):1408-13 [17693654.001]
  • [Cites] Gastric Cancer. 2007;10(3):153-8 [17922092.001]
  • [Cites] Gynecol Oncol. 2008 May;109(2):203-9 [18329082.001]
  • [Cites] J Neurooncol. 2000 Dec;50(3):257-64 [11263506.001]
  • (PMID = 20406942.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10CA-69974; United States / NCI NIH HHS / CA / U10 CA012027; United States / NCI NIH HHS / CA / U10 CA069651; United States / NCI NIH HHS / CA / U10CA-37377; United States / NCI NIH HHS / CA / U10 CA069974; United States / NCI NIH HHS / CA / U10CA-12027; United States / NCI NIH HHS / CA / U10 CA037377; United States / NCI NIH HHS / CA / U10CA-69651
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2881729
  •  go-up   go-down


54. Shrikhande SV, Saoji RR, Barreto SG, Kakade AC, Waterford SD, Ahire SB, Goliwale FM, Shukla PJ: Outcomes of resection for rectal cancer in India: the impact of the double stapling technique. World J Surg Oncol; 2007;5:35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of resection for rectal cancer in India: the impact of the double stapling technique.
  • Data on the double-stapling technique (DST) has been widely published in the West where the incidence of colorectal cancer is high.
  • The mean distance of the tumor from anal verge was 7.6 cm (2.5-15 cm) and 8.0 cm (4-15 cm) in the DST and SST groups, respectively.
  • CONCLUSION: This study, perhaps the first from India, demonstrates the feasibility of the DST in a country where the incidence of colorectal cancer is increasing.
  • The observed improvement of surgical outcomes with DST needs further studies to significantly prove these findings in a population where the tumors at presentation are predominantly Astler Coller Stage B and C.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1983 Feb;26(2):87-90 [6822175.001]
  • [Cites] Surgery. 1980 Nov;88(5):710-4 [7434211.001]
  • [Cites] Am J Surg. 1984 Apr;147(4):524-30 [6711755.001]
  • [Cites] Br J Surg. 1985 Aug;72(8):603-5 [3896372.001]
  • [Cites] Lancet. 1986 Jun 28;1(8496):1479-82 [2425199.001]
  • [Cites] Dis Colon Rectum. 1986 Dec;29(12):885-90 [2431844.001]
  • [Cites] Int Surg. 1988 Jan-Mar;73(1):19-22 [3360572.001]
  • [Cites] Br J Surg. 1990 May;77(5):510-2 [2354332.001]
  • [Cites] Dis Colon Rectum. 1991 Apr;34(4):317-22 [2007349.001]
  • [Cites] Br J Surg. 1991 Mar;78(3):308-11 [2021845.001]
  • [Cites] Dis Colon Rectum. 1991 Jun;34(6):495-7 [2036929.001]
  • [Cites] Am Surg. 1992 Apr;58(4):270-2 [1586088.001]
  • [Cites] Br J Surg. 1992 Aug;79(8):836-8 [1393488.001]
  • [Cites] Surg Gynecol Obstet. 1992 Oct;175(4):333-6 [1329243.001]
  • [Cites] World J Surg. 1992 Sep-Oct;16(5):866-71 [1462621.001]
  • [Cites] Br J Surg. 1993 Jul;80(7):924-7 [8369941.001]
  • [Cites] Dis Colon Rectum. 1994 Feb;37(2 Suppl):S35-41 [8313790.001]
  • [Cites] Dis Colon Rectum. 1995 May;38(5):480-6; discussion 486-7 [7736878.001]
  • [Cites] Dis Colon Rectum. 1995 Dec;38(12):1246-50 [7497834.001]
  • [Cites] Dis Colon Rectum. 1997 Jan;40(1):25-9 [9102256.001]
  • [Cites] Br J Surg. 1997 Apr;84(4):525-8 [9112908.001]
  • [Cites] Dis Colon Rectum. 1997 Jul;40(7):747-51 [9221846.001]
  • [Cites] Surg Today. 1997;27(8):706-9 [9306583.001]
  • [Cites] Aust N Z J Surg. 1997 Sep;67(9):599-602 [9322694.001]
  • [Cites] Surgery. 1997 Oct;122(4):779-84; discussion 784-5 [9347856.001]
  • [Cites] Br J Surg. 1998 Aug;85(8):1118-20 [9718010.001]
  • [Cites] Oncology. 1999 Apr;56(3):193-7 [10202273.001]
  • [Cites] Eur J Surg Oncol. 1999 Jun;25(3):284-91 [10336809.001]
  • [Cites] Indian J Gastroenterol. 1999 Jul-Sep;18(3):118-21 [10407566.001]
  • [Cites] Tech Coloproctol. 2004 Nov;8 Suppl 1:s79-81 [15655652.001]
  • [Cites] Trop Gastroenterol. 2001 Apr-Jun;22(2):83-6 [11552491.001]
  • [Cites] Br J Surg. 2001 Dec;88(12):1607-12 [11736973.001]
  • [Cites] Surg Clin North Am. 2002 Oct;82(5):983-93 [12507204.001]
  • [Cites] Int J Colorectal Dis. 2003 Nov;18(6):463-9 [14517685.001]
  • [Cites] Surg Today. 2004;34(1):32-9 [14714226.001]
  • [Cites] Br J Surg. 1980 Mar;67(3):198-200 [7362961.001]
  • [Cites] Dis Colon Rectum. 1983 Apr;26(4):231-5 [6839891.001]
  • (PMID = 17374176.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1839092
  • [General-notes] NLM/ Original DateCompleted: 20070726
  •  go-up   go-down


55. Fariña-Sarasqueta A, Gosens MJ, Moerland E, van Lijnschoten I, Lemmens VE, Slooter GD, Rutten HJ, van den Brule AJ: TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients. Anal Cell Pathol (Amst); 2010;33(1):1-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients.
  • AIM: Although the predictive and prognostic value of thymidylate synthase (TS) expression and gene polymorphism in colon cancer has been widely studied, the results are inconclusive probably because of methodological differences.
  • With this study, we aimed to elucidate the role of TS gene polymorphisms genotyping in therapy response in stage III colon carcinoma patients treated with 5-FU adjuvant chemotherapy.
  • PATIENTS AND METHODS: 251 patients diagnosed with stage III colon carcinoma treated with surgery followed by 5-FU based adjuvant therapy were selected.
  • RESULTS: There was a positive association between tumor T stage and the VNTR genotypes (p=0.05).In both univariate and multivariate survival analysis no effects of the studied polymorphisms on survival were found.
  • CONCLUSION: We conclude that the TS VNTR and SNP do not predict response to 5-FU therapy in patients with stage III colon carcinoma.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cell Oncol (Dordr). 2011 Aug;34(4):407-8
  • (PMID = 20966539.001).
  • [ISSN] 2210-7185
  • [Journal-full-title] Analytical cellular pathology (Amsterdam)
  • [ISO-abbreviation] Anal Cell Pathol (Amst)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 2.1.1.45 / Thymidylate Synthase; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC4605551
  •  go-up   go-down


56. Bock O, Neuse J, Hussein K, Brakensiek K, Buesche G, Buhr T, Wiese B, Kreipe H: Aberrant collagenase expression in chronic idiopathic myelofibrosis is related to the stage of disease but not to the JAK2 mutation status. Am J Pathol; 2006 Aug;169(2):471-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant collagenase expression in chronic idiopathic myelofibrosis is related to the stage of disease but not to the JAK2 mutation status.
  • Whereas no correlation was found between the JAK2 status and MMP gene products, there was an evident association with the stage of disease.
  • We conclude that the expression of matrix-modeling genes in cIMF is not influenced by the JAK2 mutation status but is predominantly related to the stage of disease.

  • Genetic Alliance. consumer health - Myelofibrosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Mol Diagn. 2006 May;8(2):170-7 [16645202.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):248-58 [16397238.001]
  • [Cites] Blood. 2000 Nov 15;96(10):3374-80 [11071630.001]
  • [Cites] J Immunol. 2001 Mar 1;166(5):3491-8 [11207308.001]
  • [Cites] Anal Biochem. 2001 Aug 1;295(1):116-7 [11476553.001]
  • [Cites] Br J Haematol. 2001 Oct;115(1):195-204 [11722433.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Methods. 2001 Dec;25(4):409-18 [11846610.001]
  • [Cites] Br J Haematol. 2002 Dec;119(3):709-12 [12437648.001]
  • [Cites] Am J Clin Pathol. 2003 Jan;119(1):152-8 [12520711.001]
  • [Cites] Circ Res. 2003 May 2;92(8):827-39 [12730128.001]
  • [Cites] J Pathol. 2003 Jul;200(4):448-64 [12845612.001]
  • [Cites] Eur J Haematol. 2003 Oct;71(4):276-82 [12950237.001]
  • [Cites] Acta Haematol. 2004;111(3):155-9 [15034237.001]
  • [Cites] Cell Adhes Commun. 1993 Sep;1(2):93-9 [8081879.001]
  • [Cites] Cell. 1998 Feb 6;92(3):391-400 [9476898.001]
  • [Cites] Blood. 1998 Dec 15;92(12):4641-51 [9845530.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2627-36 [10194442.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Dec;287(6):G1227-37 [15284024.001]
  • [Cites] J Cell Biol. 2004 Nov 22;167(4):757-67 [15545316.001]
  • [Cites] Lancet. 2005 Mar 19-25;365(9464):1054-61 [15781101.001]
  • [Cites] J Pathol. 2005 Apr;205(5):548-57 [15726648.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):387-97 [15837627.001]
  • [Cites] N Engl J Med. 2005 Apr 28;352(17):1779-90 [15858187.001]
  • [Cites] Nature. 2005 Apr 28;434(7037):1144-8 [15793561.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4508-15 [15705794.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4187-90 [15817681.001]
  • [Cites] Br J Haematol. 2005 Jul;130(1):76-82 [15982347.001]
  • [Cites] Haematologica. 2005 Aug;90(8):1128-32 [16079113.001]
  • [Cites] Leuk Lymphoma. 2005 Sep;46(9):1261-8 [16109602.001]
  • [Cites] J Exp Med. 2005 Sep 5;202(5):663-71 [16147977.001]
  • [Cites] Semin Hematol. 2005 Oct;42(4):248-58 [16210038.001]
  • [Cites] FEBS Lett. 2005 Oct 24;579(25):5487-93 [16213498.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3370-3 [16037387.001]
  • [Cites] J Cell Physiol. 2006 Jan;206(1):1-8 [15920734.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8520-30 [16293880.001]
  • [Cites] Nat Cell Biol. 2000 Oct;2(10):737-44 [11025665.001]
  • (PMID = 16877349.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / Tissue Inhibitor of Metalloproteinases; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2; EC 3.4.24.- / Collagenases; EC 3.4.24.- / Matrix Metalloproteinases
  • [Other-IDs] NLM/ PMC1780160
  •  go-up   go-down


57. Liney KE, Hagger JA, Tyler CR, Depledge MH, Galloway TS, Jobling S: Health effects in fish of long-term exposure to effluents from wastewater treatment works. Environ Health Perspect; 2006 Apr;114 Suppl 1:81-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Early life-stage roach, Rutilus rutilus, were exposed for 300 days to treated wastewater effluent at concentrations of 0, 15.2, 34.8, and 78.7% (with dechlorinated tap water as diluent).
  • Concentrations of treated effluents that induced feminization of male roach, measured as vitellogenin induction and histological alteration to gonads, also caused statistically significant alterations in kidney development (tubule diameter), modulated immune function (differential cell count, total number of thrombocytes), and caused genotoxic damage (micronucleus induction and single-strand breaks in gill and blood cells).

  • MedlinePlus Health Information. consumer health - Hazardous Waste.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Environ Sci Technol. 2003 Mar 15;37(6):1142-9 [12680667.001]
  • [Cites] Comp Biochem Physiol A Mol Integr Physiol. 2003 May;135(1):25-38 [12727547.001]
  • [Cites] Ecotoxicology. 2003 Feb-Aug;12(1-4):345-63 [12739880.001]
  • [Cites] Aquat Toxicol. 2003 May 29;63(4):431-46 [12758007.001]
  • [Cites] Ecotoxicol Environ Saf. 2003 Jul;55(3):300-6 [12798764.001]
  • [Cites] Environ Toxicol Chem. 2003 Jul;22(7):1507-16 [12836975.001]
  • [Cites] Environ Health Perspect. 2003 Oct;111(13):1601-7 [14551037.001]
  • [Cites] J Toxicol Environ Health B Crit Rev. 2004 Jan-Feb;7(1):1-24 [14681080.001]
  • [Cites] Aquat Toxicol. 2004 Mar 30;67(1):45-56 [15019250.001]
  • [Cites] Toxicology. 2004 Mar 15;196(3):237-45 [15036750.001]
  • [Cites] Environ Sci Technol. 2001 Feb 1;35(3):462-70 [11351715.001]
  • [Cites] Aquat Toxicol. 2000 Nov;51(1):69-78 [10998500.001]
  • [Cites] Aquat Toxicol. 2001 Feb;51(4):431-41 [11090901.001]
  • [Cites] Dis Aquat Organ. 2001 Apr 10;44(3):161-70 [11383563.001]
  • [Cites] Vet Immunol Immunopathol. 1991 Sep;29(3-4):339-51 [1949594.001]
  • [Cites] Fundam Appl Toxicol. 1994 Jan;22(1):1-7 [7907300.001]
  • [Cites] Chem Res Toxicol. 1994 Jan-Feb;7(1):23-8 [8155821.001]
  • [Cites] Cancer Res. 1994 Nov 1;54(21):5515-7 [7923187.001]
  • [Cites] Mutat Res. 1994 Dec 1;311(2):191-7 [7526183.001]
  • [Cites] Environ Health Perspect. 1995 Jun;103(6):582-7 [7556011.001]
  • [Cites] Mutat Res. 1995 Nov;345(1-2):87-95 [8524359.001]
  • [Cites] Environ Mol Mutagen. 1996;27(2):116-39 [8603665.001]
  • [Cites] Nature. 1996 Nov 21;384(6606):221-2 [8918871.001]
  • [Cites] Environ Health Perspect. 1996 Oct;104(10):1096-101 [8930552.001]
  • [Cites] Toxicol Appl Pharmacol. 1997 Mar;143(1):205-12 [9073609.001]
  • [Cites] Mutat Res. 1997 Apr 24;390(1-2):21-31 [9150749.001]
  • [Cites] Crit Rev Toxicol. 1998 Jul;28(4):319-61 [9711432.001]
  • [Cites] J Endocrinol. 1998 Sep;158(3):327-39 [9846162.001]
  • [Cites] J AOAC Int. 1998 Nov-Dec;81(6):1209-16 [9850583.001]
  • [Cites] Sci Total Environ. 1999 Jan 12;225(1-2):81-90 [10028705.001]
  • [Cites] Mutat Res. 1999 Mar 8;424(1-2):107-15 [10064854.001]
  • [Cites] Environ Health Perspect. 1999 May;107(5):385-90 [10210694.001]
  • [Cites] Environ Health Perspect. 2005 Oct;113(10):1299-307 [16203238.001]
  • [Cites] Environ Toxicol Chem. 2001 Jun;20(6):1276-90 [11392137.001]
  • [Cites] Environ Sci Technol. 2001 Jun 15;35(12):2476-81 [11432551.001]
  • [Cites] Ambio. 2001 May;30(3):122-6 [11436658.001]
  • [Cites] Arch Environ Contam Toxicol. 2001 Apr;40(3):392-8 [11443371.001]
  • [Cites] Aquat Toxicol. 2001 Sep;54(1-2):101-12 [11451429.001]
  • [Cites] Mar Environ Res. 2000 Jul-Dec;50(1-5):283-7 [11460705.001]
  • [Cites] Environ Sci Technol. 2001 Jul 15;35(14):2909-16 [11478242.001]
  • [Cites] ILAR J. 2001;42(4):285-91 [11581520.001]
  • [Cites] Environ Toxicol Chem. 2001 Oct;20(10):2133-41 [11596741.001]
  • [Cites] Environ Toxicol Chem. 2001 Oct;20(10):2268-75 [11596760.001]
  • [Cites] Biol Reprod. 2002 Feb;66(2):272-81 [11804939.001]
  • [Cites] Neurotoxicol Teratol. 2002 Jan-Feb;24(1):71-9 [11836073.001]
  • [Cites] Environ Toxicol Chem. 2002 Mar;21(3):507-14 [11878463.001]
  • [Cites] Comp Med. 2001 Feb;51(1):56-9 [11926303.001]
  • [Cites] Environ Sci Technol. 2002 Apr 15;36(8):1751-6 [11993873.001]
  • [Cites] Environ Sci Technol. 2002 Jun 1;36(11):2311-21 [12075783.001]
  • [Cites] Mar Environ Res. 2004 Aug-Dec;58(2-5):489-94 [15178071.001]
  • [Cites] Toxicol Lett. 2004 Jun 15;151(1):113-34 [15177647.001]
  • [Cites] Mutat Res. 1976 Dec;41(2-3):321-32 [796719.001]
  • [Cites] CRC Crit Rev Toxicol. 1977 May;5(1):67-101 [17515.001]
  • [Cites] Exp Cell Res. 1988 Mar;175(1):184-91 [3345800.001]
  • [Cites] Toxicol Pathol. 1990;18(1 Pt 1):32-8 [2362986.001]
  • [Cites] Anal Biochem. 1990 Jul;188(1):155-8 [2221356.001]
  • [Cites] Comp Biochem Physiol C. 1991;100(1-2):133-6 [1677844.001]
  • [Cites] J Biol Chem. 1991 Sep 5;266(25):16380-6 [1653233.001]
  • [Cites] Appl Environ Microbiol. 1991 Jul;57(7):2101-3 [1892400.001]
  • [Cites] Mutat Res. 1999 Dec 16;431(1):105-21 [10656490.001]
  • [Cites] Crit Rev Toxicol. 2000 Jan;30(1):71-133 [10680769.001]
  • [Cites] Endocr Rev. 2000 Feb;21(1):40-54 [10696569.001]
  • [Cites] J Chromatogr A. 2000 Mar 3;872(1-2):309-14 [10749507.001]
  • [Cites] Mutat Res. 2000 Oct 31;470(2):221-8 [11027977.001]
  • [Cites] Aquat Toxicol. 2001 Apr;52(2):157-76 [11164537.001]
  • [Cites] Mutat Res. 2001 Apr 5;491(1-2):39-44 [11287296.001]
  • [Cites] Mutagenesis. 2002 Jul;17(4):345-52 [12110632.001]
  • [Cites] Environ Health Perspect. 2002 Sep;110(9):917-21 [12204827.001]
  • [Cites] Environ Pollut. 2002;120(3):735-8 [12442797.001]
  • [Cites] Mar Environ Res. 2003 Mar;55(2):137-59 [12502035.001]
  • [Cites] Ecotoxicology. 2002 Dec;11(6):423-34 [12521139.001]
  • [Cites] FEBS Lett. 2003 Jan 30;535(1-3):153-8 [12560095.001]
  • [Cites] Environ Mol Mutagen. 2003;41(2):85-91 [12605376.001]
  • [Cites] Environ Sci Technol. 2003 Feb 1;37(3):462-7 [12630459.001]
  • (PMID = 16818251.001).
  • [ISSN] 0091-6765
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogens; 0 / Hazardous Waste; 0 / Industrial Waste; 0 / Steroids; 0 / Vitellogenins; 0 / Water Pollutants, Chemical
  • [Other-IDs] NLM/ PMC1874182
  •  go-up   go-down


58. Goel A, Littenberg B, Burack RC: The association between the pre-diagnosis mammography screening interval and advanced breast cancer. Breast Cancer Res Treat; 2007 May;102(3):339-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The association between the pre-diagnosis mammography screening interval and advanced breast cancer.
  • BACKGROUND: While screening has been demonstrated to reduce breast cancer mortality, the optimal screening interval is unknown.
  • We designed a study to determine the risk of an advanced breast cancer diagnosis by varying the interval between mammograms.
  • METHODS: We reviewed a single state's mammography records of women diagnosed with breast cancer between 1994 and 2002.
  • The pre-diagnosis screening interval was the number of days between the last two eligible mammograms preceding a cancer diagnosis.
  • Advanced breast cancer was >or=stage IIB, tumor size >2 cm, or >or=one lymph node with cancer.
  • RESULTS: The probability of an advanced breast cancer diagnosis did not differ between women with an annual pre-diagnosis screening interval and women with a biennial interval (21.1% vs. 23.7%, P=0.262).
  • A longer pre-diagnosis screening interval was weakly associated with advanced breast cancer (21.8% for intervals 0.75-2.49 years vs. 26.8% for longer intervals, P=0.070).
  • In multivariate analysis, we found an interaction between the pre-diagnosis screening interval and age.
  • Among women 50 years or older, the risk of an advanced breast cancer diagnosis risk was higher for women with a pre-diagnosis screening interval exceeding 2.49 years compared to women with shorter screening intervals (OR 1.99 [1.02-3.90]).
  • CONCLUSIONS: We found no difference in advanced breast cancer rates between women using mammography annually or biennially.
  • Among women 50 years or older, the advanced breast cancer rate increased when the pre-diagnosis screening interval exceeded 2.49 years.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 2000 Jun;174(6):1769-77 [10845521.001]
  • [Cites] Radiology. 2000 Dec;217(3):832-40 [11110951.001]
  • [Cites] Breast Cancer Res Treat. 2001 Jul;68(1):33-43 [11678307.001]
  • [Cites] Arch AIDS Res. 1996;10(1-2):73-82 [12320022.001]
  • [Cites] Cancer. 2002 Apr 15;94(8):2160-8 [12001112.001]
  • [Cites] Ann Intern Med. 2002 Sep 3;137(5 Part 1):344-6 [12204019.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1784-92 [16251534.001]
  • [Cites] CA Cancer J Clin. 2003 May-Jun;53(3):141-69 [12809408.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3244-8 [12947058.001]
  • [Cites] J Natl Cancer Inst. 2004 Sep 1;96(17):1311-21 [15339969.001]
  • [Cites] CA Cancer J Clin. 1997 May-Jun;47(3):150-3 [9152172.001]
  • [Cites] J Natl Cancer Inst. 2004 Dec 15;96(24):1832-9 [15601639.001]
  • [Cites] Med Sci Monit. 2005 Mar;11(3):RA86-93 [15735580.001]
  • [Cites] Anal Quant Cytol Histol. 2002 Dec;24(6):345-54 [12508694.001]
  • (PMID = 16927175.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R03 CA101493; United States / NCI NIH HHS / CA / 5R03CA101493; United States / NCI NIH HHS / CA / R03 CA101493-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS14929; NLM/ PMC1839955
  •  go-up   go-down


59. Elgaili EM, Abuidris DO, Rahman M, Michalek AM, Mohammed SI: Breast cancer burden in central Sudan. Int J Womens Health; 2010;2:77-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer burden in central Sudan.
  • Breast cancer is a worldwide disease resulting in many deaths.
  • Although breast cancer incidence is lower in Sub-Saharan African countries than in developed countries, African women are more likely than women in the developed world to be diagnosed at later stages of the disease and, thus, are more likely to die from it.
  • This descriptive study was undertaken to shed light on the type, stage and age distribution of breast cancer at diagnosis in women living in central Sudan encompassing al-Gezira, Blue Nile, White Nile, and Sennar States.
  • Cases comprised 1255 women from central Sudan diagnosed with breast cancer and referred to and treated at Institute of Nuclear Medicine, Molecular Biology, and Oncology, from January 1999 to December 2006.
  • Invasive ductal carcinoma was the most common pathology (82%) and women presenting with stage III or higher tumors that had already metastasized, while ductal carcinoma in situ was the least prevalent (0.5%) finding.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21072300.001).
  • [ISSN] 1179-1411
  • [Journal-full-title] International journal of women's health
  • [ISO-abbreviation] Int J Womens Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2971742
  • [Keywords] NOTNLM ; Africa / epidemiology / estrogen receptor / female breast cancer / progesterone receptor
  •  go-up   go-down


60. Kommoss S, Schmidt D, Kommoss F, Hedderich J, Harter P, Pfisterer J, du Bois A: Histological grading in a large series of advanced stage ovarian carcinomas by three widely used grading systems: consistent lack of prognostic significance. A translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 protocol). Virchows Arch; 2009 Mar;454(3):249-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological grading in a large series of advanced stage ovarian carcinomas by three widely used grading systems: consistent lack of prognostic significance. A translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 protocol).
  • While there is no doubt that histologic grading is applicable in early stage ovarian carcinoma, it is still in controversial discussion concerning advanced stage ovarian carcinoma.
  • It was the aim of this study to assess the three most widely used grading systems for ovarian carcinoma in terms of prognostic significance, concordance rates, and reproducibility in a large number of advanced stage ovarian carcinomas of all types after standardized chemotherapy.
  • Representative hematoxylin and eosin slides from 334 cases of stage IIB-IV ovarian carcinoma (prospective randomized, multi-center, phase III study) were used.
  • Grading of advanced stage ovarian carcinomas was of no value for estimation of prognosis in this homogeneously treated patient group.
  • [MeSH-minor] Aged. Clinical Trials, Phase III as Topic. Female. Humans. Kaplan-Meier Estimate. Middle Aged. Prognosis. Randomized Controlled Trials as Topic. Reproducibility of Results. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2008 Feb;52(3):393-5 [18081817.001]
  • [Cites] Cancer. 1980 Feb;45(3):572-81 [7353206.001]
  • [Cites] Obstet Gynecol. 1982 May;59(5):576-82 [7070728.001]
  • [Cites] APMIS. 1991 Apr;99(4):353-8 [2036219.001]
  • [Cites] Gynecol Oncol. 1984 Jan;17(1):117-23 [6693048.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Am J Surg Pathol. 2007 Aug;31(8):1168-74 [17667538.001]
  • [Cites] Gynecol Oncol. 2003 Jun;89(3):447-52 [12798710.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] Cancer. 1998 Mar 1;82(5):893-901 [9486579.001]
  • [Cites] Anal Quant Cytol Histol. 1986 Dec;8(4):354-7 [3814303.001]
  • [Cites] Histopathology. 2000 May;36(5):433-8 [10792484.001]
  • [Cites] Lancet. 2001 Jan 20;357(9251):176-82 [11213094.001]
  • [Cites] Int J Gynecol Pathol. 2000 Oct;19(4):348-53 [11109164.001]
  • [Cites] Gynecol Oncol. 2006 Oct;103(1):67-71 [16516280.001]
  • [Cites] Acta Obstet Gynecol Scand. 1971;50(1):1-7 [5558593.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Biometrics. 1977 Mar;33(1):159-74 [843571.001]
  • [Cites] Int J Gynecol Pathol. 1988;7(3):197-211 [2846458.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 3;95(17):1320-9 [12953086.001]
  • [Cites] Int J Gynecol Pathol. 2008 Apr;27(2):175-81 [18317226.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):496-504 [15087669.001]
  • [Cites] Int J Gynecol Pathol. 2003 Jan;22(1):52-6 [12496698.001]
  • [Cites] Int J Gynecol Pathol. 1989;8(2):147-55 [2714932.001]
  • [Cites] Int J Gynecol Pathol. 2000 Jan;19(1):7-15 [10638449.001]
  • [Cites] J Obstet Gynaecol Res. 2001 Dec;27(6):313-8 [11794816.001]
  • (PMID = 19172293.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  •  go-up   go-down


61. Ford CE, Lau SK, Zhu CQ, Andersson T, Tsao MS, Vogel WF: Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma. Br J Cancer; 2007 Mar 12;96(5):808-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma.
  • We sought to determine expression levels of DDRs in human lung cancer, investigate prognostic determinates, and determine the prevalence of recently reported mutations in these receptor tyrosine kinases.
  • Tumour samples from 146 non-small cell lung carcinoma (NSCLC) patients were analysed for relative expression of DDR1 and DDR2 using quantitative real-time PCR (qRT-PCR).
  • Multivariate analysis revealed DDR1 is an independent favourable predictor for prognosis independent of tumour differentiation, stage, histology, and patient age.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism. Receptor Protein-Tyrosine Kinases / biosynthesis. Receptors, Mitogen / biosynthesis
  • [MeSH-minor] Animals. Cell Line, Tumor. DNA Mutational Analysis. Humans. Male. Mice. Mutation. Polymorphism, Genetic. Prognosis. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):133-44 [16014883.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):123-32 [16014882.001]
  • [Cites] Hum Mol Genet. 2005 Oct 15;14 Spec No. 2:R197-205 [16244318.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):257-62 [16231326.001]
  • [Cites] J Immunol. 2006 Feb 1;176(3):1928-36 [16424224.001]
  • [Cites] Am J Pathol. 2006 Mar;168(3):866-77 [16507902.001]
  • [Cites] J Neurooncol. 2006 Feb;76(3):239-48 [16234985.001]
  • [Cites] Cell Signal. 2006 Aug;18(8):1108-16 [16626936.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5330-7 [16707459.001]
  • [Cites] Lancet Oncol. 2006 Jun;7(6):499-507 [16750500.001]
  • [Cites] Clin Lung Cancer. 2006 May;7 Suppl 4:S138-44 [16764754.001]
  • [Cites] Nucleic Acids Res. 2006;34(12):e85 [16840529.001]
  • [Cites] Am J Respir Crit Care Med. 2006 Aug 15;174(4):420-7 [16690978.001]
  • [Cites] Neurosurgery. 2000 Dec;47(6):1400-9 [11126911.001]
  • [Cites] J Clin Invest. 2001 Mar;107(6):727-35 [11254672.001]
  • [Cites] Circ Res. 2002 Jun 14;90(11):1147-9 [12065315.001]
  • [Cites] Int J Cancer. 2003 Jan 20;103(3):344-51 [12471617.001]
  • [Cites] EMBO J. 2003 Mar 17;22(6):1289-301 [12628922.001]
  • [Cites] Autoimmunity. 2002 Dec;35(8):521-9 [12765478.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1575-85 [15111304.001]
  • [Cites] Nephron Exp Nephrol. 2004;97(2):e62-70 [15218324.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10(13):4427-36 [15240533.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Am J Pathol. 1993 Feb;142(2):413-23 [8382008.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5677-81 [8390675.001]
  • [Cites] Oncogene. 1995 Feb 2;10(3):569-75 [7845682.001]
  • [Cites] Oncogene. 1995 Feb 2;10(3):609-18 [7845687.001]
  • [Cites] Pathobiology. 1997;65(4):195-203 [9396043.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7591-5 [16140923.001]
  • (PMID = 17299390.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Mitogen; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / discoidin receptor
  • [Other-IDs] NLM/ PMC2360060
  •  go-up   go-down


62. Eidemüller M, Ostroumova E, Krestinina L, Epiphanova S, Akleyev A, Jacob P: Comparison of mortality and incidence solid cancer risk after radiation exposure in the Techa River Cohort. Radiat Environ Biophys; 2010 Aug;49(3):477-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of mortality and incidence solid cancer risk after radiation exposure in the Techa River Cohort.
  • In the present paper, analysis of solid cancer mortality and incidence risk after radiation exposure in the Techa River Cohort in the Southern Urals region of Russia is described.
  • The analysis was performed by means of the biologically based two-stage clonal expansion (TSCE) model and conventional excess relative risk models.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Carcinogenesis. 2007 Feb;28(2):479-87 [16973671.001]
  • [Cites] Occup Environ Med. 2005 Jul;62(7):465-72 [15961623.001]
  • [Cites] Mutat Res. 2006 May 11;597(1-2):87-97 [16417911.001]
  • [Cites] Int J Radiat Biol. 1989 Jan;55(1):85-92 [2562980.001]
  • [Cites] Cancer Causes Control. 2008 Apr;19(3):317-28 [18058248.001]
  • [Cites] Health Phys. 2001 Oct;81(4):395-405 [11569634.001]
  • [Cites] Radiat Res. 2007 Apr;167(4):396-416 [17388693.001]
  • [Cites] Cancer Causes Control. 1997 May;8(3):309-22 [9498895.001]
  • [Cites] Mutat Res. 2006 May 11;597(1-2):73-7 [16417909.001]
  • [Cites] Radiat Environ Biophys. 2002 Mar;41(1):45-8 [12014408.001]
  • [Cites] Radiat Environ Biophys. 1996 May;35(2):127-9 [8792461.001]
  • [Cites] Radiat Res. 2007 Jul;168(1):1-64 [17722996.001]
  • [Cites] Radiat Res. 2004 Oct;162(4):377-89 [15447045.001]
  • [Cites] Mutat Res. 2009 Oct 2;669(1-2):48-55 [19416732.001]
  • [Cites] Sci Total Environ. 1994 Mar 1;142(1-2):1-8 [8178126.001]
  • [Cites] Health Phys. 2000 Jul;79(1):24-35 [10855775.001]
  • [Cites] Radiat Environ Biophys. 2008 Jul;47(3):375-88 [18481074.001]
  • [Cites] Radiat Res. 2003 Oct;160(4):381-407 [12968934.001]
  • [Cites] Radiat Environ Biophys. 2007 Nov;46(4):383-94 [17562061.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16226-31 [12446840.001]
  • [Cites] Radiat Res. 2003 May;159(5):581-96 [12710869.001]
  • [Cites] Radiat Environ Biophys. 2005 Oct;44(2):119-29 [16136318.001]
  • [Cites] Radiat Res. 2003 May;159(5):567-80 [12710868.001]
  • [Cites] Radiat Environ Biophys. 2008 Nov;47(4):469-79 [18648838.001]
  • [Cites] Int J Epidemiol. 2007 Oct;36(5):1038-46 [17768163.001]
  • [Cites] Radiat Res. 2008 Feb;169(2):138-48 [18220471.001]
  • [Cites] Radiat Res. 2005 Nov;164(5):602-11 [16238437.001]
  • [Cites] Radiat Res. 2005 Nov;164(5):591-601 [16238436.001]
  • [Cites] Radiat Res. 1997 Oct;148(4):348-58 [9339951.001]
  • [Cites] Stat Methods Med Res. 1997 Dec;6(4):305-15 [9447651.001]
  • [Cites] Health Phys. 2000 May;78(5):542-54 [10772028.001]
  • [Cites] Radiat Res. 1999 Oct;152(4):339-51 [10477911.001]
  • [Cites] Risk Anal. 1997 Jun;17(3):391-9 [9232020.001]
  • [Cites] Mutat Res. 2004 Dec 2;568(1):21-32 [15530536.001]
  • [Cites] Radiat Res. 2001 Jul;156(1):78-94 [11418076.001]
  • [Cites] J Natl Cancer Inst. 1981 Jun;66(6):1037-52 [6941039.001]
  • (PMID = 20461395.001).
  • [ISSN] 1432-2099
  • [Journal-full-title] Radiation and environmental biophysics
  • [ISO-abbreviation] Radiat Environ Biophys
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


63. Maw MK, Fujimoto J, Tamaya T: Overexpression of inhibitor of DNA-binding (ID)-1 protein related to angiogenesis in tumor advancement of ovarian cancers. BMC Cancer; 2009;9:430
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The inhibitor of DNA-binding (ID) has been involved in cell cycle regulation, apoptosis and angiogenesis.
  • RESULTS: ID-1 histoscores and mRNA levels both significantly (p < 0.001) increased in ovarian cancers according to clinical stage, regardless of histopathological type.
  • CONCLUSION: ID-1 increased in ovarian cancer cells during tumor progression.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Sci. 2006 Sep;97(9):861-7 [16805819.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9637-41 [10449746.001]
  • [Cites] Mol Cancer Res. 2007 Apr;5(4):321-9 [17426247.001]
  • [Cites] Br J Cancer. 2007 Nov 19;97(10):1409-15 [18000500.001]
  • [Cites] Br J Cancer. 2008 Nov 18;99(10):1557-63 [19002177.001]
  • [Cites] Nature. 1999 Oct 14;401(6754):670-7 [10537105.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1332-40 [10728695.001]
  • [Cites] Nature. 2001 Feb 22;409(6823):1067-70 [11234019.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):7812-6 [11427735.001]
  • [Cites] Cancer. 2001 Nov 15;92(10):2569-77 [11745191.001]
  • [Cites] Oncogene. 2001 Dec 20;20(58):8317-25 [11840324.001]
  • [Cites] Oncogene. 2001 Dec 20;20(58):8334-41 [11840326.001]
  • [Cites] J Urol. 2002 Jun;167(6):2598-602 [11992094.001]
  • [Cites] Carcinogenesis. 2002 May;23(5):721-5 [12016143.001]
  • [Cites] Cancer Biol Ther. 2002 Mar-Apr;1(2):91-6 [12170780.001]
  • [Cites] Cancer Cell. 2002 Dec;2(6):473-83 [12498716.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):779-85 [12576450.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):525-30 [12842081.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13543-8 [14578451.001]
  • [Cites] Carcinogenesis. 2004 Jun;25(6):881-7 [14742319.001]
  • [Cites] Apoptosis. 2004 May;9(3):279-89 [15258459.001]
  • [Cites] Trends Mol Med. 2004 Aug;10(8):387-92 [15310459.001]
  • [Cites] Arch Pathol Lab Med. 1985 Aug;109(8):716-21 [3893381.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):815-22 [10487839.001]
  • [Cites] J Virol. 2004 Dec;78(24):13470-8 [15564458.001]
  • [Cites] Oncol Rep. 2005 May;13(5):983-8 [15809768.001]
  • [Cites] Nat Rev Cancer. 2005 Aug;5(8):603-14 [16034366.001]
  • [Cites] Carcinogenesis. 2005 Oct;26(10):1668-76 [15905202.001]
  • [Cites] Cancer Sci. 2005 Nov;96(11):784-90 [16271072.001]
  • [Cites] Int J Cancer. 2006 Mar 15;118(6):1356-63 [16184548.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):2072-81 [16287090.001]
  • [Cites] Mod Pathol. 2006 Jul;19(7):931-41 [16575399.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):843-5 [1279431.001]
  • [Cites] Nucleic Acids Res. 1994 Mar 11;22(5):749-55 [8139914.001]
  • [Cites] Cancer Res. 1994 Dec 1;54(23):6065-8 [7954447.001]
  • [Cites] Cell Growth Differ. 1995 Jul;6(7):837-43 [7547505.001]
  • [Cites] Br J Cancer. 1996 Apr;73(8):884-8 [8611421.001]
  • [Cites] Mol Cell Biol. 1996 Sep;16(9):4604-13 [8756616.001]
  • [Cites] Mol Cell Biol. 1997 Oct;17(10):5888-96 [9315646.001]
  • [Cites] Mol Cell Biol. 1998 Apr;18(4):2371-81 [9528806.001]
  • [Cites] Trends Cell Biol. 1998 Feb;8(2):58-65 [9695810.001]
  • [Cites] Cancer Lett. 2006 Dec 8;244(2):203-10 [16469432.001]
  • (PMID = 20003244.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / ID1 protein, human; 0 / ID2 protein, human; 0 / Inhibitor of Differentiation Protein 1; 0 / Inhibitor of Differentiation Protein 2; 0 / Inhibitor of Differentiation Proteins; 0 / Neoplasm Proteins; 147785-34-0 / ID3 protein, human
  • [Other-IDs] NLM/ PMC2796680
  •  go-up   go-down


64. Preoperative bi-fractionated accelerated radiation therapy for combined treatment of locally advanced rectal cancer in a consectutive series of unselected patients. Int Semin Surg Oncol; 2007 Sep 20;4:23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative bi-fractionated accelerated radiation therapy for combined treatment of locally advanced rectal cancer in a consectutive series of unselected patients.
  • METHODS: patients were screened following these eligibility criteria: histology-proven adenocarcinoma of the rectum; distal tumour extent at 12 cm or less from the anal verge; clinical stage T3-4/anyN, or anyT/N1-2; ECOG Performance Status 0-2.
  • Twenty-eight patients were stage II and 19 stage III.
  • 2 patients experienced a severe grade 4 gastrointestinal toxicity (a colo-vaginal fistula and an intestinal obstruction, both successfully treated).
  • CONCLUSION: bifractionated accelerated RT administered in the preoperative setting to patients bearing locally advanced rectal cancer is reliable and safe, as its immediate and late toxicity (mainly infectious) is acceptably low and long-term survivals are achievable.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1990 Feb;211(2):187-95 [2405793.001]
  • [Cites] Am J Surg. 1994 Jan;167(1):90-4; discussion 94-5 [8311145.001]
  • [Cites] Ann Surg. 1998 Feb;227(2):157-67 [9488510.001]
  • [Cites] J Natl Cancer Inst. 2000 Mar 1;92(5):388-96 [10699069.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] Ann Surg. 2001 Nov;234(5):633-40 [11685026.001]
  • [Cites] Lancet. 2000 Jul 8;356(9224):93-6 [10963244.001]
  • [Cites] Ann Surg. 1994 Nov;220(5):676-82 [7979617.001]
  • [Cites] Br J Radiol. 1989 Aug;62(740):679-94 [2670032.001]
  • [Cites] Strahlenther Onkol. 2002 May;178(5):259-62 [12082685.001]
  • [Cites] Br J Surg. 1996 Jul;83(7):964-8 [8813788.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):67-73 [7826163.001]
  • [Cites] Dis Colon Rectum. 1992 Aug;35(8):757-61 [1643999.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 May;10(5):593-8 [6735750.001]
  • [Cites] N Engl J Med. 1997 Apr 3;336(14):980-7 [9091798.001]
  • [Cites] N Engl J Med. 1994 Aug 25;331(8):502-7 [8041415.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2396 [10561302.001]
  • [Cites] Strahlenther Onkol. 2004 Jan;180(1):5-14 [14704839.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(2):387-92 [1587760.001]
  • [Cites] Lancet. 2001 Oct 20;358(9290):1291-304 [11684209.001]
  • [Cites] Clin Radiol. 1971 Apr;22(2):145-55 [5575251.001]
  • (PMID = 17883838.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2063497
  •  go-up   go-down


65. Salerno GV, Daniels IR, Moran BJ, Heald RJ, Thomas K, Brown G: Magnetic resonance imaging prediction of an involved surgical resection margin in low rectal cancer. Dis Colon Rectum; 2009 Apr;52(4):632-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging prediction of an involved surgical resection margin in low rectal cancer.
  • PURPOSE: Low rectal cancers (<5 cm from the anal verge), compared with all others, have greater positive resection margin rates, attributed to mesorectal tapering and higher perforation risk.
  • METHODS: The following features were analyzed by using preoperative magnetic resonance imaging from 101 consecutive patients with low rectal tumors: tumor location (posterior/anterior) and magnetic resonance stage (Stage 1-2, tumor within the intersphincteric plane; Stage 3-4 tumor extending into the intersphincteric plane).
  • Magnetic resonance imaging tumor regression grade was measured where posttreatment magnetic resonance imaging was available and compared with histopathologic findings.
  • Magnetic resonance imaging tumor regression grade strongly predicted for positive resection margins; 11 of 15 patients with little treatment response had positive resection margins, compared with 2 of 15 with >50 percent complete treatment response on magnetic resonance imaging (P < 0.001).
  • CONCLUSION: Significant magnetic resonance imaging positive resection margin predictors are tumor into or beyond the intersphincteric plane and magnetic resonance imaging tumor regression grade.
  • [MeSH-major] Anal Canal / pathology. Rectal Neoplasms / pathology. Rectal Neoplasms / surgery

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dis Colon Rectum. 2010 Mar;53(3):362; author reply 362-3 [20173488.001]
  • (PMID = 19404067.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


66. Wu DH, Shaffer AD, Thompson DM, Yang Z, Magnotta VA, Alam R, Suri J, Yuh WT, Mayr NA: Iterative active deformational methodology for tumor delineation: Evaluation across radiation treatment stage and volume. J Magn Reson Imaging; 2008 Nov;28(5):1188-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Iterative active deformational methodology for tumor delineation: Evaluation across radiation treatment stage and volume.
  • PURPOSE: To introduce, implement, and assess an iterative modification to the active deformational image segmentation method as applied to cervical cancer tumors.
  • MATERIALS AND METHODS: A comparison by Jaccard similarity (JS) between this active deformational method and manual segmentation was performed on tumors of various sizes across preradiation, 3 weeks postradiation, and 6 weeks postradiation using a General Linear Mixed Model across 121 studies from 52 patients with Stage IIB-IV cervical cancers.
  • The analysis illustrated a rate of improvement in JS with increasing tumor volume that differed between the preradiation and 6 weeks postradiation stage (P=0.0474).
  • The deformation-based segmentation method appears to demonstrate utility for delineating cervical cancer tumors, particularly in the earliest stages of radiation treatment, where agreement is greatest.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 Wiley-Liss, Inc.
  • [Cites] IEEE Trans Med Imaging. 2006 Nov;25(11):1472-82 [17117776.001]
  • [Cites] J Magn Reson Imaging. 2006 Dec;24(6):1316-25 [17058203.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5687-94 [17179104.001]
  • [Cites] Methods Inf Med. 2003;42(1):89-98 [12695800.001]
  • [Cites] Med Image Anal. 2006 Apr;10(2):215-33 [16311065.001]
  • [Cites] Stud Health Technol Inform. 1997;39:369-78 [10168933.001]
  • [Cites] J Magn Reson Imaging. 2005 Jan;21(1):1-11 [15611946.001]
  • [Cites] J Appl Clin Med Phys. 2005 Fall;6(4):106-10 [16421504.001]
  • [Cites] IEEE Trans Med Imaging. 2003 Feb;22(2):189-99 [12715995.001]
  • (PMID = 18972365.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA071906-05; United States / NCI NIH HHS / CA / R01 CA071906; United States / NCI NIH HHS / CA / R01 CA071906-05; United States / NCI NIH HHS / CA / R01CA71906-05
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS63971; NLM/ PMC2720022
  •  go-up   go-down


67. Matsumoto T, Nakamura S, Esaki M, Yada S, Moriyama T, Yanai S, Hirahashi M, Yao T, Iida M: Double-balloon endoscopy depicts diminutive small bowel lesions in gastrointestinal lymphoma. Dig Dis Sci; 2010 Jan;55(1):158-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We examined 29 patients with primary GI lymphoma by oral and anal DBEs.
  • However, clinical stage was more advanced in patients with the lesions than in those without (P < 0.05).
  • The lesions were more frequently found in T-cell lymphoma (100%) and follicular lymphoma (77%) than in the other types of lymphoma (15%) (P < 0.05).
  • Diminutive small intestinal lesions occur in patients with GI lymphoma, especially in those with follicular lymphoma and T-cell lymphoma.
  • [MeSH-major] Endoscopy, Gastrointestinal. Gastrointestinal Neoplasms / diagnosis. Intestine, Small / pathology. Lymphoma / diagnosis

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endoscopy. 2005 Jun;37(6):594-6 [15933938.001]
  • [Cites] Gastrointest Endosc. 2001 Feb;53(2):216-20 [11174299.001]
  • [Cites] Endoscopy. 2007 Feb;39 Suppl 1:E86-7 [17440873.001]
  • [Cites] Endoscopy. 2005 Dec;37(12):1174-80 [16329013.001]
  • [Cites] Ann Oncol. 2003 Apr;14(4):623-9 [12649111.001]
  • [Cites] Cancer. 1961 Mar-Apr;14:249-57 [13695582.001]
  • [Cites] Histopathology. 2003 Aug;43(2):135-43 [12877728.001]
  • [Cites] Cancer. 1972 Jan;29(1):252-60 [5007387.001]
  • [Cites] Haematologica. 2008 Feb;93(2):201-6 [18223283.001]
  • [Cites] Am J Pathol. 2003 Jan;162(1):105-13 [12507894.001]
  • [Cites] Endoscopy. 2008 Sep;40 Suppl 2:E149 [18633862.001]
  • [Cites] Endoscopy. 2007 Feb;39 Suppl 1:E204 [17614049.001]
  • [Cites] Gastrointest Endosc. 2008 Apr;67(4):763-5 [18207144.001]
  • [Cites] Histopathology. 2005 Nov;47(5):467-78 [16241994.001]
  • [Cites] Am J Gastroenterol. 2007 May;102(5):987-96 [17378908.001]
  • [Cites] Am J Surg Pathol. 1996 Apr;20(4):442-52 [8604811.001]
  • [Cites] Am J Pathol. 1992 Jun;140(6):1327-35 [1376556.001]
  • [Cites] Endoscopy. 2008 Apr;40(4):343-6 [18067068.001]
  • [Cites] Endoscopy. 2007 Feb;39 Suppl 1:E347-8 [18273791.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):216-24 [11812943.001]
  • [Cites] Cancer. 2003 May 15;97(10):2462-73 [12733145.001]
  • [Cites] Endoscopy. 2005 Jan;37(1):66-70 [15657861.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3861-73 [11559724.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Nov;2(11):1010-6 [15551254.001]
  • [Cites] Endoscopy. 2007 Feb;39 Suppl 1:E26-7 [17285496.001]
  • [Cites] Hum Pathol. 1999 May;30(5):581-7 [10333231.001]
  • [Cites] Hum Pathol. 1994 Oct;25(10):1020-9 [7927306.001]
  • [Cites] N Engl J Med. 2004 Jan 15;350(3):239-48 [14724303.001]
  • [Cites] Endoscopy. 2007 Feb;39 Suppl 1:E339-40 [18273786.001]
  • [Cites] J Gastroenterol. 2004 Aug;39(8):739-46 [15338367.001]
  • [Cites] Am J Gastroenterol. 1999 May;94(5):1139-52 [10235185.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3136-41 [16769982.001]
  • [Cites] Blood. 1996 Dec 15;88(12):4445-51 [8977236.001]
  • [Cites] Ann Oncol. 1994 May;5(5):397-400 [8075046.001]
  • [Cites] AJR Am J Roentgenol. 2008 Jul;191(1):175-81 [18562742.001]
  • [Cites] Am J Surg Pathol. 2000 May;24(5):688-93 [10800987.001]
  • [Cites] Endoscopy. 2008 Sep;40 Suppl 2:E8-9 [18278712.001]
  • [Cites] Cancer. 2000 Jan 15;88(2):286-94 [10640959.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2740-6 [12860953.001]
  • [Cites] Nature. 2000 May 25;405(6785):417 [10839527.001]
  • [Cites] Am J Surg Pathol. 1989 Aug;13(8):691-9 [2665536.001]
  • [Cites] Br J Cancer. 2000 Aug;83(4):454-7 [10945490.001]
  • (PMID = 19241169.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Kruijt B, van der Snoek EM, Sterenborg HJ, Amelink A, Robinson DJ: A dedicated applicator for light delivery and monitoring of PDT of intra-anal intraepithelial neoplasia. Photodiagnosis Photodyn Ther; 2010 Mar;7(1):3-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A dedicated applicator for light delivery and monitoring of PDT of intra-anal intraepithelial neoplasia.
  • The objective of this study was to develop an applicator for delivery of light and monitoring of photodynamic therapy (PDT) in the anal cavity for treatment of anal intraepithelial neoplasia grade III (AIN III), which can progress to invasive anal cancer.
  • For light delivery and monitoring of PDT, an applicator based on standard anoscopy equipment was developed which facilitates, in addition to a light treatment fiber, fiber optic probes to monitor blood saturation, blood volume, fluorescence and fluence (rate) at two different locations in situ.
  • Patients were given a light dose of 10-17 J cm(-2) at a fluence rate of 45-50 mW cm(-2) based on in situ measured light treatment parameters.
  • [MeSH-major] Anus Neoplasms / diagnosis. Anus Neoplasms / drug therapy. Carcinoma in Situ / diagnosis. Carcinoma in Situ / drug therapy. Lighting / instrumentation. Photochemotherapy / instrumentation. Photosensitizing Agents / administration & dosage

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20230986.001).
  • [ISSN] 1873-1597
  • [Journal-full-title] Photodiagnosis and photodynamic therapy
  • [ISO-abbreviation] Photodiagnosis Photodyn Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Photosensitizing Agents
  •  go-up   go-down


69. Hessien MH, El-Sharkawi IM, El-Barbary AA, El-Beltagy DM, Snyder N: Non-invasive index of liver fibrosis induced by alcohol, thioacetamide and Schistosomal infection in mice. BMC Gastroenterol; 2010;10:53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-invasive index of liver fibrosis induced by alcohol, thioacetamide and Schistosomal infection in mice.
  • BACKGROUND: Non invasive approaches will likely be increasing utilized to assess liver fibrosis.
  • This work provides a new non invasive index to predict liver fibrosis induced in mice.
  • The following methods were employed: (i) The METAVIR system was utilized to grade and stage liver inflammation and fibosis;.
  • (ii) Determination of hepatic hydroxyproline and collagen; and (iii) Derivation of a new hepatic fibrosis index from the induced changes, and its prospective validation in a group of 70 mice.
  • These parameters were highly correlated with both the histological stage and the grade.
  • They were combined in a logarithmic formula, which non-invasively scores the severity of liver fibrosis through a range (0 to 2), starting with healthy liver (corresponding to stage 0) to advanced fibrosis (corresponding stage 3).Receiver operating characteristic curves (ROC) for the accuracy of the index to predict the histological stages demonstrated that the areas under the curve (AUC) were 0.954, 0.979 and 0.99 for index values corresponding to histological stages 1, 2 and 3, respectively.
  • Also, the index was correlated with stage and grade, (0.947 and 0.859, respectively).
  • The AUROC was 0.869 and there was good correlation with the stage of fibrosis and grade of inflammation.
  • CONCLUSION: The index fulfils the basic criteria of non-invasive marker of liver fibrosis since it is liver-specific, easy to implement, reliable, and inexpensive.

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • Hazardous Substances Data Bank. THIOACETAMIDE .
  • Hazardous Substances Data Bank. ETHANOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 1999 Dec;30(6):1529-30 [10610352.001]
  • [Cites] Hepatology. 2009 Jun;49(6):1821-7 [19291784.001]
  • [Cites] N Engl J Med. 2001 Feb 15;344(7):495-500 [11172192.001]
  • [Cites] Lancet. 2001 Apr 7;357(9262):1069-75 [11297957.001]
  • [Cites] Hum Exp Toxicol. 2001 May;20(5):251-4 [11476157.001]
  • [Cites] Hepatology. 2002 Oct;36(4 Pt 1):986-92 [12297848.001]
  • [Cites] Am J Gastroenterol. 2002 Oct;97(10):2614-8 [12385448.001]
  • [Cites] Hepatology. 1997 Dec;26(6):1393-8 [9397976.001]
  • [Cites] Hepatology. 1999 Jan;29(1):14-20 [9862843.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] J Hepatol. 2003 Aug;39(2):222-30 [12873819.001]
  • [Cites] J Hepatol. 2003 Aug;39(2):239-44 [12873821.001]
  • [Cites] Hepatology. 2003 Aug;38(2):518-26 [12883497.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2003 Feb;2(1):69-72 [14607650.001]
  • [Cites] Anal Biochem. 1979 Jun;95(2):351-8 [36810.001]
  • [Cites] Res Exp Med (Berl). 1980;177(3):201-11 [6449727.001]
  • [Cites] Pharmacol Ther. 1985;29(1):129-56 [3914644.001]
  • [Cites] Pharmacol Toxicol. 1987 Mar;60(3):171-4 [3588511.001]
  • [Cites] Exp Pathol. 1988;34(4):229-36 [2853079.001]
  • [Cites] Hepatology. 1996 Aug;24(2):289-93 [8690394.001]
  • [Cites] Arch Biochem Biophys. 1959 May;82(1):70-7 [13650640.001]
  • [Cites] Gastroenterology. 2005 Feb;128(2):343-50 [15685546.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Feb;3(2):167-74 [15704051.001]
  • [Cites] Alcohol Clin Exp Res. 2006 Aug;30(8):1429-35 [16899047.001]
  • [Cites] J Hepatol. 2007 May;46(5):775-82 [17321634.001]
  • [Cites] Clin Chim Acta. 2007 Jun;381(2):119-23 [17442291.001]
  • [Cites] Rinsho Byori. 2007 Aug;55(8):751-7 [17882797.001]
  • [Cites] Hepatology. 2008 Feb;47(2):455-60 [18038452.001]
  • [Cites] Cancer Res. 2008 Mar 15;68(6):2033-42 [18339886.001]
  • [Cites] Chest. 2008 May;133(5):1101-6 [18071010.001]
  • [Cites] Anal Biochem. 2000 Oct 1;285(1):16-20 [10998259.001]
  • (PMID = 20515488.001).
  • [ISSN] 1471-230X
  • [Journal-full-title] BMC gastroenterology
  • [ISO-abbreviation] BMC Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 075T165X8M / Thioacetamide; 3K9958V90M / Ethanol; 9007-34-5 / Collagen; EC 2.3.2.2 / gamma-Glutamyltransferase; GAN16C9B8O / Glutathione; RFM9X3LJ49 / Bilirubin; RMB44WO89X / Hydroxyproline
  • [Other-IDs] NLM/ PMC2894747
  •  go-up   go-down


70. Jiang Y, Ma Y: A fast capillary electrophoresis method for separation and quantification of modified nucleosides in urinary samples. Anal Chem; 2009 Aug 1;81(15):6474-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Modified nucleosides are formed at the post-transcriptional stage by chemical modification of normal nucleosides within the ribonucleic acid (RNA).
  • The elevated levels of modified nucleosides in the urine samples have served as potential cancer biomarkers in many studies.
  • Although different analytical techniques have been reported for determining nucleosides levels, they are practically difficult to use as a routine tool for early cancer screening.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19552424.001).
  • [ISSN] 1520-6882
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nucleosides
  •  go-up   go-down


71. Vargas C, Martinez A, Kestin LL, Yan D, Grills I, Brabbins DS, Lockman DM, Liang J, Gustafson GS, Chen PY, Vicini FA, Wong JW: Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy. Int J Radiat Oncol Biol Phys; 2005 Aug 1;62(5):1297-308
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy.
  • PURPOSE: We analyzed our experience treating localized prostate cancer with image-guided off-line correction with adaptive high-dose radiotherapy (ART) in our Phase II dose escalation study to identify factors predictive of chronic rectal toxicity.
  • MATERIALS AND METHODS: From 1999-2002, 331 patients with clinical stage T1-T3N0M0 prostate cancer were prospectively treated in our Phase II 3D conformal dose escalation ART study to a median dose of 75.6 Gy (range, 63.0-79.2 Gy), minimum dose to confidence limited-planning target volume (cl-PTV) in 1.8 Gy fractions (median isocenter dose = 79.7 Gy).
  • For each case, the rectum (rectal solid) was contoured from the sacroiliac joints or rectosigmoid junction (whichever was higher) to the anal verge or ischial tuberosities (whichever was lower), with a median volume of 81.2 cc.
  • Toxicity was quantified using the National Cancer Institute Common Toxicity Criteria 2.0.
  • Thirty-four patients (crude rate = 10.3%) experienced Grade 2 chronic rectal toxicity at a median interval of 1.1 years.
  • Nine patients (crude rate = 2.7%) experienced Grade > or =3 chronic rectal toxicity (1 was Grade 4) at a median interval of 1.2 years.
  • The 3-year rates of Grade > or =2 and Grade > or =3 chronic rectal toxicity were 20% and 4%, respectively.
  • Acute toxicity predicted for chronic: Acute Grade 2-3 rectal toxicity (p < 0.001) including any acute rectal Grade 2-3 tenesmus (p = 0.02) and pain (p = 0.008) were significant predictors of chronic Grade > or =2 rectal toxicity.
  • Dose-volume histogram predicted for chronic toxicity: Rectal wall absolute and relative V50, V60, V66.6, V70, and V72 and rectal solid relative V60-V72 were significantly associated with chronic Grade > or =2 rectal toxicity both as categorical and continuous variables (t test, linear regression) and when divided into subgroups (chi-square table).
  • The chronic rectal toxicity Grade > or =2 risk was 9%, 18%, and 25% for the rectal wall relative V70 <15%, 25%-40%, and >40% respectively.


72. Lingappa M, Song H, Thompson S, Bruchertseifer F, Morgenstern A, Sgouros G: Immunoliposomal delivery of 213Bi for alpha-emitter targeting of metastatic breast cancer. Cancer Res; 2010 Sep 01;70(17):6815-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoliposomal delivery of 213Bi for alpha-emitter targeting of metastatic breast cancer.
  • Current treatment for late-stage metastatic breast cancer is largely palliative. alpha-Particles are highly potent, short-range radiation emissions capable of sterilizing individual cells with one to three traversals of the cell nucleus.
  • Efficacy in a rat/neu transgenic mouse model of metastatic mammary carcinoma was investigated.
  • We have shown that the (213)Bi radiolabeled immunoliposomes are effective in treating early-stage micrometastases, giving median survival times similar to those obtained with antibody-mediated delivery of (213)Bi in this animal model.

  • Hazardous Substances Data Bank. BISMUTH, ELEMENTAL .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Biother Radiopharm. 2004 Dec;19(6):706-15 [15665617.001]
  • [Cites] Health Phys. 1960 Feb;2:225-38 [13818815.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11631-8 [16357174.001]
  • [Cites] Curr Pharm Des. 2006;12(36):4729-49 [17168775.001]
  • [Cites] Bioconjug Chem. 2007 Nov-Dec;18(6):2061-7 [17935286.001]
  • [Cites] Expert Opin Drug Deliv. 2008 Feb;5(2):189-204 [18248318.001]
  • [Cites] Cancer Biother Radiopharm. 2008 Feb;23(1):74-81 [18298331.001]
  • [Cites] Cancer Res. 2008 May 15;68(10):3873-80 [18483272.001]
  • [Cites] Clin Cancer Res. 2008 Oct 1;14(19):6116-24 [18829490.001]
  • [Cites] Cancer Res. 2009 Dec 1;69(23):8941-8 [19920193.001]
  • [Cites] J Nucl Med. 2010 Feb;51(2):311-28 [20080889.001]
  • [Cites] J Nucl Med. 1999 Nov;40(11):1935-46 [10565792.001]
  • [Cites] Pharmacol Rev. 1999 Dec;51(4):691-743 [10581328.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3569-76 [10910070.001]
  • [Cites] Pharm Res. 2002 Mar;19(3):265-9 [11934232.001]
  • [Cites] J Nucl Med. 2004 Feb;45(2):253-60 [14960644.001]
  • [Cites] Science. 2004 Mar 19;303(5665):1818-22 [15031496.001]
  • [Cites] Expert Opin Ther Targets. 2004 Aug;8(4):335-53 [15268628.001]
  • [Cites] Bioconjug Chem. 1992 Jul-Aug;3(4):342-5 [1390990.001]
  • [Cites] Cancer Res. 1993 Aug 15;53(16):3765-70 [8339289.001]
  • [Cites] Biochim Biophys Acta. 1994 Feb 23;1190(1):99-107 [8110825.001]
  • [Cites] Cancer Res. 1994 Jul 1;54(13):3352-6 [8012948.001]
  • [Cites] Nucl Med Biol. 1995 Apr;22(3):387-90 [7627155.001]
  • [Cites] J Nucl Med. 1995 Sep;36(9):1639-44 [7658225.001]
  • [Cites] J Leukoc Biol. 1996 Sep;60(3):337-44 [8830790.001]
  • [Cites] Biochemistry. 1997 Jan 7;36(1):66-75 [8993319.001]
  • [Cites] J Nucl Med. 1997 Mar;38(3):489-93 [9074545.001]
  • [Cites] Appl Radiat Isot. 1999 May;50(5):895-904 [10214708.001]
  • [Cites] Int J Pharm. 1999 Oct 15;188(1):87-95 [10528086.001]
  • [Cites] J Biol Chem. 1959 Mar;234(3):466-8 [13641241.001]
  • [Cites] Anal Chem. 2005 Oct 1;77(19):6288-91 [16194090.001]
  • (PMID = 20651254.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA113797; United States / NCI NIH HHS / CA / R01 CA113797-04; United States / NCI NIH HHS / CA / R01 CA187037
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoconjugates; 0 / Isothiocyanates; 0 / Liposomes; 0 / Radioisotopes; 142434-84-2 / N-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-N,N',N',N'',N''-pentaacetic acid; 7A314HQM0I / Pentetic Acid; EC 2.7.10.1 / Receptor, ErbB-2; U015TT5I8H / Bismuth
  • [Other-IDs] NLM/ NIHMS248891; NLM/ PMC2977986
  •  go-up   go-down


73. Jelski W, Mroczko B, Szmitkowski M: The diagnostic value of alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) measurement in the sera of colorectal cancer patients. Dig Dis Sci; 2010 Oct;55(10):2953-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The diagnostic value of alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) measurement in the sera of colorectal cancer patients.
  • BACKGROUND: The activity of total alcohol dehydrogenase (ADH) and class I isoenzymes is significantly higher in colorectal cancer tissue than in healthy mucosa.
  • The activity of these enzymes in cancer cells is probably reflected in the sera and could thus be helpful for diagnosing colorectal cancer.
  • AIM: The aim of this study was to investigate a potential role of ADH and aldehyde dehydrogenase (ALDH) as tumor markers for colorectal cancer.
  • METHODS: Serum samples were taken from 182 patients with colorectal cancer before treatment and from 160 control subjects.
  • Total ADH activity and class III and IV isoenzymes were measured by photometric, but ALDH activity and ADH I and II by the fluorometric method, with class-specific fluorogenic substrates.
  • RESULTS: There was significant increase in the activity of ADH I isoenzyme and ADH total in the sera of colorectal cancer patients compared to the control.
  • The sensitivity and specificity of ADH I increased with the stage of the carcinoma.
  • CONCLUSION: The results suggest a potential role for ADH I as marker for colorectal cancer.
  • [MeSH-major] Alcohol Dehydrogenase / blood. Aldehyde Dehydrogenase / blood. Biomarkers / blood. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / metabolism. Isoenzymes / blood

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 1989 Oct 23;257(1):105-9 [2806555.001]
  • [Cites] Clin Chem. 1993 Nov;39(11 Pt 1):2298-304 [8222224.001]
  • [Cites] Clin Exp Med. 2006 Jun;6(2):89-93 [16820997.001]
  • [Cites] Anal Biochem. 1989 Apr;178(1):57-62 [2729580.001]
  • [Cites] Dig Dis Sci. 2004 Jun;49(6):977-81 [15309886.001]
  • [Cites] Clin Exp Med. 2007 Dec;7(4):154-7 [18188528.001]
  • [Cites] Anal Biochem. 1979 Oct 15;99(1):65-71 [231394.001]
  • [Cites] Dig Dis Sci. 2005 Jun;50(6):1019-24 [15986847.001]
  • [Cites] Hematol Oncol Clin North Am. 2002 Aug;16(4):775-810 [12418049.001]
  • [Cites] Digestion. 1996;57(2):105-8 [8785998.001]
  • [Cites] Clin Chem Lab Med. 2008;46(10):1423-8 [18844497.001]
  • [Cites] Clin Chim Acta. 2006 Sep;371(1-2):143-7 [16603145.001]
  • [Cites] Clin Chim Acta. 2007 May 1;380(1-2):208-12 [17368603.001]
  • [Cites] Alcohol Clin Exp Res. 1996 May;20(3):551-5 [8727253.001]
  • [Cites] Alcohol Clin Exp Res. 1996 Dec;20(9):1569-76 [8986205.001]
  • [Cites] Int J Colorectal Dis. 2007 Jan;22(1):33-8 [16520929.001]
  • [Cites] Clin Chem Lab Med. 2003 May;41(5):646-51 [12812262.001]
  • [Cites] BMJ. 2000 Feb 12;320(7232):424-7 [10669448.001]
  • (PMID = 20069455.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Isoenzymes; EC 1.1.1.1 / Alcohol Dehydrogenase; EC 1.2.1.3 / Aldehyde Dehydrogenase
  •  go-up   go-down


74. Shui G, Guan XL, Gopalakrishnan P, Xue Y, Goh JS, Yang H, Wenk MR: Characterization of substrate preference for Slc1p and Cst26p in Saccharomyces cerevisiae using lipidomic approaches and an LPAAT activity assay. PLoS One; 2010;5(8):e11956
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Phosphatidic acid (PA) is a key regulated intermediate and precursor for de novo biosynthesis of all glycerophospholipids.
  • A comprehensive high-performance liquid chromatography-based multi-stage MRM approach (more than 500 MRM transitions) was developed and further applied to quantify individual phospholipids in both strains to confirm these changes.
  • These results were consistent with those from a non-radioactive LPAAT enzymatic assay using C17-LPA and acyl-CoA donors as substrates.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • Saccharomyces Genome Database. Saccharomyces Genome Database .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 2008 Feb 11;180(3):473-82 [18250201.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):2830-5 [18287005.001]
  • [Cites] J Cell Sci. 2008 Aug 15;121(Pt 16):2671-84 [18653539.001]
  • [Cites] J Biol Chem. 2008 Oct 31;283(44):30235-45 [18772128.001]
  • [Cites] J Biol Chem. 2009 Jan 2;284(1):1-5 [18718904.001]
  • [Cites] Cell Metab. 2009 Feb;9(2):165-76 [19187773.001]
  • [Cites] Prog Lipid Res. 1999 Sep-Nov;38(5-6):461-79 [10793891.001]
  • [Cites] J Biol Chem. 2001 Nov 9;276(45):41710-6 [11544256.001]
  • [Cites] Anal Chem. 2002 Mar 1;74(5):941-9 [11924996.001]
  • [Cites] Nat Genet. 2002 May;31(1):21-3 [11967537.001]
  • [Cites] Methods Enzymol. 2002;350:87-96 [12073338.001]
  • [Cites] Expert Opin Ther Targets. 2003 Oct;7(5):643-61 [14498826.001]
  • [Cites] Nature. 2003 Oct 16;425(6959):686-91 [14562095.001]
  • [Cites] Plant Cell Physiol. 2004 May;45(5):503-10 [15169931.001]
  • [Cites] J Bacteriol. 1997 Dec;179(24):7611-6 [9401016.001]
  • [Cites] J Bacteriol. 1999 Mar;181(5):1458-63 [10049376.001]
  • [Cites] Mass Spectrom Rev. 2005 May-Jun;24(3):367-412 [15389848.001]
  • [Cites] Nat Rev Drug Discov. 2005 Jul;4(7):594-610 [16052242.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Aug 25;823(1):26-36 [15990370.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9415-25 [16230405.001]
  • [Cites] J Lipid Res. 2006 Mar;47(3):593-604 [16369050.001]
  • [Cites] J Lipid Res. 2006 Apr;47(4):745-54 [16436371.001]
  • [Cites] Yeast. 2006 Apr 30;23(6):465-77 [16652392.001]
  • [Cites] FASEB J. 2006 Jun;20(8):1152-61 [16770014.001]
  • [Cites] Cancer. 2006 Oct 1;107(7):1511-9 [16944535.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2006;7:175-99 [16722806.001]
  • [Cites] J Lipid Res. 2007 Jan;48(1):235-41 [17053274.001]
  • [Cites] J Lipid Res. 2007 Sep;48(9):1976-84 [17565170.001]
  • [Cites] J Biol Chem. 2007 Oct 19;282(42):30845-55 [17675291.001]
  • [Cites] J Biol Chem. 2007 Oct 19;282(42):30562-9 [17726007.001]
  • [Cites] FEBS Lett. 2007 Nov 27;581(28):5511-6 [17996202.001]
  • [Cites] J Biol Chem. 2007 Nov 23;282(47):34288-98 [17890783.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Feb 17;106(7):2136-41 [19174513.001]
  • [Cites] Mol Biosyst. 2009 Mar;5(3):276-87 [19225619.001]
  • [Cites] FEBS J. 2009 Nov;276(21):6412-24 [19796168.001]
  • [Cites] Mol Biosyst. 2010 Jun;6(6):1008-17 [20485745.001]
  • [Cites] Int J Neuropsychopharmacol. 2009 Aug;12(7):953-64 [19203412.001]
  • (PMID = 20694142.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fatty Acids; 0 / Saccharomyces cerevisiae Proteins; EC 2.3.- / Acyltransferases; EC 2.3.- / Cst26 protein, S cerevisiae; EC 2.3.1.52 / 2-acylglycerophosphate acyltransferase; EC 3.6.4.2 / Dyneins; EC 3.6.4.2 / SLC1 protein, S cerevisiae
  • [Other-IDs] NLM/ PMC2915916
  •  go-up   go-down


75. Yu J, Ohuchida K, Nakata K, Mizumoto K, Cui L, Fujita H, Yamaguchi H, Egami T, Kitada H, Tanaka M: LIM only 4 is overexpressed in late stage pancreas cancer. Mol Cancer; 2008;7:93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] LIM only 4 is overexpressed in late stage pancreas cancer.
  • BACKGROUND: LIM-only 4 (LMO4), a member of the LIM-only (LMO) subfamily of LIM domain-containing transcription factors, was initially reported to have an oncogenic role in breast cancer.
  • If so, this could result in a better understanding of tumorigenesis in pancreatic cancer.
  • METHODS: We measured LMO4 mRNA levels in cultured cells, pancreatic bulk tissues and microdissected target cells (normal ductal cells; pancreatic intraepithelial neoplasia-1B [PanIN-1B] cells; PanIN-2 cells; invasive ductal carcinoma [IDC] cells; intraductal papillary-mucinous adenoma [IPMA] cells; IPM borderline [IPMB] cells; and invasive and non-invasive IPM carcinoma [IPMC]) by quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR).
  • RESULTS: 9 of 14 pancreatic cancer cell lines expressed higher levels of LMO4 mRNA than did the human pancreatic ductal epithelial cell line (HPDE).
  • In bulk tissue samples, expression of LMO4 was higher in pancreatic carcinoma than in intraductal papillary-mucinous neoplasm (IPMN) or non-neoplastic pancreas (p < 0.0001 for both).
  • These results suggested that LMO4 is overexpressed at late stages in carcinogenesis of pancreatic cancer.
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Analysis of Variance. Carcinoma, Pancreatic Ductal / genetics. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / genetics. Carcinoma, Papillary / pathology. Cell Line, Tumor. Humans. LIM Domain Proteins. Neoplasm Staging. Protein-Serine-Threonine Kinases / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction